# Proceedings of the Tenth Canadian Cancer Research Conference 1978 

EDITED BY P.C. SCHOLEFIELD
# PROCEEDINGS OF THE TENTH CANADIAN CANCER RESEARCH CONFERENCE 

Honey Harbour, Ontario, 1973

Edited by P.G. Scholefield

PUBLISHED FOR
THE NATIONAL CANCER INSTITUTE
OF CANADA
25 Adelaide St. E., Toronto, Ontario, Canada
BY UNIVERSITY OF TORONTO PRESS# Preface 

The formal sessions at the Tenth Canadian Cancer Research Conference were devoted to discussions of Endogenous Viruses, Enviromental Factors, Tumor Immunology, and Chemotherapy. In selecting the speakers for these sessions, the Program Committee (Dr H.F. Stich, Chairman; Dr G.J. Goldenberg; Dr G.A. LePage; Dr J.A. McCarter; Dr R. Simard, and Dr J.E. Till) was guided by the desire to have at least one paper in each session concerned primarily with the disease as it occurs in man. All speakers were reminded that, since the audience at these conferences is heterogeneous with respect to discipline and degree of experience, the presentation should aim to stimulate the beginner as well as to inform the expert.

Follow-up of the formal sessions was based on the experience of the previous Conference and took two forms. The first arose from the fact that delegates interested in specific fields were able to meet with the main conference speakers during the subsequent workshop sessions when it was possible to discuss problems of mutual interest at the desired level. The entire third day was devoted to such workshops. The following topics were discussed and the name of the individual who chaired each workshop is indicated.

Wednesday 13 June 1973

| Morning workshops | Afternoon workshops |
| :-- | :-- |
| RNA tumor viruses | RNA tumor viruses |
| A.F. Graham | J.K. Ball |
| DNA tumor viruses | DNA tumor viruses |
| P. Bourgaux | P. Cheevers |
| Morphology of tumors and | Morphology of tumors and |
| tumor viruses | tumor viruses |
| A.F. Howatson | G. Tremblay |
| Carcinogenesis | Carcinogenesis |
| D.R. McCalla | G. de Lamirande |
| Cell surfaces (Receptors) | Cell surfaces (Biochemistry) |
| F. Paraskevas | H. Schachter |
| Cell differentiation | Cell differentiation |
| J.S. Haskill | V.I. Kalnins |Chemotherapy
D.E. Bergsagel

Radiation sensitizers
G.F. Whitmore

Epidemiology
A.B. Miller

Antigens and human cancer
J.M. Gold

Regulation of gene activity
R. Simard

Immunotherapy
G.J. Goldenberg

Hormonal control
N. Bruchovsky

Somatic cell genetics
L. Siminovitch

A second type of follow-up was designed for the benefit of the younger delegates. On the Tuesday evening, at the conclusion of the formal sessions, the main conference speakers made themselves available in separate cabins for informal discussions ('rap' sessions) to which only graduate students and postdoctoral fellows were invited. No record was kept of the proceedings of the workshops or of the 'rap' sessions, but the subsequent comments have suggested that these experiments in communication have added greatly to the value of the Canadian Cancer Research conferences to those who participated. It is unfortunate that these experiences can not be shared through the medium of the printed word, but their contributions to the stated objectives of this series of conferences, and to the reinforcement of the material presented at the formal sessions, will merit much consideration in future planning.

Editor<br>P.G. Scholefield

Editorial Advisory Board
A.A. Axelrad
J.M.M. Darte
R. Simard

L. Siminovitch
H.F. Stich
R.M. Taylor
J.E. Till# Contents 

Preface ..... V
ENDOGENOUS VIRUSES
The role of herpes viruses in human cancer ..... 3
Harald zur Hausen
Genetics and evolution of RNA tumor viruses ..... 10
G.S. Martin and R.A. Weiss
Occurrence, properties, and interrelationships of leukemia and sarcoma viruses of the mouse ..... 31
J.A. McCarter, J.K. Ball, and P.K.Y. Wong
ENVIRONMENTAL CARCINOGENESIS
Record linkage for studies of environmental carcinogenesis ..... 49
Howard B. Newcombe
Transplacental carcinogenesis ..... 65
A. Koestner
The use of DNA repair in the identification of carcinogens, precarcinogens, and target tissue ..... 83
H.F. Stich, D. Kieser, B.A. Laishes, and R.H.C. San
TUMOR IMMUNOLOGY
Mechanisms of humoral tumor immunity in malignant melanoma ..... 113
M.G. Lewis

- Immunotherapy for acute myelogenous leukemia ..... 130
Ray Powles
Pitfalls in tumor immunology ..... 136
Richmond T. Prehn
CHEMOTHERAPY
Selection of regimens for clinical chemotherapy ..... 149
Thomas C. Hall
The measurement of the effects of anti-cancer agents ..... 162
W.R. Bruce
Some model systems in cancer chemotherapy ..... 171
G.A. LePageENDOGENOUS VIRUSES$\cdot$
$\cdot$
$\cdot$
.# The role of herpes viruses in human cancer 

HARALD ZUR HAUSEN<br>Institut für klinische Virologie, Universität Erlangen-Nürnberg, 852 Erlangen, Loschgestr. 7, Germany

Herpes-group and oncorna viruses represent the prime candidates as etiological agents of specific human tumors. Although several serotypes of human adenoviruses have been shown to be oncogenic in rodents, there exists no evidence that they also transform human cells. Today, the EpsteinBarr virus (EBV), as a representative member of the herpes virus group, is the prime suspect among additional candidates of the same group as well as in a comparison with the oncorna viruses. The serotype 2 of herpes simplex virus has also been shown to possess properties in human cells which are characteristic for tumor viruses. The participation of human cytomegalovirus in Kaposi's sarcoma is still inconclusive.

Oncornaviruses have not yet been demonstrated consistently in any human malignancy. Their presence might be revealed, however, by the demonstration of virus-specific enzymatic activities and the existence of products which show physical properties similar to those of oncornaviruses of animal origin.

The major part of this paper will discuss the presence of Epstein-Barr virus in human tumor cells and summarize results which incriminate this virus as the etiologic agent of Burkitt's lymphoma and possibly also of the anaplastic carcinoma of the nasopharynx. Attention will be focused on the demonstration of viral nucleic acids within these tumor cells.

About three years ago we started to purify radioactive EB viral DNA and initiated DNA-DNA homology studies with DNA from tissue culture cells of Burkitt tumor origin. In first experiments we demonstrated significant hybridization of EB viral DNA with DNA derived from cells of the 'virusfree' Raji line, as compared to various control preparations of human KB and hamster Nil-2 cells. ${ }^{1}$ Similarly, increased annealing of Raji cell RNA with EB viral DNA, as compared to the above controls, was observed, indicating the continued in vivo transcription of EBV-specific RNA within these cells. No cross-hybridization of DNA from herpes simplex virus-, cytome-galovirus-, or varicella virus-infected cells with EBV-DNA was detected.These results showed that EBV may act like well-known DNA tumor viruses. Its DNA persists in Raji cells and at least part of this DNA is biologically active.

Subsequent experiments by Hampar et al. ${ }^{2}$ and Gerber ${ }^{3}$ showed that Raji cells as well as several other non-virus-producing lymphoblastoid lines contain the complete, or at least almost complete, viral genome. Treatment of these cells with 5 -BUdR or 5 -IUdR resulted in induction of viral structural antigen and viral particle synthesis.

DNA-DNA hybridizations with radioactive EB viral DNA were also applied to biopsy material derived from Burkitt lymphomas and from various other tumors of the head and neck and of the lymphatic system. ${ }^{4}$ They revealed an increased annealing of viral DNA with DNA from Burkitt lymphomas and nasopharyngeal carcinomas as compared with a number of other preparations of different origin. These included DNA from Hodgkin biopsies, various lymphomas, and carcinomas. There existed a considerable variation in hybridized counts among the Burkitt lymphoma and nasopharyngeal carcinoma biopsies tested. DNA from multiple tumors of the same donor, however, annealed with EBV-DNA in a similar range.

The extremely low yields of purified EBV-DNA and the low specific radioactivities of this material were circumvented by in vitro transcription of EBV-DNA with the aid of E. coli RNA-polymerase. The resulting complementary RNA was used in further tests. Although it has not yet been clarified which parts of the viral genome are transcribed in vitro, the use of this method has been successfully applied to the detection of latent EB viral genomes by Nonoyama and Pagano ${ }^{5}$ and by our group. ${ }^{6}$

This test permitted the detection of EB viral DNA in all those immuno-globulin-producing lymphoblastoid cell lines tested thus far which were devoid of viral structural antigens. ${ }^{7}$ Although most of them were subsequently shown to be inducible for EBV-antigen-synthesis by BUdR or IUdR, some of them appeared to be refractory to these compounds. ${ }^{8}$ DNA from two immunoglobulin-negative lines, both derived from acute lymphatic leukemias, failed to hybridize significantly with EBV-specific RNA.

Reconstruction tests with EBV complementary RNA (cRNA) as well as reassociation kinetic experiments with labelled EBV-DNA after addition of cellular DNA of various origin ${ }^{9}$ demonstrated that the cells of some of the lymphoblastoid lines were 'loaded' with EBV-DNA. Approximately 0.25 per cent of the total cellular DNA was virus-specific in one line. ${ }^{7}$

The presence of viral DNA in cells of these lines is regularly paralleled by the appearance of apparently virus-specific complement-fixing antigens. ${ }^{10,11}$ They seem to represent an expression of persisting viral genomes. Recently Reedman and Klein ${ }^{12}$ visualized such antigens by anticomplementary immunofluorescence and demonstrated their intranuclear localization.Besides the capacity to transform normal lymphocytes into continuously growing cells, EBV thus shares at least two properties with known DNA tumor viruses: it persists at a subviral level within the transformed cells and exerts at the same time an apparently specific genetic activity.

Annealing of DNA from tumor biopsies with EBV-cRNA basically confirmed the results obtained by DNA-DNA hybridizations. ${ }^{13}$ DNA from all Burkitt biopsies tested thus far revealed increased hybridization as compared to various controls. In view of the rather uniform histology of Burkitt's lymphoma, it seems reasonable to assume that the annealed label detects virus-specific DNA within tumor cells. In addition, this is supported by the presence of EBV-specific complement-fixing (Klein, personal communication) as well as membrane antigens in fresh biopsy cells and the synthesis of EBV-specific structural antigens soon after explanation of these tumor cells into tissue culture. Thus, Burkitt's lymphoma represents the first example of a human malignancy consistently associated with a transforming virus.

The regular demonstration of EBV-DNA in nasopharyngeal carcinomas by DNA-DNA hybridizations was carefully re-evaluated by annealing experiments with EBV-cRNA. With few exceptions 28 DNA preparations from different biopsies of nasopharyngeal carcinomas hybridized above the background of various control preparations. The hybridization data of some of these tumors were excessively high, indicating a considerable 'load' with EBV-DNA.

The nasopharyngeal carcinoma reveals histologically a mixed cell population: besides epithelial tumor cells it contains varying amounts of infiltrating lymphocytes which justify its original name 'lymphoepithelioma.' Until now it has been an open question whether the epithelial tumor cells or the lymphocytes, or both, harbour EB viral genomes. Our first attempt to analyse this problem was the comparison of hybridization data with the tumor histology. It was rather surprising that predominantly epithelial tumors which contained more than 50 per cent of epithelial cells annealed most efficiently with ESV-cRNA. If exclusively lymphocytes would harbour viral DNA, more than 0.5 per cent of their total DNA had to be virus-specific. This concentration exceeds all other experimental data obtained with persisting EBV genomes.

Biopsies which were negative in the hybridization tests or annealed only to a low extent represented histologically either non-tumorous tissue or predominantly lymphoid tumors. This result suggested that epithelial cells harbour the EBV genomes.

A more direct approach to localize the EBV-positive cells was the application of the anticomplementary fluorescence method ${ }^{11}$ to frozen sections of nasopharyngeal carcinoma (NPC) biopsies. Sections from two nasopharyngeal carcinomas and three other tumors were examined by using EBV-reactive as well as non-reactive sera. Cells of the Raji line, derived from a Burkitt lymphoma, served as positive control. The 'Molt' line derived from a patient with acute lymphatic leukemia, was included as negative control.

No anticomplementary fluorescence was observed in Molt cells and sections of non-lymphoepithelial tumors. Raji cells and apparently epithelial cells of the nasopharyngeal carcinomas, however, revealed a clearly positive fluorescence. In Raji cells, this fluorescence was confined mainly to the nuclear regions, whereas in the nasopharyngeal cells it appeared to be more granular, and was also observed in the cytoplasm. The brilliant staining depended on the presence of antibodies against EBV-associated antigens. No fluorescence characteristic for EBV early or structural antigens was detected within those sections.

To further substantiate these results, sections of two lymphoepitheliomas and three control tissues (one adenoma and two salivary glands) were denatured by NaOH treatment and subjected to in situ hybridizations with EBV-specific cRNA. We showed previously that this procedure permits the localization of viral DNA in EB virus-producing as well as in viral genomecarrying tissue culture cells. ${ }^{6}$ After hybridization the tumor sections were treated with RNase, exposed for three weeks to autoradiography, developed, and stained.

Whereas the control sections did not reveal any clustering of grains or accumulation of label over nuclei, this was clearly the case in nasopharyngeal carcinomas. Sections of one tumor which annealed with about 1900 c.p.m. in filter hybridizations were heavily labelled. This tumor consisted mainly of epithelial cells. The heavy labelling of the majority of nuclei, however, made their definite identification difficult, especially in view of the deteriorated morphology after NaOH denaturation. In the second tumor, which annealed with about $850 \mathrm{c} . \mathrm{p} . \mathrm{m}$. in membrane hybridizations, the situation was much better. Numerous foci of clustered nuclei were clearly labelled within those sections, whereas nuclei of the surrounding tissue were not. The arrangement of labelled clusters of these nuclei corresponded to similar foci of epithelial cells in non-denatured sections of the same tumor. Nuclei of lymphocytes and other cellular components of this tumor seemed to be unlabelled.

These results permit the conclusion that the epithelial cells of nasopharyngeal carcinomas harbour those viral genomes which are demonstrated by nucleic-acid hybridizations. Thus, this tumor represents the first example of an infection of human non-lymphatic cells with EBV. The role of the infiltrating lymphocytes remains to be clarified. They might be involved in the immune response against antigens specified by the viral DNA within epithelial cells. The presence of EBV within the epithelial tumor cells ofnasopharyngeal carcinomas substantially supports the circumstantial evidence for a casual role for EBV in this malignancy.

Little is known about the state of EB viral DNA within human tumor cells. Nonoyama and Pagano claimed to demonstrate non-integration of EBV-DNA with the host cell chromosomes ${ }^{14}$ in Raji cells. This was based on the sedimentation pattern of DNA hybridizable to EBV-cRNA in alkaline glycerol gradients. Their approach, however, might be questioned in view of alkali-labile spots within herpes virus DNA as reported by Bachenheimer et al. ${ }^{15}$

The constant concentration of viral DNA in Raji cells observed over a period of two years of continuous cultivation ${ }^{12}$ favours covalent linkage of viral and host-cell DNA as the most reasonable explanation. Further experiments are needed to substantiate these results.

Recently another member of the herpes virus group, herpes simplex virus (HSV) type 2, was suspected of playing a role in the induction of human cervical carcinoma. This was suggested by seroepidemiological studies ${ }^{16,17}$ and also by the presence of virus-specific antigens within some carcinoma cells. ${ }^{18}$ Duff and Rapp ${ }^{19}$ showed the transforming capacity of partially UV-inactivated HSV 2 for hamster cells. Darai and Munk reported transformation of human lung cells after long incubation at $42^{\circ} \mathrm{C}$ shortly after infection. ${ }^{20}$ It was expected that nuclei acid hybridizations would be of considerable help in elucidating the relationship of HSV 2 to cervical carcinoma cells.

Dr Schulte-Holthausen in my department tested DNA from thirteen biopsies derived from cervical carcinomas in nucleic-acid homology tests with HSV 2-cRNA (H. Schulte-Holthausen, unpublished results). He was unable to observe increased hybridizations in any of the preparations tested. Although the failure to demonstrate HSV 2-DNA in these biopsies did not exclude a possible etiologic role for this agent in human cervical cancer, it showed clearly that we are not dealing with a relationship similar to EBV and Burkitt's lymphoma and nasopharyngeal carcinoma. The sensitivity of most of the HSV 2-experiments would have permitted the detection of more than one genome equivalent per tumor cell. Thus, a small content of virusspecific molecules could escape their discovery by this method.

By using a more sensitive assay, Frenkel et al. ${ }^{21}$ reported HSV 2-specific RNA in a virus-free cervical tumor by analysing DNA-RNA hybrids by hydroxylapatite column chromatography. The viral RNA transcripts were complementary to 5 per cent of HSV 2-DNA and corresponded to both early and late transcripts. Their analysis of this cervical DNA for the presence of HSV 2-DNA sequences revealed that only a fragment, representing approximately 40 per cent of the total HSV 2-DNA was present. In addition, the concentration of this fragment corresponded to about 1 mole per mole ofcellular DNA. Finally, they showed that at least parts of this fragment are covalently linked to host DNA.

It remains to be seen whether fragments of HSV 2-DNA are found consistently in human cervical carcinoma cells and whether they caused the transformation of these cells. The available data reveal already the enormous versatility of herpes virus-host cell interactions. It might be worthwhile to re-evaluate the oncogenic potential of any number of this group of viruses.

# REFERENCES 

1 zur Hausen, H. and Schulte-Holthausen, H. Presence of EB virus nucleic acid homology in a 'virus-free' line of Burkitt tumour cells. Nature, 227:245-248, 1970
2 Hampar, B., Derge, J.G., Martos, L.M., and Walker, J.L. Synthesis of Epstein-Barr virus after activation of the viral genome in virus-negative human lymphoblastoid cells (Raji) made resistant to 5 -bromodeoxyuridine. Proc. Natl. Acad. Sci. U.s., $69: 78-82,1972$
3 Gerber, P. Activation of Epstein-Barr virus by 5-bromodeoxyuridine in virus-free human cells. Proc. Natl. Acad. Sci. u.s., 69:83-85, 1972
4 zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Santesson, L. EBV-DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature, 228:1056-1058, 1970
5 Nonoyama, M. and Pagano, J.S. Detection of Epstein-Barr viral genome in nonproductive cells. Nature 233:103-105, 1971
6 zur Hausen, H. and Schulte-Holthausen, H. Detection of Epstein-Barr virus genomes in human tumor cells by nucleic acid hybridization. In Oncogenesis and Herpes viruses (P.M. Biggs, G. de Thé, and L.N. Payne, eds.), pp. 321-325. Lyon: IARC, 1972
7 zur Hausen, H., Diehl, V., Wolf, H., Schulte-Holthausen, H., and Schneider, U. Occurrence of EB viral genomes in human lymphoblastoid cell lines. Nature, 237, $189-190,1972$
8 Klein, G. and Dombos, L. Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome. Intern. J. Cancer, 11:327-337, 1973
9 Nonoyama, M. and Pagano, J.S. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature, 242:44-47, 1973
10 Pope, J.H., Horne, M.K., and Wetters, E.J. Significance of a complement-fixing antigen associated with herpes-like virus and detected in the Raji cell line. Nature, 222:186-187, 1969
11 Vonka, V., Benyesh-Melnick, M., and McCombs, R.M. Antibodies in human sera to soluble and viral antigens found in Burkitt lymphoma and other lymphoblastoid cell lines. J. Natl. Cancer Inst., 44:865-873, 1970
12 Reedman, B.M. and Klein, G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement fixing antigen in producer and nonproducer lymphoblastoid cell lines. Intern. J. Cancer, 11, 499-520, 1973
13 zur Hausen, H. Epstein-Barr virus in human tumor cells. In Intern. Rev. Exptl. Pathology, Academic Press, 11:233-258, 197214 Nonoyama, M. and Pagano, J.S. Separation of Epstein-Barr virus DNA in nonvirusproducing cells. Nature, 238:169-171, 1972
15 Bachenheimer, S.L., Kieff, E.D., Leer, L., and Roizman, B. Comparative studies of DNA's of Marek's disease and herpes simplex viruses. In Oncogenesis and Herpesviruses (P.M. Biggs, G. de Thé, and L.N. Payne, eds.), pp. 74-81. Lyon: IARC, 1972
16 Nahmias, A.J., Josey, W.E., Naib, Z.M., Luce, C., and Guest, B. Antibodies to herpes virus hominis types 1 and 2 in humans. Women with cervical cancer. Am. J. Epidemiol., 91:547-552, 1970
17 Rawls, W.E., Tomkins, W., and Melnick, J.L. The association of herpesvirus type 2 and carcinoma of the cervix. Am. J. Epidemiol., 89, 547-554, 1969
18 Royston, J. and Aurelian, L. Immunofluorescent detection of herpesvirus antigens in exfoliated cells from human cervical carcinoma. Proc. Natl. Acad. Sci. u.s., 67:204-212, 1970
19 Duff, R. and Rapp, F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nature, 233:48-50, 1971
20 Darai, G. and Munk, K. Human embryonic lung cells abortively infected with herpes virus hominis type 2 show some properties of cell transformation. Nature, 241:268-269, 1973
21 Frenkel, N., Roizman, B., Cassai, E., and Nahmias, A. DNA fragment of herpes simplex 2 and its transcription in human cervical cancer tissue. Proc. Natl. Acad. Sci. u.s. 69:3784-3789, 1972.# Genetics and evolution of RNA tumor viruses 

G.S. MARTIN and R.A. WEISS<br>Imperial Cancer Research Fund Laboratories, P.O. Box 123, Lincoln's Inn Fields, London, WC2A 3PX. U.K.

RNA tumor viruses represent a homogeneous group, with similar physical and chemical properties and modes of replication. A detailed account of the biology and molecular biology of RNA tumor viruses is provided in a recent book on tumor viruses edited by Tooze. ${ }^{68}$ Here we shall briefly discuss some aspects of the biology of these viruses in order to discuss some ideas about their origin and genetic structure, placing emphasis on the avian tumor viruses as the accompanying contribution by McCarter reviews the murine viruses.

The RNA tumor virus particle contains a 60-70S RNA genome comprised of 3-4 subunits. Associated with this genome are several internal proteins designated group-specific (gs) antigens because they share common antigen specificities within each group of viruses, e.g. the avian leukosis group or the murine leukemia group. The virus particle is enclosed in a lipoprotein envelope (derived from the cell membrane) which bears virus-coded envelope antigens that elicit neutralizing antibodies; these antigens are glycoproteins ${ }^{14}$ which are required for the virus to penetrate the cell via receptor sites at the cell surface. The avian tumor viruses have been classified into six subgroups, A to F, on the basis of their envelope properties; members of the same subgroup interfere with each other, show antigenic cross-reactivity, and have similar host-range properties.

The replication of RNA tumor viruses (Fig. 1) shows an early sensitivity to inhibitors of DNA synthesis, and a continuous sensitivity to inhibitors of DNA-dependent RNA synthesis. These observations led Temin ${ }^{61}$ to postulate that these viruses replicate via a DNA intermediate, the provirus. This idea is supported by the discovery that the virion contains an enzyme, 'reverse transcriptase,' which is capable of using viral RNA as a template for DNA synthesis. ${ }^{65}$ Virus mutants which lack functional reverse transcriptase are unable to replicate or to transform cells. However, a reverse transcriptase mutant of Rous sarcoma virus is complemented by phenotypic mixing with![img-0.jpeg](img-0.jpeg)

Figure 1 Replicative cycle of an RNA tumor virus.
'helper' leukosis viruses, ${ }^{25}$ indicating that the enzyme is required only for the initiation of infection. Furthermore, temperature sensitive reverse transcriptase mutants ${ }^{27}$ are able to replicate if allowed an initial period at the permissive temperature, confirming that the enzyme is required only for an early step in virus growth. In vitro experiments show that the enzyme is capable of copying all the sequences in the viral RNA, ${ }^{12}$ but the DNA is synthesized as short segments ${ }^{19}$ and it is still obscure how complete provirus synthesis occurs in vivo. It appears that a DNA-RNA hybrid is formed and then a doublestranded DNA provirus which probably integrates into one of the host-cell chromosomes. Even after provirus formation, cellular DNA synthesis and probably a subsequent mitosis are required for the formation of progeny virus and for cell transformation. ${ }^{62,74}$ To form the genomes of progeny virus, RNA strands are transcribed from the DNA provirus. Since negative strand RNA is not found in infected cells, it is assumed that the viral messenger RNA is identical with genome RNA, which may itself act as messenger. Viral replication is completed by budding from the cell membrane, which is modified by the insertion of the viral glycoproteins. The budding and release of virus particles does not kill the cell, so that it is possible for the cell to become converted into a malignant cell and at the same time produce viral progeny.

RNA tumor viruses are classified into three groups, the sarcoma, leukemia, and mammary tumor viruses, according to the type of cell that they transform. Leukemia viruses can be classified further into lymphoid, myeloid, and erythroid leukemia viruses. Sarcoma and leukemia viruses of a given host species share common $g s$ antigens, but the murine mammary tumor viruses differ from murine leukemia viruses antigenically and morphologically. Lymphoid leukemia viruses (LLV) and murine mammary tumor viruses (MMTV) occur commonly in nature. The neoplasms associatedwith LLV and MMTV have long latent periods and the viruses are frequently transmitted 'vertically,' from mother to offspring. For instance, viremic hens produce large quantities of avian LLV in the ovary and oviduct ${ }^{9}$ which infect the cells of the early embryo. Although the embryo rapidly becomes viremic, it usually grows normally and does not develop leukemia before maturity. Thus the bird may live to pass on the virus to the next generation as well as by horizontal infection. The sarcoma viruses and non-lymphoid leukemia viruses cause rapidly developing neoplasms; there may be strong natural selection against these viruses, therefore, and vertical transmission is not known. However, under artificial laboratory conditions these viruses are maintained easily and they have been used extensively in experimental studies. Many sarcoma viruses and non-lymphoid leukemia viruses are defective for replication and infectious stocks are maintained through complementation by 'helper' LLVs; the significance of defectiveness will be discussed below.

Sarcoma viruses transform fibroblasts or cell lines in vitro. The transformed cells show altered growth properties, such as the ability to grow at high cell density or in agar suspension (reviewed by Macpherson ${ }^{39}$ ). They also show a variety of cell surface changes, including alterations in cell morphology, membrane glycoproteins and glycolipids, increased transport of small molecules, and increased agglutinability by plant lectins. The infection of a cell in culture by a single infectious sarcoma virus particle leads to the production, by cell division or successive cycles of re-infection or both, of a group of transformed cells: this is the basis of the focus assay for sarcoma viruses. ${ }^{86}$ The leukemia viruses, on the other hand, although capable of replication in fibroblasts, do not usually transform them and other assays are therefore required. An assay for avian myeloblastosis virus, based on the transformation of yolk-sac myeloblasts in vitro, has been developed by Moscovici and Zanetti, ${ }^{45}$ but transformation of hemopoietic cells in vitro by strains of lymphoid leukemia viruses has not yet been achieved. Some leukemia viruses will produce plaques in cultures of certain cell types. ${ }^{54,32,21}$ Other methods for detecting and assaying leukemia viruses include interference tests, where pre-infection of cells with leukemia virus confers resistance to superinfection with sarcoma virus, and virus particle production by assaying $g s$ antigens or reverse transcriptase. Infection with murine mammary tumor viruses cannot yet be assayed in vitro.

In addition to proviruses which may be acquired by infection, all chickens and mice also appear to carry endogenous or 'germinal' proviruses which are transmitted genetically in the chromosomes of the germ cells from one generation to the next. Since endogenous viral genomes are not transmitted as virus particles, the genetic transmission by-passes host-range restrictions (see below) as well as requirements for the synthesis of viral RNA andproteins. They are inherited just like other segments of host chromosomal DNA and do not depend on independent replication. Compelling evidence for the existence of inherited viral genomes ${ }^{68}$ has accrued from the discovery of viral antigens and of DNA homologous to viral RNA in embryonic tissues, the spontaneous release of infectious virus from certain host cells, and perhaps most convincing, experiments in which normal, 'uninfected' cells are induced chemically to release virus in culture. With mouse cells the most effective inducing agents are iodo- and bromo-deoxyuridine, ${ }^{38}$ while with chick embryo cells treatment with methylcholanthrene or nitroquinoline oxide activates virus. ${ }^{78}$ It is not yet clear whether all genetically transmitted viruses are actually oncogenic. However, the genetic transmission of LLV and MMTV is now well established, though the lymphoid and mammary neoplasms typically appear only after the viral genomes become activated to replicate as viruses. Once activated they can also be infectiously transmitted to susceptible hosts and cause further tumors in those hosts.

# INFLUENCE OF HOST GENES ON INFECTION BY RNA TUMOR-VIRUSES 

The susceptibility of the host cell to infection by an RNA tumor virus is controlled by a variety of genetic factors. Some of these factors affect the ability of the virus to penetrate into the host cell, while others affect subsequent intracellular events in the replication cycle of the virus. The host genotype also controls whether the cell will respond to infection by becoming transformed.

In chickens, four loci, the 'tumor virus' or $t v$ loci ( $t v-a, t v-b, t v-c$, and $t v-e$ ), have been described, each affecting susceptibility to a specific virus subgroup (the subgroups A, B, C, and E). In each case the allele for susceptibility is dominant, suggesting that these genes govern the synthesis of a product required for virus growth. It is most likely that this product is a receptor required for virus penetration, ${ }^{73}$ since the resistance can be overcome either by phenotypic mixing with a virus of another subgroup (i.e. with different envelope glycoproteins) or by using Sendai virus to promote entry of the virus into the cell. Virus does adsorb to genetically resistant cells, so that the receptors must be required for a later step in penetration. Another locus which affects susceptibility to subgroup E viruses has been identified by Payne et al. ${ }^{49}$ At this locus, the $I^{v}$ locus, resistance is dominant, but it can be overcome by phenotypic mixing with virus of another subgroup, indicating that the block is again at the level of penetration. Resistance appears to result from saturation of the surface receptors with E subgroup envelope antigen produced by the endogenous virus which belongs to subgroup E , because it is correlated with the presence of E subgroup antigen at the cellsurface and with other indications of the expression of endogenous viral genes. ${ }^{76}$

In the mouse, loci governing the synthesis of surface receptors have not been found. Murine leukemia viruses can be classified according to their host range into three types: N-tropic, B-tropic, and NB-tropic viruses. N-tropic viruses plate 100-1000 fold more efficiently on NIH-Swiss mouse embryo cells than on Balb/c cells. B-tropic viruses plate more efficiently on Balb/c than on NIH-Swiss cells; and NB-tropic viruses plate with equal efficiency on both types of cells. All mouse strains resemble either NIH-Swiss or Balb/c in showing a greater sensitivity to either N-tropic or B-tropic viruses. Crosses between these strains show that a single locus is responsible for these differences in sensitivity. Resistance to each class of virus is dominant: thus the heterozygote is resistant to both N-tropic and B-tropic viruses. The locus is denoted $F v-1$, since it has been found to be identical with a previously identified locus governing sensitivity to Friend leukemia virus. ${ }^{36}$ The resistance appears to be produced at a later step than penetration, because the tropism of a virus strain is not correlated with the serotype (envelope antigens) and cannot be overcome by phenotypic mixing.

Host genes which appear to affect the ability of the infected cell to become transformed have also been identified. One example is the $F v-2$ locus in the mouse: the recessive allele produces an absolute resistance to spleen focus formation by Friend leukemia virus but probably does not affect the replication of the virus in fibroblasts in vitro or in the spleen in vivo. ${ }^{35}$ The mutation thus appears to affect the ability of the erythroid target cell to become transformed by the virus. In chickens it has been found that lines with the same susceptibility to infection by lymphoid leukemia virus strain RPL-12 differ in their incidence of leukemia following infection, ${ }^{47}$ suggesting a genetic effect on the ability of the target cell to become transformed. However, it may be argued that the transformed cells are more readily rejected in the resistant lines. Clearly in vitro systems for studying transformation by leukemia viruses are needed to determine the mechanism by which resistance is produced.

GENETIC CONTROL OF ENDOGENOUS VIRUS EXPRESSION
As described above, normal cells which are not producing virus can become induced to release genetically transmitted, endogenous viruses. The frequency of induction of endogenous virus, both in vivo and in vitro, is also subject to genetic control. Cells of the high leukemic mouse strain AKR can be readily induced to produce an N -tropic virus in vitro; since the cells are sensitive to N -tropic viruses, that is, they are $F v-I^{\mathrm{nn}}$, the induced virus grows to high titre. Crosses of AKR mice to low-virus strains which are also $F v-I^{\text {nn }}$ indicate that inducibility, both in vivo and in vitro, is dominant to non-inducibilityand is determined by two independently segregating genes, $V_{1}$ and $V_{2}$, either of which can give a positive phenotype. ${ }^{51}$ When AKR mice are mated to $F v-I^{\text {bb }}$ strains carrying B-tropic viruses that appear in later life, no induction of the B-tropic virus occurs in the $F_{1}$ or in back-crosses to the $F v-I^{\text {bb }}$ parent, indicating that the induction loci in the AKR strain are specific to the virus carried by that strain. ${ }^{52}$ Indeed, these virus-inducing loci may represent viral rather than host genes. Essentially similar results have been obtained using the Balb/c line. ${ }^{59}$ Inducibility loci have also been demonstrated in chickens of lines 7 and 100: some of the chickens of these strains produce spontaneously the endogenous E subgroup virus of chickens, and crosses between inducible and non-inducible chickens demonstrate that, as with the induction of mouse leukemia virus, inducibility is dominant. ${ }^{8}$

Even when the inducibility alleles are present, virus is spontaneously activated in a small proportion of cells only. Mice and chickens become viremic relatively early in life if they carry both the inducibility allele and the appropriate susceptibility alleles to allow horizontal spread of the virus from cell to cell once it is activated. In Line 100 chickens, where the virus appears fairly early in embryonic development and persists throughout life, the birds become immunologically tolerant. In AKR mice the virus appears too late in embryonic development ${ }^{53}$ to induce classical immunological tolerance, but the antibody response elicited is unable to cope adequately with the infection. ${ }^{46}$

It has not yet been reported whether endogenous viruses induced in vitro are tumorigenic in vivo, although the results of such experiments should soon be known. However, it is likely that at least some genetically transmitted viruses are oncogenic. Meier et al. ${ }^{43}$ have shown that in crosses between the AKR and a low cancer strain, those mice showing infectious virus early in life (that is those which receive one of the two virus-inducing genes from the AKR strain) show a much higher incidence of leukemias and other tumors later in life than those which do not show early signs of virus production. Similarly, the incidence of mammary cancer in mice expressing the genetically transmitted virus is 100 per cent. ${ }^{2}$ However, in Line 100 chickens in which spontaneous production of the endogenous virus of chickens occurs, viremic birds do not appear to have a raised incidence of leukemia, suggesting that the virus is not leukemogenic, at least in this strain. ${ }^{8}$

Genes similar to those controlling the induction of leukemia viruses have also been identified in studies on mouse mammary tumor virus (MMTV). Some strains of this virus, including the classical Bittner strain, or MMTV-S, are transmitted through the milk, but when this is prevented genetic transmission can be demonstrated. This has been most clearly shown in the GR strain of mice, which carries the Muhlbock or 'plaque-inducing' strain of mammary tumor virus, MMTV-P. Crosses between GR mice and low mammary cancer strains indicate that a single autosomal dominant gene is re-sponsible for MMTV-P induction. ${ }^{2}$ Bentvelzen and Daams ${ }^{3}$ used the appearance of an MMTV-specific antigen in the serum of young mice to study the expression of MMTV in crosses between high and low mammary cancer strains. Their results were consistent with the interpretation that a single locus controlled the appearance of MMTV-specific antigen. If this is, in fact, a viral gene, these results imply that the viral genome is integrated at the same site in different strains of mice. In some heterozygotes the antigenpositive allele was dominant, whereas in others the antigen-negative allele was dominant. On the basis of these and other results Bentvelzen ${ }^{2}$ has proposed that control of MMTV expression involves a repressor similar to those involved in controlling the expression of the genes of lysogenic bacteriophage; dominant antigen-positive alleles can be interpreted as operator mutants, while recessive alleles can be interpreted as repressor mutants. Bishop et al. ${ }^{6}$ have measured the amount of MMTV-specific RNA in tissues of a variety of different strains of mice. In general, the amount of RNA correlates with virus production, but in some cases large quantities of MMTV RNA were found in the absence of any detectable MMTV or viral antigen production, suggesting that control may occur at the level of translation.

Partial expression of the endogenous viral genome can also occur and is again under genetic control. Cells which are not producing complete virus may synthesize some gene products specified by the endogenus virus, e.g. $g s$ antigens. ${ }^{48,60}$ In chickens a dominant allele at an autosomal locus determines $g s$ antigen expression ${ }^{48}$ and in most strains of chicken viral envelope antigen synthesis appears concomitantly with $g s$ antigen and has been detected by the ability to complement the envelope defect of Bryan strain RSV when introduced into cells of that genotype, i.e. the endogenous viral gene products perform the function of a helper virus. ${ }^{75}$ Measurements of viral RNA by nucleic acid hybridization suggest that $g s$ negative cells do not produce viral RNA, whereas $g s$ positive cells do. ${ }^{28,6}$ Thus it appears that the $g s$ locus in chickens regulates the partial transcription of the viral genome. Like the inducibility loci, it may represent a viral locus rather than a host locus, and it would be interesting to know if the $g s$ locus is allelic with the inducibility or $V$ locus. In both cases, viral gene expression is dominant, and in chickens which are homozygous for the recessive alleles, exogenous viruses replicate normally. This suggests that the endogenous viral genome is not controlled by L repressor, unless one invokes a widespread occurrence of operator mutants, as Bentvelzen ${ }^{2}$ has suggested for mouse mammary tumor virus. In some mouse strains, $g s$ antigen expression appears to be recessive. ${ }^{60}$

MUTANTS OF AVIAN SARCOMA VIRUSES
Genetic analysis of the avian sarcoma viruses has shown that the genome of avian sarcoma viruses contains genes necessary for the maintenance ofthe transformed state of the cell. This first became evident when 'trans-formation-defective' mutants of sarcoma viruses were isolated from virus stocks treated with UV-light ${ }^{20,69}$ or hydroxylamine. ${ }^{23}$ These mutants replicate in, but can no longer transform fibroblasts, although some of them induce leukemias in vitro, ${ }^{5}$ and we use the term 'transformation-defective' to mean non-transforming for fibroblasts: in this sense lymphoid leukemia viruses are transformation-defective. It was found later that similar transformationdefective mutants segregate spontaneously from clones of several strains of non-defective sarcoma viruses. ${ }^{70,41}$ These mutants have smaller genomes than the non-defective sarcoma viruses from which they arise ${ }^{15}$ and it appears that they arise by deletion of genetic information necessary for transformation of fibroblasts but not necessary for viral replication. The term 'oncogenes' has been proposed for such information by Huebner and Todaro ${ }^{27}$ and we shall use this term in discussing genes necessary for neoplastic transformation, irrespective of whether this information is contained in cells or viruses. Transformation-defective mutants have the converse properties to 'replica-tion-defective' viruses, such as Bryan strain Rous sarcoma virus, which transform cells but require helper viruses for replication. Thus transformation is not necessary for the production of infectious virus, and virus production is not necessary for cell transformation.

Further evidence for the existence of viral 'oncogenes' as distinct from 'virogenes' (the genes necessary for viral replication) has come from the isolation of temperature-sensitive mutants of sarcoma viruses which are capable of viral replication but not cell transformation at the non-permissive temperature. ${ }^{40}$ Many temperature-sensitive mutants for transformation have now been isolated ${ }^{68}$ and all so far behave in a similar way: a cell infected and transformed by one of these mutants at the permissive temperature reverts to a phenotypically normal state when shifted to the non-permissive temperature, and will retransform when shifted down to the permissive temperature. Alterations in cellular growth properties and membrane organization change concomitantly with changes in cell morphology. ${ }^{31,42}$ Wyke ${ }^{81}$ has shown recently that temperature-sensitive mutants of transformation isolated from the Prague strain of Rous sarcoma virus fall into at least four complementation groups, but it is not yet known if these represent distinct genes.

In addition to mutants which affect the maintenance of the transformed state, mutants which are temperature-dependent for viral replication or both replication and transformation have been isolated. For example, Friis and Hunter ${ }^{18}$ have described a mutant of Rous sarcoma virus which is temper $\mathrm{\iota}-$ ture-sensitive for a late step in replication but does not affect cell transformation; as would be expected, this mutant is complemented by leukemia viruses. On the other hand, two reverse transcriptase mutants ${ }^{37}$ show an early, transient defect in both replication and transformation, presumably because the provirus is not formed.Thus the temperature-sensitive mutants can be classified into three types according to their behaviour at the non-permissive temperature: transformation mutants, defective in transformation but not replication; replication mutants, able to produce stable cell transformation but unable to produce infectious virus; and co-ordinate mutants, unable either to replicate or to transform cells at the non-permissive temperature.

THE STRUCTURE OF THE VIRAL GENOME AND THE MECHANISM OF RECOMBINATION

The RNA extracted from the virions of a non-defective strain has a molecular weight of about $10 \times 10^{6}$, but dissociates on heating or treatment with dimethyl sulphoxide into 3 or 4 subunits of molecular weight about $3 \times 10^{6}{ }^{11}$ The association of subunits into the 'native' molecule occurs extracellularly shortly after the virus has matured. ${ }^{15}$ The RNA subunits can be resolved by gel electrophoresis in two size classes, $a$ and $b .{ }^{13}$ Duesberg et al. ${ }^{15}$ prepared stocks of sarcoma viruses from clones of singly infected cells, in order to eliminate any heterogeneity due to the accumulation of transformationdefective mutants or other genetic variants during successive cycles of infection, and found that the RNA of sarcoma viruses grown in this way contained only the higher molecular weight class of subunit, the $a$ subunit. Stocks of leukemia virus, or transformation-defective mutants of a sarcoma virus, contain only the lower molecular weight class of subunit, the $b$ class. (Stocks of sarcoma virus prepared by successive cycles of infection contain both $a$ and $b$ subunits; it is not clear if the $a$ and $b$ subunits are present in distinct particles, or if there are some virions containing both $a$ and $b$ subunits.) Oligonucleotide fingerprinting and hybridization studies ${ }^{15}$ indicate that the $a$ subunits contain the sequences present in the $b$ subunits, as would be expected from the observation that transformation-defective mutants can arise from sarcoma viruses.

The concept that the viral genome is composed of independently replicating subunits is supported by studies on viral recombination. It was found by Vogt ${ }^{71}$ and by Kawai and Hanafusa ${ }^{35}$ that cultures doubly infected with a sarcoma virus and a leukemia virus of another subgroup produced, at high frequency, recombinant viruses containing the host-range (antigenic) marker of the leukemia virus and the transformation marker of the sarcoma virus. Weiss et al., ${ }^{79}$ in a study of recombination between exogenous and endogenous viruses, found that many recombinants were heterozygous for the hostrange marker, that is, they produced progeny of both host-range types. This indicated that the genome is at least partially polyploid, though the progeny rapidly segregated into one or the other host-range type. Furthermore, recombinants were only produced in cells in which the endogenous viralgenome was transcribed into RNA suggesting that the recombination occurred at the RNA level rather than by exchange between DNA molecules.

Two models of the viral genome are consistent with these observations. ${ }^{72}$ In the first model each subunit is genetically distinct, and since each gene is represented only once, the viral genome is haploid. Thus, if the genes within a subunit are represented by numbers enclosed by parentheses, the $a$ subunits of the sarcoma virus genome could be represented as (12345) (6 78910 ) (11121314 15), while the $b$ subunits of a leukosis virus, or of a transforma-tion-defective mutant of a sarcoma virus, would be (345) (89 10) (13 14 15). On this model, simultaneous or successive deletions in each subunit would be necessary to generate a transformation-defective virus. On the second model the subunits of the viral RNA are genetically identical and since each gene is represented several times, the genome is polyploid. Thus, on this model the genome of a sarcoma virus released from a clone of singly infected cells would be represented as (12345) (12345) (12345), while the subunits of a transformation-defective mutant would be (345) (345) (345). A variant of this second model would be to assume that only one subunit is successful in initiating infection, so that the virus would be fionctionally haploid: deletion in one subunit could then result in the production of a transformation-defective variant. Recombination might involve subunit reassortment or the formation of a heterozygote at virus maturation, followed possibly by molecular recombination: this latter step could occur on provirus formation during the next replicative cycle, either by copy-choice transcription of DNA off different RNA subunits or by breakage-reunion between DNA proviruses. The distinction between the haploid and polyploid models may perhaps be elucidated by further recombination studies, which may indicate if there are linkage groups in the genome. It may also be possible to distinguish the models by inactivation studies on sarcoma viruses released by singly infected cells: if the inactivation is multi-hit, then the genome would appear to be polyploid. It should be added that if the genome is polyploid, then the total genome size is only about $3 \times 10^{8}$, and it is difficult to see how all the proteins, believed to be coded by the viral genome on the basis of genetic and biochemical work, can be accommodated in a genome of this size.

RECOMBINATION-DEFECTIVE VIRUSES
Many transforming viruses are defective for replication. Infectious stocks of these viruses always contain 'helper' transformation-defective viruses which complement the defects in replication of the transforming viruses, often by phenotypic mixing, i.e., the helper virus provides structural components for the transforming virus. The classical example of this phenomenon is theBryan strain Rous sarcoma virus (BH-RSV), which apparently does not code for envelope antigens. ${ }^{56}$ When a cell is singly infected with BH-RSV, the cell transforms, but the progeny virus particles it releases are not infectious. If, however, the cell is superinfected with a leukemia 'helper' virus, progeny BH-RSV is now released and carries the envelope specificity of the helper virus; it is called a pseudotype.

When BH-RSV is re-cloned, non-infectious virus is produced once more. This indicates that it is only carried by phenotypic mixing and does not recombine with the helper virus with respect to the envelope antigen. ${ }^{33,79}$ Most isolates of murine sarcoma virus are also defective ${ }^{1}$ though McCarter will describe a non-defective form in this volume. Most isolates of myeloid and erythroid leukemia virus are also defective, for example, avian myeloblastosis virus, ${ }^{45}$ avian myelocytoma 29 virus, ${ }^{22}$ avian erythroblastosis strain R, ${ }^{28}$ and Friend erythroleukemia virus of mice. ${ }^{16,58}$ Many other transforming viruses, for example, strains of feline sarcoma virus and avian sarcoma virus, may prove to be defective because it is known that infectious stocks contain excess transformation-defective viruses which can act as helper viruses. Thus the helper-independent strains of avian sarcoma viruses, which have been used extensively for genetic studies, may prove to be exceptions among transforming viruses. Since the defective character of helper-dependent viruses are stable on long-term passage with helper viruses, they are defective for both replication and recombination. However, it is possible that defective viruses can recombine with their helper viruses for some gene loci but not others. For example, there is suggestive evidence ${ }^{25}$ that BH-RSV recombines with helper viruses in respect to the reverse transcriptase gene but not the envelope antigen gene.

Until we know more about the organization of the viral genome and the mechanism of recombination, we cannot say which stage of recombination does not function in defective viruses. If the genome is essentially haploid and recombination takes place by reassortment of unique segments, there must be a block to reassortment in defective viruses. Since the defective genome is transmitted in virions coded by the helper virus, there is no apparent restriction on the assembly of the genome segments with the helper virus proteins. Therefore one must assume that the genome segments of the two parents cannot be packaged together. Lack of space seems an unlikely reason for this in view of the genetic redundancy implicit in heterozygotes; the genome segment bearing transformatoin genes should be able to displace one of the duplicated segments to yield a haploid, non-defective virion. If the viral genome is polyploid, the block to recombination might occur either for reassortment of genetic elements during virion assembly or for recombination of proviral elements in the next replicative cycle. Defective proviral recombination could be a result of the non-homologous nature of thegenomic segments. If this were the case, defective viruses could transmit the helper virus genome without forming a stable recombinant. The transmitted helper virus genome would be lost as quickly as heterozygotes segregate to homozygotes or haploids ${ }^{79}$ but one should be able to select for non-defective reassortments, at least for a few generations. McCarter's competent murine sarcoma virus (this volume) may be an example of this phenomenon.

# ORIGIN OF TRANSFORMING VIRUSES 

The apparent ubiquity of RNA tumor viruses in mice and chickens has led to two types of models for cancer, both of which stress the importance of RNA tumor viruses.

The first type of model, which includes those proposed by Gross, ${ }^{24}$ Lieberman and Kaplan, ${ }^{34}$ Bentvelzen et al., ${ }^{4}$ and Huebner and Todaro, ${ }^{27}$ is based on the activation of latent, vertically transmitted RNA tumor viruses. The most specific model is that of Huebner and Todaro, who have proposed a universal mechanism of oncogenesis in that all cancer is due to the activation, by carcinogens or age, of genetically transmitted RNA tumor viruses. These viruses are presumed on the model to contain genetic determinants of transformation functions, called 'oncogenes,' in addition to those of viral replication functions, called 'virogenes'27 or 'germinal provirus.'2 The central feature of the viral oncogene model is that the genes necessary for transformation are present in the germ-line and need only be expressed for transformation to occur. Thus the model is phylogenetic, in that the oncogenic information is believed to have been preserved in evolution, and it is also epigenetic in that the oncogenic information is not generated during somatic development but is simply 'switched on' at some time during the life of the organism.

Temin, ${ }^{63,64}$ on the other hand, has argued that oncogenic information would be eliminated by natural selection since it is not of advantage to the host. Although sarcoma viruses do have functions necessary for the transformation of fibroblasts, it is not yet known whether the endogenous, genetically transmitted viruses have analogous functions involved in leukemogenesis and mammary carcinogenesis. Temin ${ }^{64}$ points out that transformation by lymphoid leukemia viruses and mammary tumor viruses is inefficient; there is usually a long time-lag between the onset of virus production and the development of tumors. He therefore considers that those viruses, rather than carrying specific oncogenes, 'behave more like non-viral carcinogens in their mechanisms of neoplastic transformation; that is, they increase the probability of a misevolution of cellular genetic elements, the protoviruses.' Temin ${ }^{63}$ argued originally that cancer results from somatic mutation of protoviruses, which are involved in growth control and which replicate ina way similar to that of RNA tumor viruses, i.e. by information transfers from DNA to RNA and back to DNA, because the protoviruses can specify reverse transcriptase. This allows not only for mutation but for changes in location of genetic elements. The RNA tumor viruses, on Temin's model, have evolved from protoviruses and therefore have homology with them. However, reverse transcriptases with properties similar to the viral enzyme have not been detected in normal somatic cells ${ }^{30,80}$ and the evolution of virogenes and oncogenes from protoviruses remains highly speculative.

The protovirus and oncogene models are not wholly mutually exclusive, and Todaro and Huebner ${ }^{67}$ have adopted some of the precepts of the protovirus hypothesis, such as the independent control and location of virogenes and oncogenes. It may well be that neither hypothesis is correct, and that most natural cancers are caused neither by RNA tumor viguses nor by elements replicating in the same way as these viruses. Nevertheless, it seems plausible to generalize from studies with transforming viruses and postulate that malignant growth depends on the expression of specific cellular genes, whether these are present in the germ-line or not, although these genes need have no association with viruses. What, then, is the origin of the oncogenes borne by RNA tumor viruses? As mentioned in the introduction, RNA viruses which cause rapidly developing tumors, such as the sarcoma viruses and myeloid or erythroid leukemia viruses, do not occur commonly in nature. One would certainly expect strong natural selection against the perpetuation of such highly oncogenic viruses, or at least against their expression, particularly when the oncogenes of these viruses are not required for viral replication.

In Figures 2 and 3 we present a model which is a collage of the protovirus and oncogene concepts. We propose that oncogenes evolve not from protoviruses, but from normal genes involved in growth control. These genes may mutate in somatic cells to cause neoplastic growth. Viruses which are not transforming for any type of tissue - virogenes without oncogenes - presumably originate from cellular elements replicating via reverse transcriptase, that is, protoviruses. The oncogenes are not homologous to virogenes and would not commonly be transmitted or encapsulated as RNA tumor viruses. However, we propose that on rare occasions this may happen, giving rise to infectious, transforming agents. Such a virus would arise by a rare recombination event in which the oncogenes would become linked to the unrelated virogenes.

We further propose that transforming viruses can arise from completely non-oncogenic viruses or from transformation-defective viruses by recombination with oncogenes (Fig. 3). It is significant that the murine sarcoma viruses that have appeared de novo in the laboratory have arisen from animals or cells infected with lymphoid leukemia viruses (LLVs). ${ }^{88}$ Pre-![img-1.jpeg](img-1.jpeg)

Figure 2 Model of the evolution of RNA tumor viruses.
liminary studies (H.G. Purchase, P.K. Vogt, and R.A. Weiss, unpublished data) indicate that transforming viruses may arise similarly on rare occasions from avian LLVs. Leaving aside for the moment the question whether LLVs carry specific oncogenes for lymphoblastic transformation, it is clear that they could serve to rescue further oncogenes by recombining with them in the same way as proposed for virogenes. Indeed, as Temin ${ }^{64}$ pointed out, the replication of LLVs with their machinery for reverse transcription and
![img-2.jpeg](img-2.jpeg)

Figure 3 Origin of transforming viruses. Steps 1-3 involve rare genetic alterations (non-homologous recombination); steps 4-5 involve common genetic deletions.![img-3.jpeg](img-3.jpeg)

Figure 4 A model for a defective transforming virus genome.
integration, provides enhanced opportunities for somatic cell mutation. This will accelerate the evolution of new oncogenes from normal growth regulatory elements.

In other words, transforming viruses may evolve from transformationdefective viruses by acquiring and transducing cellular oncogenes. In most cases this would occur by substitution of certain virogenes by oncogenes, giving rise to a defective transforming virus, ${ }^{55}$ analogous to defective transducing phages (Fig. 4). This type of substitution would explain the simultaneous occurrence of defects in replication and recombination. ${ }^{77}$ Backrecombination with the helper virus for the substituted loci would be equally rare and would once again result in a transformation-defective virus, virtually indistinguishable from the helper virus itself. But recombination could take place frequently between virogenes of the, helper virus and the homologous loci of the defective transforming virus providing they are not closely linked to the oncogenes. This may explain the apparent ability of BH-RSV to form recombinants for the reverse transcriptase locus. If redundancy in the genome is allowed for, non-defective (helper-independent) transforming viruses may arise (Figs. 3 and 4), though these, as we have described, tend to segregate transformation-defective progeny, and possibly replicationdefective progeny too.

Our model implies that transforming viruses which have arisen independently may have derived their oncogenes from quite different sources. This may explain why transformation mutants of apparently similar avian sarcoma viruses of independent origin do not complement each other, ${ }^{81}$ in contrast with widespread complementation of virogene mutants. The independent origin of viral oncogenes from growth-control elements operating in different cell types may also explain another feature of the biology of RNA tumor viruses, namely the target cell specificity of transformation. Most strains of virus transform a limited range of cell types, while replicating in a wide variety of tissues. The most striking example is the lymphoidleukemia viruses; however, the inefficiency of transformation by these viruses suggests that the mechanism of transformation by these viruses may be in some way different (see below). The myeloid and erythroid leukemia viruses, on the other hand, resemble the sarcoma viruses in causing rapid cell transformation, but only one or a few cell types are transformed. Friend leukemia virus, for instance, transforms only cells of the erythroid series; the Harvey strain of murine sarcoma virus induces both sarcomata and erythroblastosis (J. Harvey, personal communication), while the FBJ strain of murine sarcoma virus does not induce erythroid transformation (D.B. Jones and M. Moore, personal communication). Similarly, in vitro studies show that avian myeloblastosis virus transforms myeloblasts of the chick embryo yolk-sac and other tissues ${ }^{10}$ but does not appear to transform fibroblasts, while cloned myelocytomatosis virus 29 transforms both myeloblasts and fibroblasts. ${ }^{22}$ Thus most transforming viruses exhibit some degree of target-cell specificity, but some viruses transform a broader range of cell types than others. We may expect transforming viruses to broaden the 'hostrange' of cell types which they can transform, either by mutation or further recombination, particularly under conditions of artificial selection in tumor virus laboratories. Genetic variants of transforming viruses which affect the degree of neoplastic transformation or normal differentiation of the target cell will also evolve, as has been observed with Friend virus. ${ }^{44}$ In short, two common features of transforming viruses, defectiveness and target-cell specificity, reflect, according to our model, the origin of these viruses by recombination between viral genomes and different tissue-specific growth control elements.

It is possible that the oncogene and virogene segments of the viral genome contain their own initiation and termination signals for transcription and translation. The generation of $b$ subunits from $a$ subunits, which occurs when transformation-defective mutants arise from helper-independent sarcoma viruses, could be explained by internal initiation or termination of provirus transcription. The oncogenes may remain sensitive to many of the control mechanisms operating during normal differentiation, so that the transcription of oncogenes may be selectively repressed while virogene transcription proceeds. In this case, transformation-defective viruses could arise from partial transcription of the provirus; the RNA segments comprising the genome of the virus particle are probably identical with viral messenger RNA transcripts. For instance Dodge and Moscovici ${ }^{10}$ have suggested that when myeloblasts that are producing avian myeloblastosis virus mature into granulocytes and macrophages they cease to produce transforming virus while retaining the ability to produce the transformation-defective 'helper' virus. It would be interesting to observe whether a similar phenomenon occurs after the induction of maturation of Friend leukemia cells. ${ }^{17}$The lymphoid leukemia viruses (LLV), which occur in nature, and perhaps the mammary tumor viruses, may represent the most primitive forms of RNA tumor virus. The inefficiency of transformation by these viruses may be explained in two ways. One could argue, as Temin does, that these viruses do not contain oncogenes, but transform by causing alterations in cellular control elements: for example, the reverse transcriptase might cause translocation of these elements in such a way that their expression is altered. This type of model does not readily explain the target cell specificity of transformation by LLVs, which replicate in many cell types which they do not typically transform. The target cell specificity of LLVs differs according to the species: in chickens LLVs transform B cells, ${ }^{7}$ while in mice LLVs transform T cells. ${ }^{57}$ It is noteworthy, however, that LLVs in high doses can give rise to sarcomas (Purchase, personal communication) and that LLVs act as enhancing co-carcinogens during the transformation of fibroblasts by polycyclic hydrocarbons, ${ }^{50}$ suggesting that their target cell specificity is not complete. The alternative explanation for the inefficiency of leukemia virus transformation assumes that these viruses do contain oncogenes, but that under certain conditions cellular transformation may be delayed or prevented: for example, the expression of the oncogenes may be suppressed, or the cells may not be sensitive to their products. Indeed, the latent period for leukemogenesis may have been somewhat overestimated. Thus, in the chicken, Cooper et al. ${ }^{7}$ have found foci of altered cells in the bursa of Fabricius within 8 weeks of injection of leukemia virus. Similarly, the long latent period for the development of mammary tumors can be drastically reduced by appropriate hormone treatments (Nie, Hilgers, Lenseliak, personal communication).

The model presented here for the evolution of transforming viruses from virogenes or transformation-defective viruses and cellular oncogenes, in fact, represents a special case of transduction of cellular genetic information by RNA 'tumor viruses.' It is quite possible that other kinds of genes may be transduced as well. ${ }^{77}$

# CONCLUSION 

After surveying the genetic behaviour of RNA tumor viruses, we have put forward a model of the interrelationships of viral and cellular genetic elements. The model combines features of the oncogene and protovirus hypotheses and suggests that the structure and function of the genome of RNA tumor viruses reflects their evolutionary history. The model can explain several apparently unrelated features of the biology of RNA tumor viruses, such as the occurrence of defective strains, and the relationship between neoplastic transformation and the epigenetic state of the cell.# REFERENCES 

1 Aaronson, S.A., Bassin, R.H., and Weaver, C. Comparison of murine sarcoma viruses in nonproducer and $\mathrm{S}+\mathrm{L}-$-transformed cells. J. Virol., 9: 701-704, 1972
2 Bentvelzen, P. Hereditary infections with mammary tumor viruses in mice. In RNA viruses and host genome in oncogenesis (P. Emmelot and P. Bentvelzen, eds.). Amsterdam: North-Holland, pp. 309-337, 1972
3 Bentvelzen, P. and Daams, J.H. Hereditary infections with RNA viruses that cause mammary cancer in mice. In Possible episomes in eukaryotes. ivth Lepetit Colloquium (L.G. Silvestri, ed.). Amsterdam: North-Holland, pp. 74-87, 1973
4 Bentvelzen, P., Timmermans, A., Daams, J.H., and van der Gugten, A. Genetic transmission of mammary tumor inciting viruses in mice: possible implications for murine leukemia. Biblio. Haematol., 31: 101-103, 1968
5 Biggs, P.M., Milne, B.S., Graf, T. and Bauer, H. Oncogenecity of non-transforming mutants of avian sarcoma viruses. I: Gen. Virol., 18: 399-403, 1973
6 Bishop, J.M., Jackson, N., Quintrell, N., and Varmus, H.E. Transcription of RNA tumor virus genes in normal and infected cells. In Possible episomes in eukaryotes. ivth Lepetit Colloquium (L.G. Silvestri, ed.). Amsterdam: North-Holland, pp. 61-73, 1973
7 Cooper, M.D., Payne, L.N., Dent, P.B., Burmester, B.R., and Good, R.A. Pathogenesis of avian lymphoid leukosis. I. Histogenesis. J. Natl. Cancer Inst., 91: $373-389,1968$
8 Crittenden, L.B., Smith, E.J., Weiss, R.A., and Sarma, P.S. Host gene control of endogenous avian leukosis virus production. Virology (in press)
9 Di Stefano, H.S. and Dougherty, R.M. Mechanisms for congenital transmission of avian leukosis virus. J. Natl. Cancer Inst., 37: 860-883, 1966
10 Dodge, W.H. and Moscovici, C. Colony formation by chicken hematopoietic cells and virus-induced myeloblasts. J. Cell Physiol., 81: 371-386, 1973
11 Duesberg, P.H. Physical properties of Rous sarcoma virus RNA. Proc. Natl. Acad. Sci. u.s., 60: 1511-1518, 1968
12 Duesberg, P.H. and Canaani, E. Complementarity between Rous sarcoma virus (RSV) and the in vitro-synthesized DNA of the virus-associated DNA polymerase. Virology, 42: 783, 1970
13 Duesberg, P.H. and Vogt, P.K. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc. Natl. Acad. Sci. u.s., 67: 1673-1680, 1970
14 Duesberg; P.H., Martin, G.S., and Vogt. P.K. Glycoprotein components of avian - and murine RNA tumor viruses. Virology, 41: 631-646, 1970
15 Duesberg, P.H., Canaani, E., van der Helm, K., Lai, M.M.C., and Vogt, P.K. News and views on avian tumor virus RNA. In Possible episomes in eukaryotes. ivth Lepetit Colloquium (L.G. Silvestri, ed.). Amsterdam: North-Holland, pp. 142-152, 1973
16 Fieldsteel, A.H., Kurahara, C., and Dawson, P.J. Moloney leukemia virus as a helper in retrieving Friend virus from a non-infectious reticulum cell sarcoma. Nature, 223: 1274, 1969
17 Friend, C., Scher, W., Holland, I.G., and Sato, T. Hemoglobin synthesis in murine virus-induced leukemia cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. u.s., 68: 378-382, 197118 Friis, R.R. and Hunter, E. A temperature-sensitive mutant of Rous sarcoma virus that is defective for replication. Virology, 53: 479-483, 1973
19 Garapin, A.C., McDonnell, J.P., Levinson, W.E., Quintrell, N., Fanshier, L., and Bishop, J.M. DNA polymerase associated with Rous sarcoma virus and avian myeloblastosis virus: properties of the enzyme and its product. J. Virol., 6: 589, 1970
20 Goldé, A. Radio-induced mutants of the Schmidt-Ruppin strain of Rous sarcoma virus. Virology, 40: 1022-1029, 1970
21 Graf, T. A plaque assay for avian RNA tumor viruses. Virology, 50: 567-578, 1972
22 Graf, T. Two types of target cells for transformation with avian myelocytomatosis virus. Virology, 54: 398-413, 1973
23 Graf, T., Bauer, H., Gelderblom, H., and Bolognesi, D.P. Studies on the reproductive and cell-converting abilities of avian sarcoma viruses. Virology, 43: 427-441, 1971
24 Gross, L. Attempt to recover a filterable agent from X-ray-induced leukemia. Acta Haematol., 19: 353-361, 1958
25 Hanafusa, H. and Hanafusa, T. Noninfectious RSV deficient in DNA polymerase. Virology, 43: 313-316, 1971
26 Hayward, W.S. and Hanafusa, H. Detection of avian tumor virus RNA in uninfected chick embryo cells. J. Virol., 11: 157-167, 1973
27 Huebner, R.J. and Todaro, G.J. Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci. u.s., 64: 1087-1094, 1969
28 Ishizaki, R. and Shimizu, T. Heterogeneity of strain R avian (erythroblastosis) virus. Cancer Research, 30: 2827, 1970
29 Ishizaki, R., Langlois, A.J., Chabot, J., and Beard, J.W. Component of strain MC29 avian leukosis virus with the property of defectiveness. J. Virol., 8: 821-827, 1971
30 Kang, C.-Y. and Temin, H.M. Endogenous RNA-directed DNA polymerase activity in uninfected chicken embryos. Proc. Natl. Acad. Sci. u.s., 69: 1550-1554, 1972
31 Kawai, S. and Hanafusa, H. The effects of reciprocal changes in temperature on the transformed state of cells infected with a Rous sarcoma virus mutant. Virology, 46: 470-479, 1971
32 Kawai, S. and Hanafusa, H. Plaque assay for some strains of avian leukosis virus. Virology, 48: 126-135, 1972
33 Kawai, S. and Hanafusa, H. Genetic recombination with avian tumor virus. Virology, 49: 37-44, 1972
34 Lieberman, M. and Kaplan, H.S. Leukemogenic activity of filtrates from radiationinduced lymphoid tumors of mice. Science, 130: 387-388, 1959
35 Lilly, F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia in mice. J. Natl. Cancer Inst., 45: 163, 1970
36 Lilly, F. and Pincus, T. Genetic control of murine viral leukemogenesis. Advances in Cancer Research, 17: 231-277, 1972
37 Linial, M. and Mason, W.S. Characteristics of two conditional early mutants of Rous sarcoma virus. Virology, 53: 258-273, 1973
38 Lowy, D.R., Rowe, W.P., Teich, N., and Hartley, J.W. Murine leukemia virus: high frequency activation in vitro by 5 -iododeoxyuridine and 5 -bromodeoxyuridine. Science, 174: 155-156, 1971
39 Macpherson, I.A. The characteristics of animal cells transformed in vitro. Advances in Cancer Research, 13: 169-215, 1970
40 Martin, G.S. Rous sarcoma virus: A function required for maintenance of the transformed state. Nature, 227: 1021-1023, 197041 Martin, G.S. and Duesberg, P.H. The a subunit in the RNA of transforming avian tumor viruses: I. Occurrence in different virus strains. II. Spontaneous loss resulting in nontransforming variants. Virology, 47: 494-497, 1972
42 Martin, G.S., Venuta, S., Weber, M., and Rubin, H. Temperature-dependent alterations in sugar transport in cells infected by a temperature-sensitive mutant of Rous sarcoma virus. Proc. Natl. Acad. Sci. u.s., 68: 2739-2741, 1971
43 Meier, H., Taylor, B.A., Cherry, M., and Huebner, R.J. Host-gene control of type C RNA tumor virus expression and tumorigenesis in inbred mice. Proc. Natl. Acad. Sci. u.s., 70: 1450-1455, 1973
44 Mirand, E.A. Erythropoietic response of animals infected with various strains of Friend virus. Natl. Cancer Inst. Monog., 22: 483-503, 1966
45 Moscovici, C. and Zanetti, M. Studies on single foci of hematopoietic cells transformed by avian myeloblastosis virus. Virology, 42: 61-67, 1970
46 Oldstone, M.B.A., Aoki, T., and Dixon, F.J. The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunological tolerance. Proc. Natl. Acad. Sci. u.s., 69: 134-138, 1972
47 Payne, L.N. Interactions between host genome and avian RNA tumor viruses. In RNA viruses and host genome in oncogenesis (P. Emmelot and P. Bentvelzen, eds.). Amsterdam: North-Holland, pp. 93-115, 1972
48 Payne, L.N. and Chubb, R. Studies on the nature and genetic control of an antigen in normal chick embryos which reacts in the COFAL test. J. Gen. Virol., 3: $379-391,1968$
49 Payne, L.N., Pani, P.K., and Weiss, R.A. A dominant epistatic gene which inhibits cellular susceptibility to RSV (RAV-O). J. Gen. Virol., 13: 455-462, 1971
50 Rhim, J.S., Vass, W., Cho, H.Y., and Huebner, R.J. Malignant transformation induced by 7, 12-dimethylbenz (a) anthracene in rat embryo cells infected with Rauscher leukemia virus. Intern. J. Cancer, 7: 65-74, 1971
51 Rowe, W.P. Studies of genetic transmission of murine leukemia virus by AKR mice: I. Crosses with $F v-I^{n}$ strains of mice. J. Exp. Med., 136: 1272-1285, 1972
52 Rowe, W.P. and Hartley, J.W. Studies of genetic transmission of murine leukemia virus by AKR mice: II. Crosses with Fv-Ib strains of mice. J. Exp. Med., 136: 1286-1301, 1972
53 Rowe, W.P. and Pincus, T. Quantitative studies of naturally occurring murine leukemia virus infection of AKR mice. J. Exp. Med., 135: 429-436, 1972
54 Rowe, W.P., Pugh, W.E., and Hartley, J.W. Plaque assay techniques for murine leukemia viruses. Virology, 42: 1136-1139, 1971
55 Rubin, H. Virus defectiveness and cell transformation in the Rous sarcoma. J. Cell Comp. Physiol., 64: (Suppl. 1), 173-178, 1964
56 Scheele, C.M. and Hanafusa, H. Proteins of helper-dependent RSV. Virology, 45: $401-410,1971$
57 Siegler, R. and Rich, M.A. Pathogenesis of murine leukemia. Natl. Cancer Inst. Monogr., 22: 525-547, 1966
58 Steeves, R.A. and Eckner, R.J. Host-induced changes in infectivity of Friend spleen focus-forming virus. J. Natl. Cancer Inst., 44: 587-594, 1970
59 Stephenson, J.R. and Aaronson, S.A. A genetic locus for inducibility of C-type virus in Balb/c cells: the effect of a non-linked regulatory gene on detection of virus after chemical activation. Proc. Natl. Acad. Sci. u.s., 69: 2798-2801, 1972
60 Taylor, B.A., Meier, H., and Huebner, R.J. Genetic control of the group-specific antigen of murine leukaemia virus. Nature, 241: 184-186, 197361 Temin, H.M. Nature of the provirus of Rous sarcoma. Natl. Cancer Inst. Monogr., 17: 557-570, 1964
62 Temin, H.M. Studies on carcinogenesis by avian sarcoma viruses: V. Requirement for new DNA synthesis and for cell division. J. Cell Physiol., 69: 53-64, 1967
63 Temin, H.M. Malignant transformation of cells by viruses. Perspectives Biol. Med., 14: 11-26, 1970
64 Temin, H.M. The protovirus hypothesis and cancer. In RNA viruses and host genome in oncogenesis (P. Emmelot and P. Bentvelzen, eds.). Amsterdam: North-Holland, pp. 351-363, 1972
65 Temin, H.M. and Baltimore, D. RNA-directed DNA synthesis and RNA tumor viruses. Advances in Virus Research, 17: 129-186, 1972
66 Temin, H.M. and Rubin, H. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. Virology, 6: 669-688, 1958
67 Todaro, G.J. and Huebner, R.J. The viral oncogene hypothesis: new evidence. Proc. Natl. Acad. Sci. u.s., 69: 1009-1015, 1972
68 Tooze, J. (ed.) The molecular biology of tumor viruses. Cold Spring Harbor Laboratory, pp. 1-743, 1973
69 Toyoshima, K., Friis, R.R., and Vogt, P.K. The reproductive and cell-transforming capacities of avian sarcoma virus B77: inactivation with UV light. Virology, 42: $163-170,1970$
70 Vogt, P.K. Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. Virology, 46: 939-946, 1971
71 Vogt, P.K. Genetically stable reassortment of markers during mixed infection with avian tumor viruses. Virology, 46: 947-952, 1971
72 Vogt, P.K. The genome of avian RNA tumor viruses: a discussion of four models. In Possible episomes in eukaryotes, ivth Lepetit Colloquium (L.G. Silvestri, ed.). Amsterdam: North-Holland, 1973
73 Vogt, P.K., Moscovici, C., and Duff, R. Host resistance and the biological analysis of avian tumor virus infections. Can. Cancer Conf., 8: 286-312, 1969
74 Weiss, R.A. Cell transformation induced by Rous sarcoma virus: Analysis of density dependence. Virology, 46: 209-220, 1971
75 Weiss, R.A. Helper viruses and helper cells. In RNA viruses and host genome in oncogenesis (P. Emmelot and P. Bentvelzen, eds.). Amsterdam: North-Holland, pp. 117-135, 1972
76 Weiss, R.A. Some interactions between endogenous and exogenous avian RNA tumor viruses. In ICN-UCLA Conference on Virus Research (C.F. Fox and W.S. Robinson, eds.). New York: Academic Press, 1973
77 Weiss, R.A. Transmission of cellular genetic elements by RNA tumor viruses. In Possible episomes in eukaryotes. rith Lepetit Colloquium (L.G. Silvestri, ed.). Amsterdam: North-Holland, 1973
78 Weiss, R.A., Friis, R.R., Katz, E., and Vogt, P.K. Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology, 46: 920-938, 1971
79 Weiss, R.A., Mason, W.S., and Vogt, P.K. Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. Virology, 52: $535-552,1973$
80 Weissbach, A., Bolden, A. Muller, R.;Hanafusa, H., and Hanafusa, T. Deoxyribonucleic acid polymerase activities in normal and leukovirus-infected chicken embryo cells. J. Virol., 10: 321-327, 1972
81 Wyke, J.A. Complementation of transforming functions by temperature-sensitive mutants of avian sarcoma virus. Virology, 54: 28-36, 1973# Occurrence, properties, and interrelationships of leukemia and sarcoma viruses of the mouse 

J.A. McCARTER, J.K. BALL, and P.K.Y. WONG<br>Cancer Research Unit, University of Western Ontario, London, Ontario

This paper is about leukemia and sarcoma viruses of the mouse. It deals with the occurrence of these viruses, some of their properties, relationships between them, and their possible significance in the causation of cancer.

These viruses belong to a group known as C-type particle viruses. They are fairly large in diameter ( $70-100$ millimicrons). They consist of a core that contains single-stranded ribonucleic acid (RNA) and around the core is an envelope containing proteins specified by the virus and other materials derived from cell membranes. The viruses are formed by budding at cell membranes. When isolated from mature virions using conditions that should permit the native state of the RNA to be retained, the size of the RNA appears to be of the order of 10 million daltons. When denaturing conditions are used the RNA appears to come apart into pieces, each with a molecular weight of about 3 million daltons, together with smaller molecules of RNA (4s). ${ }^{9,22,46}$ This result suggests that the RNA of the mature virion consists of several segments. However, the same result would be observed if two or more single-stranded interruptions had been produced during isolation of the RNA. It must be concluded that the structure of the RNA in the infectious virion is not known.

Some of the protein constituents of the viruses are recognizable by their antigenic properties: for example, there are intraviral components shared by various C-type viruses (group-specific antigens) which are of use in recognizing the presence of viral functions when expressed in cells. Other antigens are type-specific, viral envelope antigens, shared by various groups of murine leukemia viruses (e.g., Gross, Friend-Moloney-Rauscher). ${ }^{7}$

C-type particle viruses have been found in the cells of many vertebrates. The best studied system is the avian system. Studies of the murine system, although not so advanced as the avian system, are valuable because they extend our knowledge of this class of viruses to a mammalian system and may provide models for a search for and study of human viruses of a similarkind. The similarity between the murine and avian systems is obvious, but each has its advantages over the other. In the mouse, many established lines of cells are available in which to propagate the viruses and this is a distinct advantage over the avian system which is dependent on the use of embryo fibroblasts. Also, in the mouse, assays have become available, some of recent origin, which are better than those in the avian system. On the other hand, the avian viruses are better defined in terms of their abilities to grow in cell cultures derived from different hosts than are the murine viruses, thus providing a set of markers, 'host-range markers,' that are useful in a variety of studies. ${ }^{77}$ In the mouse system, host-range restrictions permit classifying murine virus in only three groups. ${ }^{36}$

In each system viruses can be grouped into two classes: transforming and non-transforming viruses, or sarcoma and leukemia (or leukosis) viruses respectively. Recently (Duesberg and Vogt, 1973, icn-ucla Conference) the names have been suggested: transforming and transformation-'defective' viruses respectively. We shall deat with the leukemia, or transformationdefective viruses first.

# MURINE LEUKEMIA VIRUSES 

Genetic information of murine leukemia viruses is now known to be present in every strain of mouse that has been tested. ${ }^{38,39,71}$ In some inbred strains of mice, like AKR and C58, which develop leukemia spontaneously with high incidence, virus can be demonstrated through transmission to other mice by means of extracts of tissues ${ }^{30}$ or to cells in tissue culture. ${ }^{35}$ In other strains, for example BALB/c which has a low incidence of spontaneous leukemia, infectious virus may be detectable only occasionally, for example, late in life, but gs antigens, characteristic of the murine leukemia viruses may be found in embryos and in a number of tissues, including some tumors. ${ }^{26,38,49}$ In the strain NIH Swiss, viral antigens have been found in normal hematopoietic tissues, but no infectious virus has ever been isolated from NIH Swiss mice.

There are, therefore, different expressions of viral information among different strains of mice, and even in the same strain at different times, from fully infectious, transmissible virus at one extreme to the expression of limited viral functions, for example, that function concerned with the formation of gs antigen at the other.

In vivo, in some strains of mice at least, virus may sometimes be 'activated' by treatment of the animals with ionizing radiation ${ }^{40}$ or chemicals ${ }^{10}$ or graft-versus-host reaction ${ }^{19,37}$ or by infection with another virus. ${ }^{52}$ The viruses that are induced may be infectious in vivo, but non-infectious, or only slightly so, in vitro. Generally, induced viruses grow less well in cells derived from thestrain in which they were induced than in those from a strain having a different tropism.

The radiation-induced leukemia virus Rad LV, ${ }^{40}$ and that virus induced by a chemical carcinogen ${ }^{10}$ are examples of viruses that are infectious when given to mice and readily induce tumors similar to those from which they were isolated. But these viruses do not grow well, if at all, in tissue culture. The reason for this is not apparent.

When mouse cells are cultured in vitro, virus may be produced, either spontaneously ${ }^{5,69}$ or after treatment of the cells in some manner. ${ }^{42,45,66}$ The most efficient inducing substances found thus far are 5-iododeoxyuridine and 5-bromodeoxyuridine. The mechanism of their action is not known.

To sum up to this stage, genetic information of murine leukemia viruses is present in every strain of mouse that has been tested, often in covert rather than overt form, and often the information is incomplete, either because the cells contain only part of the complete genome of a virus or because only a part of the complete genome is expressed. It is, of course, difficult to distinguish between these two models. Additionally, there is the question whether the viral information is carried as an integral part of the host cells' genome or if it is carried epigenetically, for example, as an episome. Are the viral genes integrated into the host's own genetic material, to be expressed partially or completely, as are the host's own genes under certain conditions, or does the virus exist in the cell as a chronic infectious agent, held in check at levels too low to be detected ordinarily, but replicating to detectable levels when the check removed? It is known, for example, that carcinogenic hydrocarbons diminish the levels of interferon produced by cells in culture ${ }^{20}$ and one can easily construct a hypothesis based on this observation, to account for the apparent induction of virus by chemical carcinogens.

The weight of evidence favours the idea that the viral information is integrated into the genome of the cell. Aaronson, Todaro, and Scolnick ${ }^{5}$ showed that clonal lines of BALB/3T3 cells which were free of detectable virus were induced to release infectious virus by treatment with 5 -bromodeoxyuridine, and all clones tested were inducible. Similarly, the evidence is compelling that the genome of potentially infectious murine leukemia virus is present in ur:expressed form in all cells of the AKR embryo. ${ }^{56}$

Genetic factors influencing the induction of C-type RNA viruses have been studied. Stockert and her colleagues ${ }^{65}$ have determined the chromosomal location of one of the two loci that are involved in the induction of murine leukemia virus in AKR mice. This locus may be the integrated genome of the virus. Also, evidence obtained by Stephenson and Aaronson ${ }^{64}$ is that in BALB/c cells there is a single locus for endogenous C-type virus and its expression is controlled by a non-linked regulatory gene.

This evidence supports the hypothesis of Todaro and Huebner ${ }^{71}$ that thegenome responsible for producing gs antigen, infectious virus, and the tumorigenic functions is part of the inherited genetic material of the cell. These authors presume that the viral information is in the DNA of all cells of normal vertebrates and is, therefore, vertically transmitted from parent to progeny i.e., the virogenes and oncogenes are cellular genes.

Several lines of evidence indicate that cells of the chick are similar to cells of the mouse in that normal chick cells carry at least a portion of the genetic information of RNA tumor viruses. ${ }^{21,51-33,53,78}$ Biochemical techniques have demonstrated that viral RNA (or DNA transcribed in vitro from viral RNA) is hybrid'zable with cellular DNA. This indicates the presence in cellular DNA of base sequences homologous to those of viral RNA ${ }^{19.25}$ (Varmus, H. icn-ucla Virus Research Conference, Squaw Valley, Calif., 1973).

It appears, therefore, for the two best studied systems, mouse and chicken, that viral information is an integral part of the genetic material of cells. The techniques employed are used in intensive studies of human tissues to find similar viral information. ${ }^{8,16}$

In some instances, but not all, these viruses are oncogenic. For example, the Gross virus from AKR mice and Rad LV from C57/B1 produce leukemia upon administration to susceptible animals, but they do not produce solid tumors, except as noted later.

The leukemia viruses are not cytopathogenic to mouse cells in tissue culture and do not 'transform' them, but this statement is made with qualifications that will become apparent later. The terms 'transform' and 'transformation' as used here mean a morphological alteration and change in the growth pattern of the cells which are readily recognizable.

It is claimed that mouse embryo fibroblasts subjected to infection with murine leukemia viruses and concomitant treatment with carcinogenic agents do transform cells, at least morphologically. ${ }^{24,55,56}$ Are the endogenous leukemia viruses involved in the induction of sarcomas and carcinomas by chemical carcinogens? They are undoubtedly involved in the induction of thvmic lymphoma in the C57/B1 mice by X-rays and in the CFW mouse by 7,12-dimethylbenz(a) anthracene (DMBA), but are these special cases? Over the years there have been many attempts to measure the combined effects of viruses and chemical carcinogens (review by Roe and Rowson ${ }^{57}$; McCarter and Ball, in press). In fact there have been no convincing demonstrations that the effects of combined treatment with virus and chemicals are more than additive. One has to consider, therefore that the leukemia viruses or, perhaps it is better to call them 'non-transforming' or 'trans-formation-defective' viruses, do not contain genes that, when derepressed can lead to the production of solid tumors. The production of leukemia by these viruses, if they are active at all in producing disease, may be causedby their containing other oncogenic information. Or, possibly, leukemia is a special sort of neoplasia different from that represented by solid tumors. This idea could be elaborated but would represent a diversion from the main topic of this lecture. If the so-called leukemia viruses are not involved in the production of solid tumors, and do not contain oncogenes or 'transforming' genes, then what of the sarcoma viruses?

# MURINE SARCOMA VIRUSES 

The murine sarcoma viruses are able to 'transform' cells in culture, including cells of mouse, rat, hamster, and man. ${ }^{47}$ Much less is known about the origins of murine sarcoma viruses than about murine leukemia viruses and less is known about their composition, because, until recently, it has not been possible to obtain preparations of murine sarcoma virus free of murine leukemia virus.

The Moloney strain of murine sarcoma virus (Mol-MuSV) ${ }^{48}$ and Kirsten sarcoma virus ${ }^{41}$ were obtained from rl.abdomyosarcomas that appeared in mice injected with leukemogenic viruses which had, in turn, been obtained from leukemic tissue. It is not known whether the sarcoma viruses were present in the material injected into the mice or were, perhaps, contributed by the injected mice. Dr J.K. Ball, Mrs D. Harvey, and $\mathrm{I}^{11}$ have recently shown that a clone-purified non-transforming virus (JLSV9-MuLV) isolated from an established cell line in tissue culture and having no demonstrable content of murine sarcoma virus, induces rhabdomyosarcomas in several strains of mice. From these sarcomas and from the plasma of mice bearing the tumors, two viruses have been isolated; one is a murine sarcoma virus that produces foci of transformed cells in an appropriate system and the other is a virus having the properties of the injected non-transforming virus. Where did the transforming virus come from? We have to consider the following possibilities: (1) the JLSV9-MuLV was contaminated with a MuSV. This is considered unlikely because five cloned stocks of JLSV9-MuLV in which there was no detectable MuSV behaved identically in inducing sarcomas; (2) the non-transforming virus may contain transformation genes that can be expressed in vivo but not in vitro; but this seems an unlikely explanation because the sarcoma virus is readily measurable as a separate viral entity in the viral extracts when the virus is transferred to in vitro culture; (3) the leukemia virus may 'activate' or 'rescue' an endogenous, latent murine sarcoma virus that is present in all strains of mice tested, but this seems unlikely because spontaneous tumors of the sort induced by this transforming virus are rarely if ever seen in these strains of mice. The fourth possibility seems to us to be the most likely, and the most interesting; it is that (4) JLSV9-MuLV, and possibly other non-transforming viruses likeMoloney-MuLV and Kirsten-MuLV are transducing viruses capable of picking up cellular genetic information. This possibility has already been considered previously by Rusch ${ }^{59}$ and by Vogt ${ }^{70}$, who supposed that RNA tumor viruses may be potential carriers of cellular genetic information. To understand how this could happen, it is necessary to inquiry into the nature of the viral RNA and how this is replicated and assembled into the virion. In the last two years, so much information has been acquired on the replication of the viral nucleic acid that it is impossible to review it here. Several references to the literature have, therefore, been provided, ${ }^{8,12,16-18,27,44,67,72,74}$ and only a brief review of what is thought to be the sequence of events in the viral replicative cycle will be given. Following uncoating of the virus and activation of virion-associated RNA-dependent DNA polymerase (reverse transcriptase), a DNA copy of the RNA is made, and this DNA is integrated into the host-cell chromosomal DNA. The DNA is then copied by DNAdependent RNA polymerase to give single-stranded, messengerlike viral RNA polymerase which is then assembled at cell-membranes, where envelopment occurs, followed by budding and maturation of the virion. In this process, it would seem that opportunities might exist for genetic recombination to occur between viral DNA and host-cell DNA, which could lead to the picking up of genetic material from the host cell. Alternatively, in the assembly of the strands of viral RNA, some cellular messenger RNA might be incorporated into the virion. If so, then a subsequent round of infection with formation of a DNA copy of the mRNA contained in the virus, and its integration into another cell, could result in the acquisition by that cell of the corresponding gene, which should be stably inherited. A variety of effects could be imagined to ensue from this transfer of genetic material and these effects might include those that we recognize as 'transformation' resulting in uncontrolled cell division and neoplasia. The transduced genetic material, for example, might be integrated into the new cell in a location where it might not be subject to control. It is not necessary to imagine that the transduction of a whole cistron is necessary because even the introduction of a small piece of new DNA in the wrong place in the cells' genome might result in the lack of control already mentioned. Such an event would be expected to happen rarely, but once it has happened, it should be readily recognizable and, perhaps, stable genetically. It might be expected, for example, that non-transforming JLSV9-MuLV, if passed repeatedly through murine cells without cloning, so as to allow many cycles of infection and replication, might be found to contain transforming virus after a number of passages. This may be what happened in vivo but it may also happen in vitro. Such experiments are being performed by Dr Ball. Their importance is obvious and so is the importance of deciding among the four possibilities listed above.

One way to examine the relatedness of the non-transforming virus with thetransforming virus is by molecular hybridization. ${ }^{29}$ Thus, if the first model is correct, that the non-transforming virus possesses a transformation gene that is not expressed in vitro, there should be complete homology between the nucleic acids of the transforming and non-transforming virus since they are one and the same. If the second model is correct, that the non-transforming virus rescues a transforming virus from the mouse, one might expect little or no homology between the two viruses, and if the model of the virus as a transducing virus is correct, then there should be considerable homology and the transforming virus should possess sequences homologous with those of the cellular DNA. The difficulty with the last part of these projected experiments is, however, that all of these viruses being cell-derived, should have sequences shared by cellular DNA. Perhaps it will be possible, by means of biological experiments, to demonstrate the transduction of genetic information.

Stephenson and Aaronson ${ }^{62}$ studied the degree of homology between Kirsten sarcoma virus and Kirsten leukemia virus. They did this by making DNA from the leukemia virus RNA, using reverse transcriptase, then hybridizing the DNA to the RNA isolated from the sarcoma virus. As stated earlier, it has not been possible to separate murine sarcoma virus from murine leukemia virus, but in this instance the ratio of one to the other was estimated to be $1: 1$. The RNA with which the MuLV-DNA was hybridized was therefore a mixture of RNAs derived from Ki-MuLV and Ki-MuSV. This fact was taken into account in assessing the data derived from the hybridization experiments and it was concluded that, at most, only a small portion of the genetic information of the sarcoma viral RNA is identical with that of the leukemia virus. Duesberg (ICN-Ucla Conference, March 1973) has since shown, however, that the RNA of Ki-MuSV is significantly smaller than that of Ki-MuLV. Stephenson and Aaronson ${ }^{62}$ estimated that the DNA made by reverse transcriptase represented only about 70 per cent of the Ki-MuLV RNA. Therefore not all regions of the RNA were copied and those that were might have been, in part, from sequences not present in the smaller Ki-MuSV RNA. On the other hand, if, as we suspect, MuLV and defective MuSV are formed by segregation from a competent MuSV, there need not be any homology between MuLV and defective MuSV. The question needs a thorough re-examination.

The Ki-MuSV and Mol-MuSV, though transforming viruses, are defective and cannot complete their replication cycles unless the cells infected by the sarcoma virus are also infected with a leukemia virus which acts as a helper. ${ }^{34}$ Cells infected with such defective sarcoma viruses become transformed and the cells remain transformed through subsequent cellular divisions for indefinitely long periods of time. Evidently the sarcoma viral genome is integrated into the cellular genome and replicates with it. At some subsequent time,the sarcoma virus can usually be recovered as infectious (though still defective) virus by infecting the transformed cells with MuLV and the MuLV that is used to 'rescue' the sarcoma virus need not be the same as that present in the original mixture of MuSV and MuLV. It is believed that the function of the MuLV is to provide coat proteins for which the MuSV genome is defective.

Usually, cells transformed by MuSV alone produce no viral progeny ${ }^{4,6,70}$ but some instances are known in which viral progeny are produced. Bassin et al. ${ }^{14,15}$ have described the clonal isolation of transformed mouse 3T3 cells which release non-infectious, non-transforming viruslike particles in the absence of replicating mouse leukemia helper virus. These cells are called $\mathrm{S}+\mathrm{L}-$ cells. Pcebles et al. ${ }^{54}$ have shown that murine sarcoma virus is present in the $\mathrm{S}+\mathrm{L}-$ cells because MuSV could be rescued from these cells by infection with a replicating leukemia virus. The MuSV rescued from $\mathrm{S}+\mathrm{L}-$ cells is of the $\mathrm{S}+\mathrm{L}-$ type; that is, the rescued virus, when used to infect cells, produces transformed cells that, once again, are $\mathrm{S}+\mathrm{L}-$ in phenotype. They produce non-infectious, viruslike progeny. ${ }^{2}$ These results are consistent with the idea that the genome of the $\mathrm{S}+\mathrm{L}-$ sarcoma virus is not so defective as that of the sarcoma virus that gives transformed cells of the non-producer type. The $\mathrm{S}+\mathrm{L}-$ genome probably differs from the truly defective MuSV genome in possessing genes that allow replication but not the complete set of genes which would be required to give a competent sarcoma virus. A competent sarcoma virus would be one capable of infecting and transforming a cell and replicating in it without the aid of a helper virus. Such helperindependent viruses exist in the avian system but have not until recently been described in the murine system. Earlier accounts of the existence of competent murine sarcoma virus were found to be in error, either because of the detection of an unsuspected and previously undetected helper virus, ${ }^{1}$ or because the 'competent' virions turned out to be aggregates of MuLV and MuSV. ${ }^{50,51}$

Recently, Dr J.K. Ball in the Cancer Research Laboratory at University of Western Ontario, has described a line of mouse cells, transformed by Moloney sarcoma virus, that releases infectious, transforming sarcoma virus. An intensive investigation has failed to detect leukemia virus or infectious helper virus among the progeny of these transformed producer cells. ${ }^{81}$

The viral progeny produced by these transformed cells can produce foci of transfor mation in monolayers of mouse cells and from such foci, competent MuSV has been recovered. In this way, the sarcoma virus has been carried through at least three successive passages involving clonal isolation, and the cells transformed by this viral entity produce infectious transforming virus but no detectable leukemia virus. The test for leukemia virus involves plating the transformed. producer cells at low cell number and after incuba-tion surrounding the resulting colonies with XC cells that form syncytia in the presence of leukemia virus. ${ }^{43}$

However, the majority of foci produced in mouse-cell monolayers by infection with the transforming virus have been found to contain a mixture of viruses: competent MuSV; defective MuSV and MuLV. The chances of recovering competent MuSV are least when the number of successive rounds of infection and replication are great, such as occurs in the formation of a focus of transformation because of viral spread, and are greatest when such successive rounds are least. We account for these observations by making the hypothesis that the defective MuSV and MuLV are formed by segregation from competent MuSV or, that replication-defective-transformation positive $\mathrm{R}-\mathrm{T}+$, and replication positive-transformation defective $\mathrm{R}+\mathrm{T}-$ viruses are produced from replication-positive-transformation positive, competent murine sarcoma virus. This hypothesis can be summarized in the following equation:

$$
\mathrm{R}+\mathrm{T}+\rightarrow \mathrm{R}-\mathrm{T}++\mathrm{R}+\mathrm{T}-
$$

We make the further hypothesis that these segregational events probably take place early in the infection. The situation appears to be more stable if there exists only a need for transcription of viral RNA, as presumably is the case in chronically infected cells. However, this is speculation.

The evidence is not consistent with the possibility that what appears to be a competent virus is really an interviral aggregate of MuLV and MuSV. The behaviour of aggregates is quite different from that of the competent sarcoma virus: aggregates are removed by filtration and the sarcoma virus is not; and aggregates form XC syncytia which the sarcoma virus does not. Both aggregates and sarcoma virus transform cells.

Furthermore, the interpretation that the competent sarcoma virus segregates a non-transforming virus is entirely consistent with the observed segregation of non-transforming viruses from cloned, competent avian sarcoma viruses. ${ }^{75}$ The only point of difference may be that competent murine sarcoma virus segregates with higher frequency than does competent avian sarcoma virus.

The mechanism by which segregation may occur is entirely unknown, but our observation that it occurs with greatest frequency when opportunity is provided for multiple rounds of infection to occur may provide a clue. Recombinational events between viral and cellular nucleic acids may result in the insertion of bits and pieces of the viral genome - so that what is integrated may be less than the intact viral genome - or possibly the whole thing. What happens at each round of infection can probably be described by some probability function. Intact virus will only appear if those genes required to form a complete genome can be assembled into a mature virion. The opera-tion of a mechanism such as this would be expected to provide for the appearance of cells that are transformed and producing virus, others that are transformed but not producing virus, still others that produce virus and are not transformed, others that possess viral information but produce no virus, and a spectrum of defective viruses. All of the possibilities are, in fact, now known to occur.

This information can be fitted into a hypothetical framework as follows: 1 The cells of vertebrates contain information that, in some instances at least, is complete enough to permit the production of C-type particles, RNAcontaining viruses.
2 In some instances at least, these C-type particle viruses are able to pick up cellular genetic information and, if this information is of the right sort, a 'transforming virus' is formed. There would probably be no greater frequency of formation of such a virus by infection of a cancer cell than by infection of a normal cell, especially if the mechanism for picking up the genetic information should involve crossing-over of DNA molecules.
3 The recombinant sarcoma viruses are capable of further recombinational events involving cellular DNA or other viral nucleic acids. In this manner a variety of genetic transfers occurs, some to the cell from the virus, some from the virus to the cell, and some between viruses (should two different viruses infect the same cell).

We could summarize by saying that $\mathrm{R}+\mathrm{T}-$ (replication-plus, transforma-tion-minus virus i.e. MuLV) can recombine with a transformation gene $\mathrm{T}+$ to give $\mathrm{R}+\mathrm{T}+$ (replication-plus, transformation-plus, i.e. competent MuSV). The competent $\mathrm{R}+\mathrm{T}+$, upon infecting a cell, has, upon integrating into the cell, a certain probability of leaving certain genes in the cell so that $\mathrm{R}-\mathrm{T}+$ (defective MuSV, requiring complementation by the replicative functions of MuLV) and $\mathrm{R}+\mathrm{T}-(\mathrm{MuLV})$ are generated.

Obviously, our greatest defect is our almost complete lack of information about the genomes of the leukemia and sarcoma viruses. We have as yet neither a good physical picture nor a biological picture. As stated above, it is not known whether the complete genome of these viruses corresponds to RNA of 3 or 10 million daltons, or to three or four pieces of 3 million daltons each. Nor is it known whether the pieces have the same or different composition. One difficulty is that the purity of a given viral preparation is seldom, if ever, known, either in terms of the state of maturity of the individual virions, or of the ratio of particles to infectious virions, or indeed, of the number of different Viruses, or viruses of different origins (e.g., exogenous and endogenous) that might be in the preparation.

In biological terms, we do not know whether the genome is haploid or polyploid. We have no idea how many genes there are nor what their functions may be. Recently, temperature-sensitive mutants of murine leukemiaand sarcoma viruses have become available. Stephenson, Reynolds, and Aaronson ${ }^{63}$ have described the isolation of temperature-sensitive mutants of Kirsten-MuLV and, more recently, of Rauscher-MuLV (personal communication). Scolnick, Stephenson, and Aaronson ${ }^{80}$ have also described the isolation of temperature-sensitive mutants of murine sarcoma virus. Doctors Paul Wong, Laurence Russ, and J.A. McCarter have isolated spontaneous, temperature-sensitive mutants of Moloney-MuLV ${ }^{79}$ and we have assigned three of these mutants to two complementation groups, not only on the basis of complementation values ${ }^{80}$ but also on the basis of their different physiologies. One of the mütents appears to suffer from a defect in assembly or some very late stage in formation of the virion, whereas the mutants of the other group are earlier (Wong, unpublished).

Furthermore, genetically stable wild-type recombinants were obtained with a frequency of about 8 per cent of the total progeny in pairwise-crosses between ts mutants belonging to the two different complementation groups. ${ }^{80}$ The mechanism by which such recombinants are produced is not known whether by genetic reassortment or by crossing over. We do not know with certainty whether or not reciprocal recombinants (double-mutants) are formed, but we should know before long. Neither do we know how many complementation groups there are, nor whether those produced spontaneously are only in certain genes ('hot' spots), but the isolation and testing of further mutants should answer these questions. We do not know if certain of the genes are linked and behave as a genetic unit, or if they can segregate independently, but further studies of recombination with more mutants should provide the answers. In this connection we are aware of a possibly serious limitation in the use of these temperature-sensitive mutants: most of those isolated are so leaky as to be useless for studies of complementation and recombination. We select for those that are least leaky and we may be selecting against valuable information that the leaky mutants have to tell us.

While we now know that the genome of one virion can interact with that of another, when both are exogenous and are used to infect the same cell, we do not know if the viral genome that infects the cell from outside can recombine with the endogenous viral genome. Paul Wong and J.A. McCarter measured the frequency of reversion of our ts mutants of Mol-MuLV to wild type and found values of about $10^{-4}$; thus, if these wild-type revertants at really not that at all, but are wild-type recombinants between exogeno! virus and endogenous viral genome, the frequency is not high. At this tim we have no way of knowing whether the wild-type virus arises by reversion of recombination. It should be pointed out, however, in connection with the idza that MuLVs are transducing viruses, that a frequency of $10^{-4}$ is not very low, the titre of a preparation of MuLV grown on mouse cells is commonly of the order of $10^{8}$ infectious units per ml and of those, $10^{4}$ might be derived by theprocesses under consideration - a not inconsiderable number if they were all focus-forming units.

The relationship between MuSV and MuLV is probably a key to understanding these viruses and their possible involvement in carcinogenesis. We need to know whether one is derived from the other. The problem seems to be turning out to be more complex than had been thought. Still, the idea that MuSV and MuLV are closely related in the way that has been speculated upon here, is a simple idea. The necessary techniques and materials are becoming available, and a lot of hard work remains to settle whether these ideas are right or wrong. We suspect, however, that when the nature of the genomes of these viruses is known, and the way in which they react with and alter cells is understood, an understanding of the mechanism by which chemical carcinogenesis proceeds will probably not have been helped very much, but no doubt, surprises lie ahead. Time will tell.

# REFERENCES 

1 Aaronson, S.A. Isolation of a rat tropic helper virus from M-MSVo stocks. Virology, 44: $29-36,1971$
2 Aaronson, S.A., Bassin, R.H., and Weaver, C. Comparison of murine sarcoma virus in non-producer and S+L- transformed cells. J. Virol., 9: 701-704, 1972
3 Aaronson, S.A., Hartley, J.W., and Todaro, G.J. Mouse leukemia virus: 'Spontaneous' release by mouse embryo cells after long-term in vitro cultivation. Proc. Natl. Acad. Sci. u.s., 64: 87-94, 1969
4 Aaronson, S.A. and Rowe, W.P. non-producer clones of murine sarcoma virus transformed BALB/3T3 cells. Virology, 42: 9-19, 1970
5 Aaronson, S.A., Todaro, G.J., and Scolnick, E.M. Induction of murine C-type virus from cloned lines of virus-free BALB/3T3 cells. Science, 174: 157-159, 1971
6 Aaronson, S.A. and Weaver, C. Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J. Gen. Virol., 13: 245-252, 1971
7 Aoki, T., Herbeman, R.B., Johnson, P.A., Liu, M., and Sturm, M.M. Wild type Gross leukemia virus: classification of soluble antigens (GSA). J. Virol., 10: $1208-1219,1972$
8 Axel, R., Gulati, S.C., and Spiegelman, S. Particles containing RNA-instructed DNA polymerase and virus-related RNA in human breast cancers. Proc. Natl. Acad. Sci. u.s., 69: 3133-3137, 1972

9 Bader, J.P. and Steck, T.L. Analysis of the ribonucleic acid of murine leukemia virus. J. Virol., 4: 454-459, 1969
10 Ball, J.K. and McCarter, J.A. Repeated demonstration of a mouse leukemia virus after treatment with chemical carcinogen. J. Natl. Cancer Inst., 46: 751-762, 1971
11 Ball, J.K., Harvey, D., and McCarter, J.A. Evidence for naturally occurring murine sarcoma virus. Nature, 241: 272-275, 1973
12 Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature, 226: 1209-1211, 1970
13 Baluda, M.A. and Nayak, D.P. DNA co-njumentary to viral RNA in leukemia cells induced by avian myeloblastosis virus. Proc. Natl. Acad. Sci. u.s., 66: 329-336, 197014 Bassin, R.H., Phillips, L.A., Kramer, M.J., Haapala, D.K., Peebles, P.T., Nomura, S., and Fischinger, P.J. Transformation of mouse 3T3 cells by murine sarcoma virus: release of virus-like particles in the absence of replicating murine leukemia helper virus. Proc. Natl. Acad. Sci. u.s., 68: 1520-1524, 1971
15 Bassin, R.H., Tuttle, N., and Fischinger, P.J. Isolation of murine sarcoma virus transformed mouse cells which are negative for leukemia virus from agar suspension cultures. Int. J. Cancer, 6: 95-107, 1970
16 Baxt, W.G., and Spiegelman, S. Nuclear DNA sequences present in human leukemia cells and absent in normal leucocytes. Proc. Natl. Acad. Sci. u.s., 69: 3737-3741, 1972
17 Canaani, E. and Duesberg, P. Role of 60 to 70 S avian tumor virus ribonucleic acid in its template activity for the viral deoxyribonucleic acid polymerase. J. Virol., 10: 23-31, 1972
18 Canaani, E., Helm, K.V.D., and Duesberg, P. Evidence for 30-40S RNA as precursor of the 60-70S RNA of Rous sarcoma virus. Proc. Natl. Acad. Sci., u.s. 72: 401-405, 1973
19 Cornelius, E.A. Rapid viral induction of murine lymphomas in the graft-versus-host reaction. J. Exp. Med., 136: 1533-1544, 1972
20 De Maeyer-Guignard, J. and De Maeyer, E. Effect of carcinogenic and noncarcinogenic hydrocarbons on interferon synthesis and virus plaque development. J. Natl. Cancer Inst., 34: 265-276, 1965

21 Dougherty, R.M. and Di Stefano, H.S. Lack of relationship between infection with avian leukosis virus and the presence of COFAL antigen in chick embryos. Virology, 29: 586-595, 1966
22 Duesberg, P. Physical properties of Rous sarcoma virus RNA. Proc. Natl. Acad. Sci. u.s., 60: 1511-1518, 1968
23 Duesberg, P. icn-ucLa Conference on Virus Research. Squaw Valley, Calif. March 18-23, 1973
24 Freeman, A.E., Price, P.J., Igel, H.J., Young, J.C., Maryak, J.M., and Huebner, R.J. Morphological transformation of rat embryo cells induced by diethylnitrosoamine and murine leukemia viruses. J. Natl. Cancer Inst., 44: 65-72, 1970
25 Gelb, L.D., Aaronson, S.A., and Martin, M.A. Heterogeneity of murine leukemia virus in vitro DNA: Detection of viral DNA in mamma:ian. cells. Science, 172: 1353-1355, 1971
26 Gilden, R.V. and Oroszlan, S. Group-specific antigens of RNA tumor viruses as markers for subinfectious expression of the RNA virus genome. Proc. Natl. Acad. Sci. u.s., 69: 1021-1025, 1972
27 Gillespie, D., Marshall, S., and Gallo, R.C. RNA of RNA tumour viruses contains Poly A. Nature, New Biol. 236: 227-231, 1972
28 Grindgenett, D.P., Gerard, G.F., and Green, M. A single subunit from avian myeloblastosis virus with both RNA-directed-DNA polymerase and ribonuclease H activity. Proc. Natl. Acad. Sci. u.s., 70: 230-234, 1973
29 Green, M. and Raskas, H.J. Molecular hybridization: a powerful approach to the detection of viral nucleic acid sequences in human cancer. J. Natl. Cancer Inst., 48: 1559-1565, 1972
30 Gross, L. Pathogenic properties and 'vertical'-transmission of the mouse leukemia agent. Proc. Soc. Exp. Biol. Med. 78: 342-348, 1951. See also: Gross, L. Oncogenic Viruses, 2nd ed. Oxford: Pergamon Press, 1970
31 Hanafusa, H., Miyamoto, T., and Hanafusa, T. A type of chick embryo cell that fails to support formation of infectious RSV. Virology, 40: 55-64, 197032 Hanafusa, H., Miyamoto, T., and Hanafusa, T. A cell-associated factor essential for formation of an infectious form of Rous sarcoma virus. Proc. Natl. Acad. Sci. u.s., 66: 314-321, 1970

33 Hanafusa, T. and Hanafusa, H. Isolation of leukosis-type virus from pheasant embryo cells - Possible presence of viral genes in cells. Virology, 51: 247-251, 1973
34 Hartley, J.W. and Rowe, W. Production of altered cell foci in tissue culture by defective Moloney sarcoma virus particles. Proc. Natl. Acad. Sci. u.s., 55: $780-786,1966$
35 Hartley, J.W., Rowe, W.P., Capps, W.I., and Huebner, R.J. Isolation of naturally occurring viruses of the murine leukemia virus group in tissue culture. J. Virol., * 3: 126-132, 1969
36 Hartley, J.W., Rowe, W.P., and Huebner, R.J. Host range restrictions of murine leukemia viruses in mouse embryo cell cultures. J. Virol., 5: 221-225, 1970
37 Hirsch, M.S., Black, P.H., Tracy, G.S., Leibowitz, S., and Schwartz, R.S. Leukemia virus activation in chronic allogeneic disease. Proc. Natl. Acad. Sci. u.s., 67: 1914-1917, 1970
38 Huebner, R.J., Kelloff, G.J., Sarma, P.S., Lane, W.T., Turner, H.C., Gilden, R.V., Oroszlan, S., Meier, H., Myers, D.D., and Peters, R.L. Group-specific antigen expression during embryogenesis of the genome of the C-type RNA tumor virus: implications for ontogenesis and oncogenesis. Proc. Natl. Acad. Sci. u.s., 67: 366-376, 1970
39 Huebner, R.J. and Todaro, G.J. Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci. u.s., 64: 1087-1094, 1969
40 Kaplan, H.S. On the natural history of the murine leukemias: Presidential address. Cancer Research, 27: 1325-1340, 1967
41 Kirsten, W.H. and Mayer, L.A. Morphologic responses to a murine erythroblastosis virus. J. Natl. Cancer Inst., 39: 311-335, 1967
42 Klement, V., Nicolson, M.O., and Huebner, R.J. Rescue of the genome of focusforming virus from rat non-productive lines by $5^{\prime}$-bromodeoxyuridine. Nature, New Biol., 234: 12-14, 1971
43 Klement, V., Rowe, W.P., Hartley, J.W., and Pugh, W.E. Mixed culture cytopathogenicity: A new test for growth of murine leukemia viruses in tissue culture. Proc. Natl. Acad. Sci. u.s., 63: 753-758, 1969
44 Leong, J.A., Garapin, A.C., Jackson, N., Fanshier, L., Levinson, W., and Bishop, J.M. Virus-specific ribonucleic acid in cells producing Rous sarcoma virus: detection and characterization. J. Virol., 9: 891-902, 1972
45 Lowy, D.R., Rowe, W.P., Teich, N., and Hartley, J.W. Murine leukemia virus: high frequency activation in vitro by $5^{\prime}$-iododeoxyuridine and $5^{\prime}$-bromodeoxyuridine. Science, 174: 155-156, 1971
46 McCain, B., Biswal, N., and Benyesh-Melnick, M. The subunits of murine sarcomaleukemia virus RNA. J. Gen. Virol., 18: 69-74, 1973
47 McCarter, J.A. and Ball, J.K. In press
48 Moloney, J.B. A virus-induced rhabdomyosarcoma in mice. Natl. Cancer Inst. Monogr., 22: 139-142, 1966
49 Myers, D.D., Meier, H., and Huebner, R.J. Prevalence of murine C-type RNA virus rroup specific antigen. Life Sciences, 9: 1071-1080, 1970
50 O'Connor, T.E. and Fischinger, P.J. Titration patterns of a murine sarcomaleukemia virus complex: evidence for existence of competent sarcoma virions. Science, 159: 325-329, 196851 O'Connor, T.E. and Fischinger, P.J. Physical properties of competent and defective states of a murine sarcoma (Moloney) virus. J. Natl. Cancer Inst. 43: 487-497, 1969
52 Oldstone, M.B.A., Aoki, T., and Dixon, F.J. Activation of spontaneous murine leukemia virus-related antigen by lymphocytic choriomeningitis virus. Science, 174: 843-845, 1971
53 Payne, L.N. and Chubb, R.C. Studies on the nature and genetic control of an antigen in normal chick embryo cells which reacts in the COFAL test. J. Gen. Virol., 3: 379-391, 1968
54 Peebles, P.T., Bassin, R.H., Haapala, D.K., Phillips, L.A., Nomura, S., and Fischinger, P.J. Rescue of murine sarcoma virus from a sarcoma-positive leukemia-negative cell line: requirement for replicating leukemia virus. J. Virol. 8: 690-694, 1971

55 Price, P.J., Freeman, A.E., Lane, W.T., and Huebner, R.J. Morphological transformation of rat embryo cells by the combined action of 3-methylcholanthrene and Rauscher leukemia virus. Nature, New Biol., 230: 144-146, 1971
56 Rhim, J.S., Vass, W., Cho, H.Y., and Huebner, R.J. Malignant transformation induced by 7,12-dimethylbenz(a) anthracene in rat embryo cells infected with Rauscher leukemia virus. Intern. J. Cancer, 7: 65-74, 1971
57 Roe, F.J.C. and Rowson, K.E.K. The induction of cancer by combinations of viruses and other agents. Intern. Rev. Expt. Path., 6: 181-227, 1968
58 Rowe, W.P., Hartley, J.W., Lander, M.R., Pugh, W.E., and Teich, N. Noninfectious AKR mouse embryo cell lines in which each cell has the capacity to be activated to produce infectious murine leukemia virus. Virology, 46: 866-876, 1971
59 Rusch, H.P. An integrated concept of carcinogenesis. In Currents in Biochemical Research (Green, ed.). New York: Interscience Publishers, p. 675, 1956
60 Scolnick, E.M., Stephenson, J.R., and Aaronson, S.A. Isolation of temperature sensitive mutants of murine sarcoma virus. J. Virol., 10: 653-657, 1972
61 Spiegelman, S., Burny, A., Das, M.R., Kaydar, J., Schlom, J., Travnicek, M., and Watson, K. Synthetic DNA-RNA hybrids and RNA-DNA duplexes as templates for the polymerases of the oncogenic RNA virus. Nature, 228: 430-432, 1970
62 Stephenson, J.R. and Aaronson, S.A. Murine sarcoma and leukemia viruses: genetic differences determined by RNA-DNA hybridization. Virology, 46: 480-484, 1971
63 Stephenson, J.R., Reynolds, R.K., and Aaronson, S.A. Isolation of temperaturesensitive mutants of murine leukemia virus. Virology, 48: 749-756, 1972
64 Stephenson, J.R. and Aaronson, S.A. A genetic locus for inducibility of C-type virus in BALB/c cells: The effect of a non-linked regulatory gene on detection of virus after chemical activation. Proc. Natl. Acad. Sci. u.s., 69: 2798-2801, 1972
65 Stockert, E., Sato, H., Itakura, K., Boyse, E.A., Old, L.J., and Hutton, J.J. Genetic mapping of a murine leukemia virus-inducing locus of AKR mice. Science, 178: 860-863, 1972
66 Teich, N., Lowy, D.R., Hartley, J.W., and Rowe, W.P. Studies of the mechanism of induction of infectious murine leukemia virus from AKR mouse embryo lines by 5'-iododeoxyuridine and 5'-bromodeoxyuridine. Virology, 51: 153-173, 1973
67 Temin, H.M. Mechanism of cell transformation by RNA tumor viruses. Ann. Rev. Microbiol., 25: 609-648, 1971
68 Temin, H.M. and Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature, 226: 1211-1213, 1970
69 Todaro, G.J. Spontaneous release of type C viruses from clonal lines of'spontaneously' transformed BALB/3T3 cells. Nature, New Biol., 240: 157-160, 1972
70 Todaro, G.J. and Aaronson, S.A. Properties of clonal lines of murine sarcoma virus transformed BALB/3T3 cells. Virology, 38: 174-202, 1969
71 Todaro, G.J. and Huebner, R.J. The viral oncogene hypothesis: new evidence. Proc. Natl. Acad. Sci. u.s., 69: 1009-1015, 1972
72 Tsuchida, N., Robin, M.S., and Green, M., Viral RNA subunits in cells transformed by RNA tumor viruses. Science, 176: 1418-1419, 1972
73 Varmus, H. icn-ucla conference on Virus Research. Squaw Valley, Calif. March 18-23, 1973
74 Verma, I.M., Meuth, N.L., Bromfeld, E., Manly, R.F., and Baltimore, D. Covalently linked RNA-DNA molecule as initial product of RNA tumour virus DNA polymerase. Nature, New Biol., 233: 131-134, 1971
75 Vogt, P.K. Spontaneous segregation of non-transforming viruses from cloned sarcoma viruses. Virology, 46: 939-946, 1971
76 Vogt, P.K. The emerging genetics of RNA tumor viruses. J. Natl. Cancer Inst., 48: 3-8, 1972
77 Vogt, P.K., Moscovic, C., and Duff, R. Host resistance and the biological analysis of avian tumor virus infections. Can. Cancer Conf., 8: 286-312, 1969
78 Weiss, R.A. Helper viruses and helper cells. In RNA viruses and host genome in oncogenesis (P. Emmelot and P. Bentvelzen, eds.). Amsterdam: North Holland, 1972, pp. 117-135
79 Wong, P.K-Y., Russ, L.J., and McCarter, J.A. Rapid selective procedure for isolation of spontaneous temperature-sensitive mutants of Moloney leukemia virus. Virology, 51: 424-431, 1973
80 Wong, P.K.-Y. and McCarter, J.A. Virology, 53: 319-326, 1973
81 Ball, J.K., McCarter, J.A., and Sunderland, S.M. Evidence for helper independent murine sarcoma virus. I. Segregation of replication defective and transformation defective viruses. Virology, 56 (November), 1973ENVIRONMENTAL CARCINOGENESIS$\cdot$
-# Record linkage for studies of environmental carcinogenesis 

HOWARD B. NEWCOMBE<br>Biology and Health Physics Division, Atomic Energy of Canada Limited, Chalk River, Ontario

Opportunities for preventing cancer arise mainly through knowledge of influences in the environment that can cause the disease. Unfortunately, the statistical associations between different sorts of exposure on the one hand and the subsequent occurrences of cancer on the other are seldom easy to establish. A major reason for this is that it is so very difficult to follow large numbers of exposed people for perhaps one or two decades, until the induced cancers have had time to make their appearance. It is not just a matter of recognizing the cases of cancer that occur in such a group, because those who do not develop cancer must also be followed to determine how many years they have been at risk.

The cost of such follow-up, by any conventional means, is substantial. For this reason, the relevant studies that were carried out in the past have frequently been limited in size and resolving power. Currently, however, we are entering an era in which many of the important events in our individual lives are documented in machine-readable form. If we choose to use these computerized records, the process of following large numbers of people until they die can be enormously simplified. The approach is, in fact, exceedingly cheap, in terms of unit cost, when applied to the populations of whole provinces, or even to that of the entire nation.

I propose to describe both the technical feasibility and some of the practical difficulties of this computerized approach to the problem of mass individual follow-up.

FEASIBILITYOF A
NATIONAL DEATH REGISTER
The most immediately useful files of personal records for this purpose are the provincial death indexes.

The registrations of vital events are almost universally filed in approxi-mately chronological sequence as they are received by the registry offices. To make them accessible it is necessary that they be indexed, and this is done most simply by preparing punchcards which are then sorted in alphabetic sequence and listed. Such a practice has existed in all Canadian provinces back to 1946, and earlier still in some provinces. In recent years the vital statistics index cards have been read onto magnetic tape for compact storage.

In the death index punchcards, the deceased individuals are identified not only by name, date, and place of death, but also by birth surname where different, and by birth date, birth place, and some parental information as well (Table I).

TABLE I
Identifying information on death records

|  | Birth <br> name | Birth <br> date | Birth <br> place |
| :-- | :--: | :--: | :--: |
| Deceased | + | + | + |
| Deceased's father | + | - | + |
| Deceased's mother | + | - | + |
| Deceased's spouse | $(+)^{*}$ | - | - |

* Parentheses indicate presence on paper record but not on machine record.

There is also a corresponding statistical punchcard for each death, and the two are identifiable with each other by a common event registration number. The statistics cards contain the underlying cause of death, and they are likewise converted routinely into magnetic tape.

Present practice is to sort the death index cards, or name cards alphabetically by year and province, and to use them to produce the alphabetic indexes required by provincial registry offices for searching. This subdivision into annual indexes is not as convenient as it might be for the purpose of follow-up. For example, a person who is not known to be dead could, in a follow-up study, be the subject of a separate search in all of the provincial indexes for each of the years over which he might have died. For any large study, manual searching of this kind would be quite impractical. But re-sorting of the death index magnetic tapes into consolidated indexes would be relatively inexpensive.

A single consolidated death index covering all provinces and all years back to 1946 would not be at all difficult to produce. Initially, however, it might be easier to obtain the agreement of the provincial authorities, who are the custodians of the records, for consolidation within the individual provinces rather than on a national scale. This would reduce the number of indexes to be searched to a maximum of ten. In either case, automaticsearching by computer would be exceedingly rapid and relatively cheap, even where very large numbers of people are being followed.

Consolidation on a national scale is, of course, highly desirable in view of the epidemiological purposes it could serve, but would probably require more negotiation. The maintenance of the vital registration system represents a substantial investment on the part of the provinces, and the manual searching that is done routinely in provincial registry offices to meet the public demand for certificates provides a revenue which partly offsets the cost of maintaining the system. Centralization of the files in computer accessible form constitutes a conceivable threat to such revenue. For this reason the provinces might well require, as a prior condition to such centralization, some arrangement to compensate them for the use of their records and for possible losses of revenue from the manual operation of issuing certificates. Thus the problem of national consolidation is more organizational and political than technological. The possibility of consolidation within provinces is seen, therefore, as a potentially workable compromise for the purpose of more immediate epidemiological studies.

The actual cost of consolidation, of either sort, is not a major consideration. According to one estimate, approximately $\$ 10,000$ would be required to integrate the death index tapes into a consolidated index for the whole of Canada back to 1946. ${ }^{1}$ A further $\$ 25,000$ would be required to set up an automatic searching facility. Thus an amount of money equivalent to a relatively modest research grant could cover the whole business.

There are potential multiple uses for any such facility - in particular wherever cumbersome manual methods are currently employed to update large administrative files. The Canada Pension Plan, for example, will require verification of the age and the fact of death for virtually every Canadian who has been employed. The conventional procedure would involve shipping birth and death certificates through the mails individually, plus clerical extraction of the information held by the registry office and clerical entry of the information into the files of the Canada Pension Plan. The inherent inefficiency of this conventional procedure for the many millions of registrants will be apparent when it is recalled that both the vital records and the Canada Pension Plan files are already automated. With just slight modification of the former, the two could be matched against each other at a rate of thousands of registrants per minute, so that only exceptional cases would need to be handled manually.

The principle applies similarly to other large files such as those relating to family and youth allowances, old age pensions, unemployment insurance, passports, and so on. Thus there are strong administrative reasons for bringing about the degree of automation of the vital registration system that would, as a by-product, serve the purposes of the epidemiologists for follow-up. But these administrative uses are likely to come later, rather than earlier, because of the need to negotiate appropriate financial arrangements whereby the provinces can share in any federal saving. The problem fortunately does not arise where the proposed consolidation is within provinces, and where the proposed uses are epidemiological rather than administrative.

I have dealt at length with Canada's death indexes for a number of reasons. Their use for follow-up would be technically simple, the sums of money involved would not be large, and provincial approval for their use would hopefully not be hard to get. But, above all, they would seem to be a fundamental ingredient in the design of any systematic investigation of the risk of cancer in large groups of people who are known to have been exposed to various environments that are in any way suspected of causing the disease.

# SOURCES OF DIAGNOSTIC INFORMATION 

The second requirement for a follow-up study designed to detect an increase in the risk of cancer in any group of people is one or more routine sources of cancer diagnoses. To be of use, such sources would have to identify the affected individuals unambiguously, and the most satisfactory kind of identification would include the birth name, birth date, and birth place. Of special value in this connection are three existing files, each of which covers virtually the whole of the Canadian population. They are respectively those of (a) death registrations, (b) cancer registrations, and (c) hospital insurance admission-separation records. If large numbers of people are to be followed with the aid of such files, maximum use must be made of the computerized versions of the records, and clerical extraction of data must be kept to a minimum.

The death records have already been discussed in connection with followup, and the identifying information contained in the machine-readable versions of these, at least from 1963 onward, is highly appropriate for the purpose. Questions are sometimes raised, however, about the reliability of the diagnostic information. Fortunately, most of these have been answered in an article by Barclay and Phillips ${ }^{2}$ (see Table II. In short, for all types of cancer combined the frequencies of over-diagnosis' and under-diagnosis are about 11 and 14 per cent respectively. Not only is the error small, but presumably it would be similar in all groups studied, without biasing any comparisons.

The death-statistical punchcards contain only the urderlying cause of death, as distinct from immediate and contributory causes, so visual scrutiny of microfilms of the death registrations might serve to pick up some further persons with cancer who had died of other causes. However, the use of additional sources of diagnostic information that are already available in machine-readable form could do away with the need for such clerical check-TABLE II*
Accuracy of cancer diagnoses on death certificates

| Relative <br> frequency <br> $(\%)$ | Site | Over- <br> diagnosis <br> $(\%)$ | Under- <br> diagnosis <br> $(\%)$ |
| :--: | :-- | :--: | :--: |
| 17 | Stomach | 15 | 2 |
| 10 | Respiratory | 14 | 3 |
| 9 | Lymphatic etc. | 8 | 2 |
| 8 | Large intestine | 15 | 5 |
| 8 | Prostate | 12 | 14 |
| 8 | Breast | 1 | 12 |
| 7 | Female genital | 8 | 8 |
| 6 | Urinary | 12 | 5 |
| 5 | Pancreas | 23 | 2 |
| 5 | Rectum | 4 | 5 |
| 2 | Mouth | 4 | 62 |
| 2 | Skin | 4 | 84 |
| 14 | Other | 13 | 6 |
| 100 | Combined | 11 | 14 |

* From Barclay and Phillips, 1962.
ing. If existing cancer registers and hospital insurance records are used, they would serve the double purpose of supplementing the death registration diagnoses and, at the same time, of identifying cancer patients who have not died.

The new forms used in the National Cancer Register provide for the inclusion of adequate personal identifying information, in particular birth name, birth date, and birth place (Table III). It is not yet clear how consistently this information will be filled in, but hopefully the provincial cancer registries from which the input comes will recognize the merit of adapting their own systems to permit follow-up, rather than using them solely to indicate the prevalence of the disease.

The registry operated by the Ontario Cancer Treatment and Research Foundation deserves special mention. It is not currently a contributor to the National Cancer Register, but its records provide for ample personal identification in a similar fashion (Table III). The Ontario register is also noteworthy because it has been derived by 'linking' the routine records from a number of different sources, including drug services, biopsy services, cancer clinics, and the hospital insurance system, and by extracting the information so that the same person is not counted twice. ${ }^{3,4}$

Current plans to 'link' the death registrations with the National Cancer Register by computer ${ }^{5}$ will, if they materialize, increase its value both as a source of information on incidence and prevalence, and also as a means for following selected groups to determine how many of their members develop cancer.TABLE III
Identifying information on cancer registrations

|  | Birth <br> name | Birth <br> date | Birth <br> place |
| :-- | :-- | :-- | :-- |
| National register (old) | - | + | - |
| National register (new) | + | + | + |
| Ontario register | + | + | - |

There is also provision for the Social Insurance Number on both the new national forms and the Ontario forms.

A logical extension would be the linking into the National Cancer Register also of information from the hospital insurance discharge records of cancer patients, to further ensure coverage of a high proportion of all cases, and as a continuing check on the diagnoses already recorded in the National Register. Unfortunately, personal identifying information is not currently entered from the hospital insurance admission-discharge summaries into the machine-readable versions of these records. What is even more unfortunate is that hospital patients are not identified, even on the paper records, in an adequately uniform fashion across Canada (Table IV). This difficulty may be circumvented where there is sufficient need. The Ontario Cancer Treatment and Research Foundation, for example, manages to make use of the hospital insurance records, presumably clerically, despite the inadequacies of the identifying information in that province. We have done something similar, but without clerical work, for a study of congenital anomalies of children, using the British Columbia hospital insurance records.

For our own study, the statistical records of hospital discharges that are entered routinely on magnetic tape were scanned by computer to extract those relating to diseases of special interest. A sequenced listing of these, by hospital code number and case admission number, was then used by keypunch operators to identify the original paper records. From these, the operators prepared supplementary punchcards containing the missing identifying information, which were later matched on magnetic tape with the appropriate statistical card images. A similar mechanized procedure could be adopted in some provinces for discharges with a diagnosis of cancer.

The following conclusions can then be drawn on the three major sources of diagnostic information: (a) computerized use of the death registrations on a large scale is virtually possible now; (b) the National Cancer Register should be usable in a similar fashion before too long; and (c) use of the hospital insurance discharge summaries on a wider scale may depend upon more general recognition of the merits of identifying people in an unambiguous and uniform fashion on their health records. An ultimate solution, of course,TABLE IV
Identifying information on hospital insurance records

|  | Birth <br> name | Birth <br> date | Birth <br> place |
| :-- | :--: | :--: | :--: |
| B.C. | $(+)^{*}$ | $(+)^{*}$ | - |
| Alta. | - | Age | - |
| Sask. | - | $(+)^{*}$ | - |
| Man. | - | $(+)^{*}$ | - |
| Ont. | - | $(+)^{*}$ | $(+)^{*}$ |
| Que. | - | Age | - |
| N.B. | $(+)^{*}$ | $(+)^{*}$ | - |
| N.S. | $(+)^{*}$ | $(+)^{*}$ | $(+)^{*}$ |
| P.E.I. $\dagger$ | $(+)^{*}$ | $(+)^{*}$ | - |
| Nfld. $\ddagger$ | - | $(+)^{*}$ | - |

* Parentheses indicate presence on paper record but not on machine record.
$\dagger$ Social Insurance Numbers are available on the P.E.I. records.
$\ddagger$ Personal identity numbers are available on the Nfld. records.
lies in the use of a universal system of personal identifying numbers, assigned at birth and entered on all important personal records. In this matter, however, much depends on how serious we are about wanting to know the nature of the long-term effects our various environments may have on us. But more on this subject later.

RECORDS FACILITATING FOLLOW-UP

In this discussion so far I have chosen to emphasize the concept of automated personal follow-up on a large scale, because it is the theme I most want to impress upon you. The question of starting points, or records that identify the exposures of people to different environmental influences, can be dealt with more briefly later. Before that, however, mention should be made of certain records that provide important intermediate steps in the computerized follow-up process.

Changes of name at marriage, for example, may throw the epidemiologist off the scent if he does not have access to the relevant information, the best possible sources of which are the marriage records themselves (Table V). The vital registrations can also provide other kinds of intermediate steps in the linkage process. For example, studies of influences in the family environments which are suspected of predisposing family members to cancer require knowledge of family composition. Such information may be extracted from the vital registration system by linking together the successive birth recordsTABLE V
Identifying information on marriage records

|  | Birth <br> name | Birth <br> date | Birth <br> place |
| :-- | :--: | :--: | :--: |
| Groom | + | Age | + |
| Groom's father | $(+)^{*}$ | - | $(+)^{*}$ |
| Groom's mother | $(+)^{*}$ | - | $(+)^{*}$ |
| Bride | + | Age | + |
| Bride's father | $(+)^{*}$ | - | $(+)^{*}$ |
| Bride's mother | $(+)^{*}$ | - | $(+)^{*}$ |

* Parentheses indicate presence on paper record but not on machine record.

TABLE VI
Identifying information on birth records

|  | Birth <br> name | Birth <br> date | Birth <br> place |
| :-- | :--: | :--: | :--: |
| Newborn | + | + | + |
| Newborn's father | + | Age | + |
| Newborn's mother | + | Age | + |

pertaining to the same married couple. The birth index punchcards contain sufficient family identifying information to make this possible (Table VI) and parental marriage records can be incorporated readily into the resulting sibship groupings of records. Considerable experience with this type of family linkage has been gained at Chalk River, where we have linked approximately 800,000 British Columbia birth and marriage records for the years 1946-63 into just such sibship groupings. There are some tricks in doing it, but it is not too difficult after the first compilation.

Another kind of intermediate step in the linkage process involves use of the Social Insurance Number as an identifier. There is, for example, a large centralized file of occupational records, known as Unemployment Insurance 'Book Renewal Cards,' which identify individuals only by surname and Social Insurance Number. A possible study will be mentioned later in which these records would be linked to the death registrations for the same individuals. An intermediate step is required, however, and the Social Insurance Number would have to be used to enter the Central Index of Social Insurance Numbers to extract from these the additional information (i.e. birth name, birth date, and mother's maiden name) required for matching with the death registrations (Table VII).

The use of such intermediate steps for the purpose of follow-up may sound devious and complicated, but one must remember the high speeds at which these files can be interrogated by computer. Also, such interrogation couldTABLE VII
Identifying information on records of employment, residence, and social insurance numbers

|  | Birth <br> name | Birth <br> date | Birth <br> place | S.I. <br> no. |
| :-- | :--: | :--: | :--: | :--: |
| Employment (UIC 5\%) | - | - | - | + |
| Residence (Nat. Revenue) | - | + | - | + |
| S.I. nos. (UIC) | + | + | $(+)^{*}$ | + |

* Parentheses indicate presence on paper record but not on machine record.
be carried out during routine updating operations so as not to involve special tape passes. The technical aspects will be mentioned again later. For the moment it is sufficient to indicate that the major problems are organizational rather than technical. The important limiting factor arises, not because of technical complexity, but because the idea of automated follow-up for specified purposes is still new in the minds of many. It is for this reason that agreement on the potentially possible studies may in some instances take time to arrange. Additional steps in a linkage operation could increase complexity slightly, but much more important is the possibility that they may necessitate the expenditure of further time on negotiations before such studies can be started.


# SOME POSSIBLE STARTING POINTS 

This brings us to the question of what groups of people it might be profitable to follow.

For some environmental carcinogens such as cigarette smoke, ad hoc surveys of otherwise conventional design may be necessary to identify an exposed population which is to be followed-up by the proposed automated method. For other environmental carcinogens such as medical X-rays, the exposed population might be identified through institutional records, including those of clinics and X-ray departments.

In addition to such conventional sources, however, there are some large files of centralized personal records which could be used to identify residential histories involving areas of high atmospheric pollution, or occupational histories involving various industries. And still other files, such as the birth registrations which can be arranged into sibship groupings, might be used to detect clustering of cancer cases. Finally, there are files of various kinds of personal records which are not currently centralized but which could be modified to identify a group of special interest for follow-up. In this latter connection I have in mind drug prescriptions, especially those relating to new drugs.The essential feature of any sort of personal record used as a starting point is that it must identify the individual unambiguously. Ideally this identification would include the birth name, birth date, and birth place. But the Social Insurance Number could be used instead, provided access to the Central Index of Social Insurance Numbers to extract the missing items is regarded as acceptable. If so, this source would have the added advantage of also providing the mother's maiden name which is particularly useful for resolving ambiguities.

To follow this latter thought further, let us suppose that one wishes to monitor systematically certain new prescription drugs for carcinogenic activity in man, and perhaps at the same time for teratogenic and other effects. To make a study of this sort possible, one could plan to pay pharmacists to collect the required personal identifying particulars as relating to, let us say, the first 100,000 prescriptions, and add perhaps 50 cents to the price of each prescription to cover these payments. After all, the introduction of any new prescription drug, whether we like the idea or not, is itself an experiment with human guinea pigs and it should be followed-up as systematically as possible.

In the case of a married woman, the husband's given names might also appear on the prescription for a new drug, to facilitate linkage with the birth record of any offspring who happens to be on the way. This would without doubt have hastened detection of the effects of thalidomide, and thereby prevented many deformities. If you feel that mention of a teratogen is irrelevant in the context of a cancer conference, I can, of course, substitute the drug diethyl stilbesterol, prenatal exposure to which has been found to cause vaginal cancer in young girls. In any case, one should not be too parochial in such matters, because the efficiency of the whole approach depends upon its use, simultaneously, for a multiplicity of epidemiological purposes.

Of the mechanized files that might be used as starting points for a study of carcinogenic influences in the environment, one of the most interesting is a set of punchcards representing the occupational histories of a continuing 5 per cent sample of the Canadian labour force. These so-called 'Book Renewal Cards' are produced annually for all persons enrolled in the federal unemployment insurance scheme who have Social Insurance Numbers ending in numeral 4 preceded by an odd number, i.e. about 400,000 cards each year (Table VII). They contain not only the Social Insurance Numbers and surnames of the insured persons, but their occupations and industries as well, plus the provinces and geographic locations of their employment. Collected over the years, these files indicate the employment histories of the individuals to whom they relate.TABLE VIII
Use of the s.I. number index to link occupational histories to deaths

|  | Name | Birth <br> date | Birth <br> place | S.I. <br> no. |
| :-- | :--: | :--: | :--: | :--: |
| Employment (UC) | $+\dagger$ | - | - | $+\dagger$ |
| S.I. no. index | $+\dagger$ | + | $(+)^{*}$ | $+\dagger$ |
| S.I. no. index $\ddagger$ | $+\dagger$ | $+\dagger$ | $(+)^{*}$ | + |
| Death index $\ddagger$ | $+\dagger$ | $+\dagger$ | + | - |

* Parentheses indicate presence on paper record but not on machine record.
$\dagger$ Daggers indicate overlapping identifying information on the machine records.
$\ddagger$ Mother's maiden surname is also present on both the S.I. no. index and the death index.

The file of Book Renewal Cards is potentially linkable with the Canadian Death Indexes and with the National Cancer Register, via the Central Index of Social Insurance Numbers as discussed earlier (Table VIII). Thus, it would be possible to monitor the whole of Canadian industry continuously for adverse effects of the industrial environments, no matter how long these effects might be delayed in their occurrence. Cancer would be one of the conditions that could be studied by this means, as possibly correlated with particular industries or particular occupations within the industries. The cost would not be large, and the breadth and thoroughness of such an undertaking would be unique. Other similar files pertaining to employment histories are those of the film badge services for radiation workers, operated under the authority of the Atomic Energy Control Board, and the records of annual X-ray examinations of all miners, carried out for the purpose of the provincial workmen's compensation schemes.

A different sort of file could be used as a starting point for determining in a similar fashion whether different residential histories are correlated with the subsequent occurrence of cancers and other causes of ill health and death. Such a follow-up would be useful, for example, to determine the risks among people who have lived for extended periods in areas of high atmospheric pollution (or high elevation, etc.), regardless of their place of residence at the time of becoming ill or dying. One large centralized file of personal addresses is that maintained for income tax purposes by the Department of National Revenue. In addition to name and address, the income tax 'red master tape' contains the date of birth, Social Insurance Number and, in the case of the married taxpayer, the first four characters of the spouse's given name (Table VII). Only limited information on past addresses is retained in the magnetic tape files, but such information could beextracted and accumulated compactly to yield a history of residence changes. In addition, for all families with children the addresses will also be known to the Family Allowance Administration.

Linkage of residence histories with Canada's Death and Cancer Indexes could be carried out in much the same fashion as described earlier for occupational histories.

Before concluding the discussion of starting points, brief mention should be made of other files of personal records that reveal parts of either the occupational or the residential histories, or some other information about the daily environment. The Post Office maintains on magnetic tape the names of householders in areas not covered by city directories, together with some limited information on occupation. Voters' lists at three levels of government, and municipal tax roles, are not for the most part maintained in machine-readable form, but the possibility exists for the future. The same may be said for school records, and there is already a move to identify all pupils from grade 7 or age 14 onward by Social Insurance Numbers, so that their careers can be followed through the school system and into labour force. Thus, the opportunities in the future to identify and follow-up large groups of people, whose environmental histories are of some interest, will undoubtedly exceed those of today.

Knowledge of the biological and social characteristics of the individuals represented in any study of environmental carcinogenesis may also be important for the interpretation of the results. One might mention in this connection as available from existing mechanized files: (a) the birth characteristics of the individual, such as birth weight, birth order, gestation period, and maternal age, which are available from the birth registration; (b) the previous maternal reproductive history contained in the accumulated birth records; (c) the previous medical history of the individual and his siblings recorded in the vital registrations and hospital insurance records; and (d) the economic status of the family indicated in the income tax tapes. Of these different sorts of information, that contained in the vital registration system is particularly accessible for study if the need is established.

# THE TECHNOLOGY OF RECORD LINKAGE 

At this point you may well ask how rapid, accurate, and cheap can the process of record linkage be made.

When we started doing this kind of work with a first-generation computer about 15 years ago, the linkage process was, in fact, slow. Our first test involved matching the registrations from a single year of British Columbia births, about 35,000 , back to the parental marriages in a file covering the preceding 10 -year period for that province and representing some 114,000events. The operation proceeded at a rate of about 20 incoming birth records per minute.

By 1965, a similar operation on a second-generation computer was carried out at a rate about 100 times faster (i.e. of 2300 incoming birth records per minute). In 1973 a record linkage program was developed which used a third-generation computer to match hospital insurance records for children back to the appropriate birth registrations. This recent operation was a further ten times faster, incoming hospital records being processed at a rate of 20,000 per minute or, if one is thinking in terms of very large files, at a rate of more than a million per hour.

The accuracy of the linkage is limited only by the quantity and quality of the personal identifying information, this being true equally for a computer and for a human filing clerk. Originally it had been thought by some people that only a human could make the necessarily sophisticated comparisons required where names, birthdates, and similar material have been inaccurately reported on some of the records. Contrary to this view, however, the rules of human judgment in such matters are not as complicated as one might suppose. And it is possible for a computer to extract from the files themselves information on the discriminating powers of the different agreements and disagreements that are observed when two records are compared. In fact, the computer can produce a numerical estimate of the odds that a pair of records does, or does not, relate to the same person or family.

I should like to avoid technical detail here, and illustrate the point in a simple fashion. To a human, the name John Brown carries much less discriminating power than, for example, Zacharias Quigley. The computer can reach much the same conclusion by observing how rare the names are in the files. Furthermore, it can be more precisely quantitative in its judgment than a human, and it is able to use such information to calculate the likelihood of a match between a pair of records carrying names such as these. This quantitative approach may be applied to any kind of identifying information and to any sort of agreement, disagreement, or partial agreement. ${ }^{6,7,8,9}$ In practice we have found that the linkage of records by machine is more accurate than that carried out routinely by human filing clerks, mainly because the computer does not become fatigued or bored and can be counted on to apply its rules more consistently than a human would do.

The cost of the linkage operation proper, when carried out by computer, is essentially trivial. We once calculated that it was less than the cost of the cardboard in the punchcards into which the records were originally punched. The preparation of the magnetic tape files in a suitable form for linkage, where the existing procedures have not been designed with linkage in mind, is more expensive. This cost, however, may be minimal or absent altogether where the files in their magnetic tape form are already designed for easyaccess by machine. With increasing multiple use of major files such as the Vital Statistics Indexes, in their automated forms, more of them are likely to be kept routinely in the most convenient form for access by computer. As a result, this part of the cost of additional linkage operations should diminish in the future.

One further possible barrier to large-scale record linkage may be thought to arise because of the sheer bulk of even the relatively compact magnetic tape files. In Canada there are about 700,000 births, deaths, and marriages per year, and just over $3,000,000$ hospital discharges. ${ }^{10}$ Accumulated over a 25 -year period, the records of these events would total $100,000,000$ if everything remained as it is now. With the size of the machine-readable versions of the records of events used in our own British Columbia study, each of which contains the equivalent of about 1000 binary digits or 'bits,' a total storage capacity of $10^{11}$ bits would be required for the 25 -year cumulative file. This is equivalent to more than 1000 magnetic tapes. However, equipment for storing information much more compactly is currently in limited use and should become common in the future.

Several of these mass storage devices have been developed, all with capacities of $10^{12}$ bits or more, equivalent to at least ten times the amount of information we are discussing. ${ }^{11}$ Such equipment is now reasonably compact, and the amount of actual storage medium required, for some of them, approximates a cubic foot or less. Thus the problem of mass storage of data should not represent an important obstacle to record linkage and personal follow-up in the future.

# PRIVACY AND FOLLOW-UP 

Discussions of the use of computerized files of personal records quite properly give rise to thoughts about the need to preserve the privacy of the individual. The importance of this is widely recognized and there is existing legislation, such as the Vital Statistics Act, which is designed to protect personal privacy. Further legislation of this sort will undoubtedly be needed, for example to cover personal files of the kind used by credit bureaus. And presumably similar principles should apply throughout for personal files of all kinds, wherever there are potentials uses and abuses.

In the present application, the end product is essentially statistical and does not reveal the identity of any individual person. Furthermore, the records in the large computerized files that are used to obtain this product are less readily accessible individually than are the original paper documents from which they were derived. Personal prying by idly curious people is thus not the major problem. Much more important is the control of possible systematic uses of the files that might affect individuals personally. Sincemany such uses of the original records were possible prior to the advent of computers, some quite effective legal safeguards have been in force for long time. In most provinces, for example, the hospital records of epileptics would not be accessible ot the departments that issue drivers' licences. But the possibility has little to do with computers.

Few would object to the use of vital and health records for the early detection of an effect like that of the drug thalidomide. Follow-up in this case does not affect the persons followed, but it can enable other to learn from their misfortunes and to avoid similar tragedies. The same, of course, can be said of the use of personal records to identify the carcinogenic effect of prenatal exposure to diethyl stilbestrol.

There has been a lot muddled thinking on the subject of confidentiality, and much of it stems from a curious faith in the current untidyness of the files. I would submit to you that such untidiness gives us little or no protection against possible abuse, while limiting or excluding altogether many of the potential legitimate uses of the records that could prevent illness and save lives.

# CONCLUSIONS 

If we want to know whether the things people are exposed to are good for them or bad for them, ultimately there is only one way to be certain. Thi is particularly true for any agent that has a delayed effect, including enviro mental influences that are carcinogenic. One must follow the exposed people to see what happens to them. This has always been true. But only recently has it come within our power to follow whole populations. And only recently have the episodes of ill health in these populations become so well docu mented, in such a uniform fashion, in central computerized files. These developments have opened up possibilities for finding out what does ha pen to people, and the sequences of events in their lives, with a degr : of thoroughness that would have been inconceivable in the past. The possib titics constitute a challenge for society of such magnitude that some confusion is perhaps inevitable.

Nevertheless, the choice relating to the detection of environmental carcinogens is quite simple. We can either follow-up, or remain in ignorance. It is as simple as that.

## REFERENCES

1 Cost of a consolidated death index; estimates by Mr J. Silins, personal comm tion from Mr F. Harris, October 1971
2 Barclay, T.H. Crawford and Phillips, A.J. The accuracy of cancer diagnosis death certificates. Cancer, 15, 5-9, 19623 Bruce, W.R. Application of optical character recognition and microfiche to medical records. Presented at the Sixth International Congress on Medical Records, Sydney, Australia, May 1-5, 1972; Annual Report of the Ontario Cancer Treatment and Research Foundation, 1972; and personal communication
4 MacKay, E.N. The Ontario Cancer Incidence Survey. In 'Research Projects and Investigations into Economic and Social Aspects of Health Care in Canada, 1971,' pp 180-181. Ottawa: Research and Statistics Directorate, Health and Welfare Canada, 1971
5 Miller, A.B., personal communication
6 Newcombe, H.B., Kennedy, J.M., Axford, S.J., and James A.P. Automatic linkage of vital records. Science, 130, 954-959, 1959
7 Newcombe, H.B. and Kennedy, J.M. Record linkage: making maximum use of the discriminating power of identifying information. Communications of the Association for Computing Machinery, 5, 563-566, 1962
8 Newcombe, H.B. Record linking: the design of efficient systems for linking records into individual and family histories. Am. J. Human Genetics, 19, 335-359, 1967
9 Newcombe, H.B. Present state and long-term objectives of the British Columbia population study. In Proceedings of the Third International Congress of Human Genetics, pp. 291-313. Baltimore: Johns Hopkins Press, 1967
10 In 1968, for example, there were records of 364,310 births, 153,196 deaths, and 171,766 marriages, making a total of 689,272 records of vital events in Canada for that year. If one includes with these the records of 161,531 immigrant admissions, the total becomes 850,803 . In the same year there were $3,255,169$ insurance records of hospital separations. Canada Year Book 1970-71. Ottawa: Dominion Bureau of Statistics
11 One of the most recently announced of these is the Control Data Corporation's SCROLl which uses a 12 -inch-wide magnetic tape, up to 2800 feet in length. Each such tape is sufficient to store $0.103 \times 10^{12}$ bits. The system can handle multiple tape drives, and the tape cartridges are interchangeable for off-line archival storage. The use of four heads in a tape drive makes possible a transfer rate of 35.2 million bits per second. The current standard magnetic tapes, i.e. half inch wide by 2400 feet long with 556 characters or 3336 . bits per inch, may be regarded as holding about 92 million bits each when allowance is made for inter-record gaps. One SCROLl tape, known as a cartridge, thus provides a storage capacity equivalent to 1117 fully recorded reels of half-inch tape. Control Data SCROLl: A Developmental Mass Memory Concept, Control Data Corporation, 1972# Transplacental carcinogenesis* 

A. KOESTNER<br>Department of Veterinary Pathobiology, Ohio State University, 1925 Coffey Road, Columbus, Ohio 43210

Cancer is the second highest cause of death in childhood. ${ }^{25,39}$ Since neoplastic growth follows a latency period of undetermined duration after exposure to a carcinogen, prenatal cancer induction may play a significant role in the pathogenesis of human cancer. If one translates latency periods observed in experimental tumor production in rodents to human life, estimates may range from a few years to decades. Indeed such estimates were substantiated in cases of known single human exposures to carcinogenic agents, e.g. atom bomb radiation exposure in Hiroshima and Nagasaki. ${ }^{5}$ The data from the Hiroshima studies revealed an increased incidence of leukemia starting one year following exposure. The increased incidence seemed maximal at 4-7 years after exposure, but was still apparent 14 years later. If one considers that a latency period of several years may be required before a neoplastic transformation is expressed in the form of a tumor, some neoplasms in infants, children, and adolescents may have been induced during fetal life. It is the purpose of this paper to summarize the most significant evidence in support of transplacental carcinogenesis. The discussion will deal primarily with experimental work, since the author's own experience has been concentrated over the past four years on experiments concerned with transplacental carcinogenesis in animals using resorptive N -nitroso compounds.

INDICATIONS OF HUMAN TRANSPLACENTAL CARCINOGENESIS

Existing evidence of prenatal determinants of cancer in man was summarized briefly in an editorial of the Journal of the National Cancer Institute by Miller in $1971 .{ }^{64} \mathrm{He}$ stressed as the most dramatic development in cancer research the report by Herbst et al. ${ }^{34}$ that synthetic stilbestrol therapy during pregnancy induced vaginal clear cell adenocarcinomas in 7 children 14 to 22 years later. This tumor is extremely rare so early in life. The relationship between stilbestrol treatment during pregnancy and vaginal cancer in female offspring was supported by Greenwald et al. ${ }^{30}$ and in a second report by

[^0]
[^0]:    * Supported in part by NIH Grant CA 11224Herbst et al. ${ }^{35}$ These observations represent the first evidence of transplacental carcinogenesis in man. The long latency period is consistent with experiences in animals using a variety of chemical carcinogens. Because of the relatively long latency periods in man as compared to rodents, in which most experimental work has been accomplished, it becomes increasingly more difficult to associate cancer of various organs in man to exposure of the mother to carcinogens during pregnancy. There is not much question about intrauterine determinants being responsible for neoplasms already present at birth or in early infancy such as the retinoblastoma, neuroblastoma, Wilms' tumor, and some forms of leukemia. ${ }^{63}$ For some of these (retinoblastoma), inheritance was assumed to be responsible for their increased occurrence in families, ${ }^{21}$ but sporadic occurrence has since been recognized and they must be considered as possible candidates for transplacental tumor induction by carcinogenic agents. Perhaps genetically predisposed individuals for particular tumor types experience neoplastic cell transformation from exposure to carcinogenic determinants at levels too low to affect the major segment of the population. It is the general experience of experimental oncologists that the same carcinogenic agent may produce different tumor types in different species and, within a species, in different strains of animals.

Some of the naturally occurring tumors in infants are associated with anomalies such as in the case of Wilms' tumor, ${ }^{62}$ possibly indicating that a common teratogenic and oncogenic factor acted upon the embryo and fetus at different stages of intrauterine development. Several investigators ${ }^{47,84,90,91}$ were able to reproduce some of the anomalies commonly associated with Wilms' tumor in man by feeding pregnant rats a vitamin A deficient diet. The embryonal nephroma, a tumor similar to the human Wilms' tumor, is the second most common neoplasm in young pigs ${ }^{81}$ and part of the leukemialymphoma complex in chickens where its viral etiology has been convincingly established. ${ }^{12,23}$ Although no mammalian nephroblastoma virus has yet been demonstrated, such a possibility cannot be definitely excluded.

While practically no parallel tumor types to retinoblastoma or medulloblastoma exist in animals (although a few have been reported), childhood leukemia has its counterpart in various animal species. In several animal species in which leukemia occurs, RNA-type tumor viruses have been established as the natural cause. In chicken, C-type RNA viruses are responsible for four types of leukoses, four types of sarcomas and renal carcinomas. ${ }^{4,36,38}$ In mice several types of leukemia, lymphoma, and sarcoma are caused by RNA tumor viruses. Recently, cats were shown to have both leukemia- and sarcoma-inducing RNA viruses, ${ }^{27}$ and rats and hamsters have yielded lym-phoma-inducing RNA viruses. ${ }^{29,71,89}$ The problem of establishing the etiologic relationship of the virus to the tumor lies in the fact that the tumor and virion expressions are rarely concurrent events. Natural overt expressionof the RNA tumor virus is the exception rather than the rule and has only been demonstrated convincingly in the cat ${ }^{14,48,70,75,76}$ and some strains of chickens. ${ }^{10,11,15}$ In rodents virus expression is particularly prone in laboratory mice and augmented in strains which through breeding have acquired a high genetically determined incidence of complete infectious virus. With the refinement of immunological techniques group-specific antigens (gs) have been detected in a high percentage of chickens, mice, and cats which were apparently free of neoplasia and free of infectious virus. ${ }^{38}$

It has been well documented that host genes can control RNA tumor virus expression in chickens ${ }^{73}$ and mice. ${ }^{39,82}$ It is postulated by Huebner and associates ${ }^{38}$ in support of the oncogene-virogene hypothesis that in various strains of mice different regulatory genes determine whether the RNA virogenes and oncogenes are fully expressed or partially or completely suppressed in normal or tumor tissues.

# VERTICAL TRANSMISSION OF C-TYPE RNA <br> VIRUSES IN ANIMALS 

Vertical transmission of leukemia virus in the avian species through the egg was established by Burmester in 1957. Rubin et al. ${ }^{77}$ reported that vertical transmission of the avian leukosis virus was a natural pattern in a flock of chickens used for seedstock production and was dependent upon immunological tolerance to the infectious virions on the part of egg-producing females. Selection of breeding stock free of vertical infections led to the establishment of leukosis-free flocks. Vertical transmission patterns could not be established by infecting chickens after hatching with the virus, but infection of embryos from non-tolerant chickens resulted in a vertical transmission pattern in some chickens, while others developed only partial tolerance or immunity. The outcome was apparently dependent upon several factors, including time and route of infection, degree of viremia, and the level of maternal antibodies.

The observation that leukosis-free chickens may spontancously produce embryos with demonstrable infectious virus if they are kept into old age complicates the problem of the RNA virus genome in avian leukosis and demands lifelong studies in chickens as they have already been accomplished in mice. ${ }^{38}$

Evidence has been presented that vertical transmission of tumor viruses also occurs in mammals. As a deeper understanding of viruses and viral infections emerges, several past misconceptions about viral infections are slowly eliminated. It is now recognized that absence of clinical illness does not exclude viral infection. Viruses may be masked or incorporated within the DNA molecule and genetically expressed under favourable circum-stances later in life. The viral genome may be vertically transmitted from progeny to offspring. Gross in $1951^{31,32}$ and in a more sophisticated experiment ten years later ${ }^{33}$ convincingly established the vertical passage in utero of strain A leukemic filtrates to fetal mice. He first inoculated $\mathrm{C}^{3} \mathrm{H}$ mice (a strain which is essentially free of leukemia) a few days after birth with leukemic filtrate and subsequently mated inoculated females with inoculated males, but also inoculated females or males with uninoculated mates. In cases in which inoculated females were used all offspring developed leukemia at $41 / 2-7$ months of age. No other mice developed leukemia during an observation period of 9 months. Similar results were achieved by other investigators. ${ }^{22,36,40}$ Ida ${ }^{40,41}$ confirmed transplacental transmission of Moloney leukemia and considered metastasis of leukemic cells from mother to fetus. The Moloney virus is apparently best transmitted to the offspring by nursing. ${ }^{3,6,7,56,57}$

Huebner et al. ${ }^{38}$ suggested that, in addition to these established experiments of vertical transmission of infectious virus, it appears that transmission of a mostly non-infectious RNA virus genome is a universal occurrence in mice and is probably part of their natural gene inheritance.

There are indications that the feline sarcoma virus also may be transmitted vertically. ${ }^{27}$ C-type particles were observed in the liver of eight fetal cats of three to seven weeks gestation. They were demonstrated also in primary cultures of fibroblasts obtained from another fetus. In addition, C-type particles were recognized in the maternal endometrium and in the placenta. It was suggested that the C-type virus is either transmitted to the fetus from the mother through the placenta and/or is an expression of an indigenous inheritable C-type virus gene.

Huebner et al. ${ }^{38}$ presented data indicating that the gene determinants of internal protein moieties of RNA C-type tumor viruses in chickens, mice, hamsters, and possibly in cats are operative not only in spontaneous and induced tumors but also are active during embryogenesis and during postnatal life. The investigators' evidence is based on detectable gs antigen expressions of RNA tumor virus genomes and on nearly universal immunological tolerance in these species to homotypic gs antigen. The recent demonstration of C-type RNA viruses in tumor cells of snakes, cattle, monkeys, and man suggests that the vertically transmitted RNA viral genomes may be part of the natural gene inheritance in all vertebrates. These gene expressions may be involved in normal development of the embryo and perhaps in certain useful functions in later life, particularly in regulating cell replication. When operating during normal embryogenesis and early postnatal life, it is suggested that these operons are controlled by regulatory genes and probably by hormonal and immunological mechanisms. These mechanisms may fail in infants and children because of a genetic deficiency in host-gene functionleading to childhood leukemia. During senescence there may be loss of previously effective control of the operon oncogene functions leading to an increased incidence of tumors in aged individuals.

# Chemical transplacental carcinogenesis 

First experimental proof of transplacental chemical carcinogenesis was reported by Larsen in $1947^{55}$ and was later confirmed by Smith and Rous ${ }^{76}$ and Klein. ${ }^{52}$ These investigators observed an increased incidence of bronchiolar adenomas in offspring of mice exposed to urethan during pregnancy. In these experiments no tumor types other than benign lung adenomas were observed (a naturally occurring tumor type in mice). The increased incidence at an earlier age was attributed to the transplacental exposure to urethan.

With the discovery of nitrosamines as carcinogenic agents by Magee and Barnes in $1956^{58}$ these substances also were tested as transplacental inducers of neoplasms. Mohr and Althoff, ${ }^{65,67}$ Mohr et al., ${ }^{66}$ and Mohr ${ }^{68}$ reported on the carcinogenic effect of methylnitrosamine (DENA) on pregnant hamsters, rats, and mice. At 25 weeks of age 80 per cent of the offspring of syrian hamsters developed papillomas of the trachea. Rats developed adenomas of the kidneys, and mice, in addition to a few hepatomas, adenomas of the lungs ( 50 per cent incidence). DENA passage through the placenta was confirmed by extraction with ether from the fetuses and identification by thinlayer chromatography. Nephroblastoma-like tumors were also observed by Pielsticker et al. ${ }^{74}$ and Wrba et al. ${ }^{92}$ with DENA and by Alexandrov ${ }^{1,2}$ in rats transplacentally exposed to dimethylnitrosamine. The incidence of these renal tumors was very low ( 2 of 186 in Pielsticker-Wbra's series and 7 of 186 in Alexandrov's series) and the latency period was 600 to 840 days. Nevertheless, there was no doubt that these tumors had to be linked to transplacental exposure of nitrosamines. Subsequently, oncogenesis following transplacental exposure has been demonstrated experimentally for cycasin, ${ }^{79} 1,2$-diethylhydrazine and azc- and azoxyethane, ${ }^{18}$ benzo (a) pyrene, ${ }^{8}$ methylnitrosourea, ${ }^{45,46,69,86}$ dimethylbenzanthracene, ${ }^{9}$ methylcholanthrene, ${ }^{83}$ and methyl methanesulfonate. ${ }^{51}$

Transplacental carcinogenesis took a giant step forward with the remarkable discovery by Druckrey and co-workers ${ }^{16,20,42,43,85}$ that a single exposure of pregnant rats during the later part of gestation to ethylnitrosourea (ENU) results in a high incidence of neoplasms in the offspring. Druckrey and coworkers sytematically synthesized 65 different nitrosocompounds by varying the structural elements, mostly the alkyl and acyl radicals. ${ }^{17}$ Although several derivatives were capable of inducing neoplasms by the transplacental route, none was as effective as ENU. For this reason ENU has been selected by usand by several other investigators ${ }^{45,49,53,54,80,93,94}$ as the compound of choice for transplacental tumor induction.

Several interesting conclusions emerged from Druckrey's reports:
a ENU is a potent transplacental carcinogen in the rat with a predilection for tumors of the nervous system.
b With optimal doses, 100 per cent of the offspring may develop neurogenic neoplasms within the first year of life.
c Tumors cannot be induced before the twelfth day of gestation.
d The susceptibility for induction of neurogenic tumors increases with advancing pregnancy and culminates toward the termination of the gestation period.
e Estimates indicate that the fetus may be more than 50 times more susceptible to the carcinogenic effect of ENU than the adult rat.
Our studies were initiated with the objectives to test the dose effect of ENU upon the rat fetus during the most susceptible period of late gestation; to determine the latency period, incidence, and distribution of the neoplasms resulting from ENU administration; and to characterize and classify the tumors morphologically and biochemically.

INVESTIGATIONS IN RATS $58,94,99$

# Dose-effect relationships 

The ENU experiment demonstrated that a single transplacental exposure to a neuro-oncogenic compound is capable of inducing neuro-ectodermal tumors in all offspring. There was a striking dose-effect relationship. With decreasing doses the number of tumors decreased and the survival time increased (Table I).

TABLE I
Tumor incidence and survival times of rats transplacentally exposed to ENU (From Cancer Research, $32: 2656-2660,1972$, with permission of the publisher)

| Dose <br> $(\mathrm{mg} / \mathrm{kg})$ | Strain | Rats with neuroectodermal tumors/ total no. of. rats | Rats with non-neural tumors/ total no. of rats | Mean neuroectodermal tumors/ rats with neural tumors | Mean survival time (days) |
| :--: | :--: | :--: | :--: | :--: | :--: |
| 1 | $\mathrm{SD}^{\mathrm{a}}$ | $5 / 41$ | $31 / 41$ | 1.0 | $655 \pm 128^{\text {b,c }}$ |
| 5 | SD | $19 / 24$ | $6 / 24$ | 1.6 | $477 \pm 192^{\mathrm{d}}$ |
| 20 | SD | $17 / 17$ | $5 / 17$ | 2.4 | $288 \pm 108$ |
| 50 | SD | $25 / 25$ | $6 / 25$ | 4.1 | $211 \pm 70$ |
| 50 | Fischer | $26 / 26$ | $4 / 26$ | 4.4 | $258 \pm 60$ |

[^0]
[^0]:    - The abbreviation used in the tables is: SD, Sprague-Dawley.
    - Mean $\pm$ S.D.
    - Includes 27 rats sacrificed at 733 days.
    - Includes 4 rats sacrificed at 730 days.The table indicates that all dose levels of ENU used in this study were capable of inducing neoplasms of the nervous system. The incidence of neurogenic tumors was directly related to the level of exposure. Extraneural tumors were encountered most frequently in rats of the low-dose groups which survived the two-year observation time. Most extraneural tumors were incidental findings, unrelated to the experiment, since the incidence corresponded to that expected for similar aged control rats. ${ }^{80}$ Over 50 per cent of rats exposed to $1 \mathrm{mg} / \mathrm{kg}$ ENU and over 25 per cent exposed to $5 \mathrm{mg} / \mathrm{kg}$ ENU (low-dose groups) survived the two-year observation period. All rats receiving 20 or $50 \mathrm{mg} / \mathrm{kg}$ died of neoplastic disease, most of them within the first year of life.

# Strain susceptibility 

Both strains of rats selected for this study, the random-bred Sprague-Dawley (CD) and the inbred Fischer rat (CDF), were highly susceptible to the oncogenic effect of MNU and ENU. With optimal dose levels, 100 per cent of the rats developed tumors of the nervous system. There were strain differences, however, concerning survival time since Fischer rats exposed to $50 \mathrm{mg} / \mathrm{kg}$ ENU survived longer than Sprague-Dawley rats exposed to the same dose ( $P<0.01$ ). There also were differences between these strains in regard to tumor types and location.

CLASSIFICATIONOF BEOPLASMS PRODUCED BY TRANSPLACENTAL EXPOSURETOENU
it A classification of tumors developing in rats exposed transplacentally to ENU is given in Table II.

The classification was based on the morphologic features of the predominant cell type (or types) comprising the neoplasm. Neurogenic tumors comprised 87 per cent of all neoplasms and 70 per cent of these ocgurred in the central nervous system. With the exception of a gliosarcoma and a meningioma, all tumors of the CNS were either gliomas (oligodendrogliomas, astrocytomas, mixed gliomas, anaplastic gliomas) or ependymomas or mixtures of both (glioependymomas). The majority of gliomas were differentiated while most neurinomas were highly anaplastic. Generally the gliomas became more undifferentiated as they increased in size.

Predilection sites for CNS tumors were the cerebral hemispheres, particularly the periventricular regions of the lateral ventricles, and the white matter of the lower thoracic and lumbar spinal cord. Tumors of the peripheral nervous system were located most frequently in the trigeminal nerve and the spinal roots forming the lumbosacral plexus.TABLE II
Incidence and classification of 345 tumors in rats exposed transplacentally to ENU (From Cancer Research, 32 : 2656-2660, 1972, with permission of the publisher)

| Type of tumor | Total | Sprague-Dawley, receiving ENU at |  |  |  | Fischer, receiving ENU $50 \mathrm{mg} / \mathrm{kg}$ |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: |
|  |  | $1 \mathrm{mg} / \mathrm{kg} 5 \mathrm{mg} / \mathrm{kg} 20 \mathrm{mg} / \mathrm{kg} 50 \mathrm{mg} / \mathrm{kg}$ |  |  |  |  |
| Nervous system | 290 | 5 | 30 | 40 | 102 | 113 |
| Astrocytoma | 10 | 0 | 1 | 4 | 4 | 1 |
| Oligodendroglioma | 68 | 0 | 7 | 9 | 32 | 20 |
| Mixed glioma | 99 | 1 | 6 | 10 | 19 | 63 |
| Anaplastic glioma | 8 | 0 | 2 | 1 | 5 | 0 |
| Glioependymoma | 9 | 1 | 1 | 3 | 4 | 0 |
| Ependymoma | 14 | 0 | 0 | 3 | 10 | 1 |
| Gliosarcoma | 1 | 1 | 0 | 0 | 0 | 0 |
| Meningioma | 1 | 0 | 0 | 0 | 1 | 0 |
| Neurinoma | 4 | 0 | 1 | 0 | 3 | 0 |
| Anaplastic neurinoma | 76 | 2 | 12 | 10 | 24 | 28 |
| Extraneural tumors | 55 | 31 | 7 | 6 | 7 | 4 |
| Pituitary adenoma | 17 | 16 | 1 | 0 | 0 | 0 |
| Mammary adenofibroma | 8 | 3 | 2 | 3 | 0 | 0 |
| Mammary adenocarcinoma | 5 | 2 | 1 | 0 | 2 | 0 |
| Renal mesenchymal tumor | 11 | 1 | 3 | 2 | 1 | 4 |
| Leukemia lymphoma | 5 | 4 | 0 | 0 | 1 | 0 |
| Other | 9 | 5 | 0 | 1 | 3 | 0 |

Marked differences existed between the two strains of rats. Brain tumors were responsible for 69 per cent of the deaths of Fischer rats, which is more than twice that of Sprague-Dawley rats receiving the same dose of ENU. Only one ependymoma was demonstrated in the 26 Fischer rats (exposed to $50 \mathrm{mg} / \mathrm{kg}$ ENU), while 10 occurred in 25 Sprague-Dawley rats at the same dose level (Table II). Marked differences in susceptibility to the oncogenic effect of ENU also was demonstrated by Druckrey et al., ${ }^{19}$ exposing 10 different strains of pregnant rats to ENU under identical conditions. The most susceptible strain was the inbred BDIX strain, which was used in practically all of Druckrey's experiments.

More striking than strain difference is the difference among species. We have so far not succeeded in transplacental tumor induction in cats and dogs. A pilot study in $\mathrm{C}^{3} \mathrm{M}$ mice, close to completion, resulted in a completely different spectrum of neoplasms with only a few brain tumors, 8 peripheral nerve tumors and a variety of extraneural tumors in 31 offspring. A study in hamsters ( $30 \mathrm{mg} / \mathrm{kg}$ ENU on fifteenth day of gestation) by Mennel and Zülch ${ }^{60}$ resulted in 60 per cent neurinomas, and a few isolated extraneural neoplasms, but not a single tumor of the central nervous system.

The different susceptibility among species is of significant importance in regard to transplacental carcinogenesis in man and should be explored carefully. Species phylogenetically closer to man, such as primates, should be tested. The expansion of the host-range and progress in the exploration ofthe mechanism of cancer induction by ENU and other carcinogens will lead to more definitive answers as to the circumstances under which chemical carcinogens may affect cells of the human embryo or fetus.

POSSIBLEMODEOF ACTION AND PATHOGENESIS OF CHEMICAL CARCINOGENS

Several interrelated factors play a role in transplacental carcinogenesis with chemical carcinogens. These factors include the placental barrier for the carcinogens; the maternal, placental, and fetal environment conducive for activation or conversion of non-active compounds into potent carcinogens (availability of enzymes); and, of course, fetal age, dose, and half-life of the compound. Some of these factors have been partially explored. Little is known about the interaction of the carcinogens with cellular components leading to neoplastic transformation and the circumstances responsible for the eventual expression of this transformation in the form of neoplastic growth.

# Placental barrier 

The carcinogen obviously must pass the placenta in order to affect the fetus. Whether the types of placentas in different animal species represent different barrier effects towards the passage of various carcinogenic chemicals has, to our knowledge, not been explored. The hemoendothelial placenta (one layer) in rodents, in which most transplacental studies were accomplished, may presumably be less effective as a barrier than the hemochorial human placenta ( 3 layer), the endotheliochorial canine placenta ( 4 layers), the syndesmochorial bovine placenta ( 5 layers), or the epitheliochorial porcine and equine placentas ( 6 layers).

Various methods were used by individual investigators to assure transplacental passage of the carcinogen as the sole route of fetal cancer induction. Bulay and Wattenberg ${ }^{8}$ injected benzo(a) pyrene subcutaneously into pregnant mice. In order to exclude the possibility of benzo(a) pyrene being transmitted to the newborn by nursing (since this substance, like other polycyclic hydrocarbons, is secreted through milk), the mice were delivered by caesarian section and nursed by uninoculated foster mothers.

Tomatis et al. ${ }^{83}$ produced a high incidence of neoplasms in offspring of 3-methylcholanthrene-treated mice, whether they were nursed by their own mothers or foster-nursed by untreated females. The crossing of the placenta was further substantiated by recovery of unchanged methylcholanthrene from the fetus following administration of ${ }^{14} \mathrm{C}$-methylcholanthrene to the pregnant mice.The short half-life of ENU makes such studies unnecessary. Druckrey et al. ${ }^{17}$ determined the half-life of ENU in saline at $20^{\circ} \mathrm{C}$ and $\mathrm{pH}^{\top}$ to be 90 minutes. The half-life shortens at slightly higher pH levels. The compound decomposes into harmless catabolites. Since tumors have been induced transplacentally in rats at day 15 and earlier, the transplacental route is assured as the sole route of cancer induction.

# ACTIVATION OF CARCINOGENS 

If carcinogens require enzymes for activation such as the nitrosamines, their effect will depend upon the presence and activity of such enzymes in either the maternal or fetal tissues. The activation in the maternal tissue may in some cases not be sufficient because of the instability of the active catabolites. The mechanism of blastomogenic action of dimethylnitrosamine is dependent upon enzymatic demethylation and formation of diazomethane or carbonic ion. According to Alexandrov, ${ }^{1}$ demethylation is weak in the embryo even as late as one to two days before parturition. This may explain the lower sensitivity to the blastomogenic effect of dimethylnitrosamine during embryogenesis as compared to postnatal life.

In contradistinction to the nitrosamines, ENU does not require enzymatic hydroxylation since cleavage of the alkyl radical occurs spontaneously at neutral or slightly alkalic $\mathrm{pH} .{ }^{43}$ This may explain in part the high oncogenic activity of ENU by the transplacental route. In a recent report by Osske et al. ${ }^{72}$ tumors were induced transplacentally in fetuses by feeding precursors (ethylurea and sodium nitrite) to pregnant rats for one week starting on the fifteenth day of gestation. It is assumed that ethylnitrosourea forms from these precursors in the presence of hydrochloric acid in the stomach of the mother and is then passed on to the fetus.

It is obvious that compounds that require enzymes for their activation may show tropism for organs in which the necessary enzymes are particularly active.

FETALAGEANDDOSE EFFECT
For those compounds which require the presence of enzymes in fetal tissue the time of their activity in the fetus is predetermined. It has not been clarified why it is so difficult, if not impossible, to induce tumors transplacentally before organogenesis is completed. In a few experiments tumors were induced in the early part of gestation. ${ }^{79}$ Generally, tumors are not inducible in rat and mouse fetuses before the twelfth day of pregnancy. The most sensitive time is the perinatal period. These factors have been studied most thoroughly for ENU. ${ }^{43}$ ENU and MNU are like many other carcinogens inthat they also are teratogens and mutagens. As teratogens they are responsible for a series of malformations, particularly of the limbs and the CNS. ${ }^{14}$ The CNS has the longest teratogenic determination period, extending from the ninth day of gestation until the second postnatal week. ${ }^{87,88}$ No causal relationship is detectable between the teratogenic and oncogenic effects after transplacental exposure of the fetus to ENU. ${ }^{88}$ In an extensive study Wechsler ${ }^{87}$ examined both compounds MNU and ENU at various stages of gestation and at different dose levels. Of all organs he found the central nervous system most sensitive to the teratogenic and carcinogenic effects of these compounds. The time period of susceptibility of the fetus to the teratogenic effect of MNU and ENU differed from that of the carcinogenic effect of these compounds. MNU proved to be more toxic and more teratogenic but less oncogenic than ENU.

The teratogenic effects of both compounds also depended upon the doses of MNU and ENU, ${ }^{80,87,88}$ as was discussed earlier. Although the dose influenced the latency period, the incidence of tumors, and the number of neoplasms per animal, it apparently had no influence upon the degree of differentiation of neoplastic cells.

# PATHOGENESIS 

If we consider the short half-life of MNU and ENU and their chemical interaction with cellular components, the neoplastic transformation of target cells is probably completed within a short period of time. The expression of neoplastic transformation in the form of uncontrolled proliferation occurs, Wower, several months after experimental exposure to the compound. The events between exposure (transformation) and expression are completely unknown.

We demonstrated in Hela cell-DNA the formation of 7-methyl-quanine after exposure to MNU. Following methylation a semi-conservative DNA synthesis was demonstrated independent of the $S$ phase of the cycle. This was considered to be a repair-synthesis. ${ }^{50}$ Similar to the methylation of DNA bases by MNU, Goth and Rajewsky ${ }^{28}$ demonstrated ethylation of nucleic acids by ENU. In spite of the difference in susceptibility between adult and fetal rats, the degree of ethylation was similar in the two age groups. Surprisingly, levels of ethylated 7 -guanine from liver DNA were approximately twice those of the brain although hepatic tumors have not been induced with ENU. Either this chemical interaction is of no consequence to carcinogenesis or perhaps the importance of this mechanism depends upon the capacity of various tissues for DNA repair.

Since the phenotypic characteristics of a cell at any time are a function of not only the genetic potential of that cell but also of the mechanisms whichregulate this information, we have initiated studies directed towards determining both the qualitative and quantitative effects that MNU has upon nuclear proteins. It was determined that the basic nuclear proteins or histones are methylated by this chemical carcinogen. MNU depressed both postsynthetic histone acetylation and histone methylation. ${ }^{13,14}$ Dose response curves are currently being determined for these two metabolic alterations of histones which help govern the genetic activity of chromatin.

We were interested also in determining the duration of the latency period, the onset of the initial growth period, and the various stages of tumor development. ${ }^{81}$ Pregnant inbred BD 9 rats were inoculated intravenously with 50 mg per kg of ENU on the twenty-second day of gestation. The offspring were examined on the first day and then the first, second, third, fourth, fifth, and sixth months. At every period, 8 to 10 animals were euthanatized and prepared for histological examination.

Previous studies, using identical procedures, resulted in death from tumors of the central and peripheral nervous systems within 7 to 9 months. Based on previous studies, established predilection sites were prepared for histological examination. We were surprised to recognize early neoplastic proliferation, particularly of the trigeminal nerve at the age of one month. At two months close to 100 per cent of the animals had early neoplastic proliferation or microtumors. Surprisingly only $30-40$ per cent of the animals developed macrotumors at the optimal manifestation time ( 7 months), indicating that an early proliferative phase may be blocked and regress. See Figure 1.

The latency period differed for different tumor types and locations. For instance, the latency period was shortest for the trigeminal neurinoma, longer for tumors of the spinal cord and spinal roots, and longest for tumors of the brain. The growth period from the earliest detectable proliferations to macrotumors were similar for tumors of the central and peripheral nervous systems. However, the period from induction to early proliferation was significantly shorter for tumors of the peripheral nervous system. This suggests that the kinetics of neoplastic growth are similar, while factors controlling expression
![img-4.jpeg](img-4.jpeg)

Latency period
Figure 1of neoplastic transformation differ between tumors of the central and peripheral nervous systems.

The question of why brain target cells need a longer latency period than sheath cells of peripheral nerves cannot yet be answered. A series of fundamental questions remain unanswered. Is the crucial cell alteration accomplished solely by a molecular-chemical interaction between N -nitrosourea and cellular molecules? If so, which chemical changes are critical for neoplastic transformation? Could it be that the chemical carcinogen acts only as an activator of an oncogenic virus or as a derepressant of an oncogene? Following neoplastic transformation, which changes of the internal environment are responsible for neoplastic growth of transformed cells? The answers to these questions are presently being sought in several laboratories. They are fundamental to our understanding of carcinogenesis.

# REFERENCES 

1 Alexandrov, V.A. Blastomogenic effect of dimethylnitrosamine on pregnant rats and their offspring. Nature (Lond.), 218: 280-281, 1968
2 Alexandrov, V.A. Transplacental oncogenic effect of methylnitrosourea on offspring of rats (in Russian). Vop. Onkol., 15: 55-61, 1969
3 Barnes, W.A. and Cole, R.K. The effect of nursing on the incidence of spontaneous leukemia and tumors in mice. Cancer Research, 1: 99-101, 1941
4 Beard, J.W. Avian virus growths and their etiologic agents. Advances in Cancer Research, 7: 1-127, 1963
5 Brill, A., Tomonaca, M., and Heyssel, R.M. Leukemia in man following exposure to ionizing radiation. A summary of the findings in Hiroshima and Nagasaki and a comparison with other human experience. Ann. Internal. Med. 56: 590-609, 1962
6 Buffett, R.F., Grace, J.T., Jr., Di Berardino, L.A., and Mirand, E.A. Vertical transmission of murine leukemia virus. Cancer Research, 29: 588-595, 1969
7 Buffett, R.F., Grace, J.T., Jr., Di Berardino, L.A., and Mirand, E.A. Vertical transmission of murine leukemia virus through successive generations. Cancer Research, 29: 596-602, 1969
8 Bulay, O.M. and Wattenberg, L.W. Carcinogenic effects of subcutaneous administration of benzo(a)pyrene during pregnancy on the progeny. Proc. Soc. Exptl. Biol. Med., 135: 84-86, 1970
9 Bulay, O.M. and Wattenberg, L.W. Carcinogenic effects of polycyclic hydrocarbon carcinogen administration to mice during pregnancy on the progeny. J. Natl. Cancer Inst., 46: 397-402, 1971
10 Burmester, B.R. Transmission of tumor inducing avian viruses under natural conditions. Texas Repts. Biol. Med., 15: 540-558, 1957
11 Burmester, B.R., Walter, W.G., Gross, M.A., and Fontes, A.K. The oncogenic spectrum of two 'pure' strains of avian leukosis. J. Natl. Cancer Inst., 23: 277-291, 1959
12 Carr, J.G. Renal adenocarcinoma induced by fowl leukemia virus. Brit. J. Cancer, 10: $379-383,1956$
13 Chilina, A.R., Ives, D.H., and Koestner, A. Methylation of Hela Cell histones byN-Methylnitrosourea (MNU) and the effect of this carcinogen on histone methylation and acetylation. Proc. Soc. Exptl. Biol. Med., 31 (e) : 84881972
14 Chilina, A.R., Ives, D.H., and Koestner, A. Effect of N-Nitrosomethylurea (MNU) upon histones and histone methylation and acetylation, J. Neuropath. Exptl. Neurol., 32: 158, 1973
15 Dougherty, R.M., DiStefano, H.S., and Roth, F.K. Virus particles and viral antigens in chicken tissues free of infectious avian leukosis virus. Proc. Natl. Acad. Sci., 58: 808-817, 1967
16 Druckrey, H., Ivankovic, S., Preussman, R. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature, 210: 1378-1379, 1966
17 Druckrey, H., Preussmann, R., Ivankovic, S., Schmähl, D. Organotrope car-inogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z. Krebsforsch., 69: 103-201, 1967

18 Druckrey, H., Ivankovic, S., Preussman, R., Landschutz, C., Stekar, J., Brunner, U., and Schlagen, B. Transplacentar induction of neurogenic malignomas by 1,2-diethylhydrazine, azo- and azoxyethane in rats. Experientia, 24: 561-562, 1968
19 Druckrey, H., Landschütz, C., Ivankovic, S. Transplazentare Erzeugung maligner Tumoren des Nervensystems. II. Äthylnitrosoharnstoff an 10 genetisch definierten Rattenstämmen. Z. Krebsforsch., 73: 371-386, 1970
20 Druckrey, H., Schagen, B., Ivankovic, S. Erzeugung neurozener Malignome durch einmalige Gabe von Äthylnitrosoharnstoff ( ÄNH) an neugeborene und junge BD IX-Ratten. Z. Krebsforsch., 74: 141-161, 1970
21 Falls, H.F. and Neel, J.V. Genetics of retinoblastoma. Arch. Ophthalmol., 46: $367-389,1951$
22 Fekete, E. and Otis, H.K. Observation on leukemia in AKR mice born from transferred ova and nursed by low leukemia mothers. Cancer Research, 14: 445-447, 1954
23 Feldman, W.H. and Olson, C. Keratinizing embryonal nephroma of the kidneys of the chicken. Am. J. Cancer, 19: 47-55, 1933
24 Flir, K. Zur vergleichenden Pathologie der Nierengeschwülste. Deut. tierärztl. Wochschr., 61: 147-150, 1954
25 Fraumeni, J.F., and Miller, R.W. Cancer deaths in the newborn. Am. J. Diseases Children, 117: 186-189, 1969
26 Furth, J., Cole, R.K., and Boon, M.C. Effect of maternal influence upon spontaneous leukemia of mice. Cancer Research, 2: 280-283, 1942
27 Gardner, M.B. Current information on feline and canine cancers and relationship or lack of relationship to human cancer. J. Natl. Cancer Inst., 46: 28i-290, 1971
28 Goth, R. and Rajewsky, M.F. Ethylation of nucleic acids by ethylnitrosourea-1-14C in the fetal and adult rat. Cancer Research, 32: 1501-1505, 1972
29 Graffi, A., Schraum, T., Bender, E., Graffi, I., Horn, K.H., and Bierwolf, D. Cell-free transmissible leukosis in Syrian hamsters, probably of viral aetiology. Brit. J. Cancer, 22: 577-581, 1968
30 Greenwald, P., Barlow, J.J., Nasca, P.C. et al. Vaginal cancer after maternal treatment with synthetic estrogen. New Engl. J. Med., 285: 390-392, 1971
31 Gross, L. Spontaneous leukemia developing in $\mathrm{C}^{2} \mathrm{H}$ mice following inoculation in infancy, with AK-leukemia extracts, or AK-embryos. Proc. Soc. Exptl. Biol. Med., 76: 27-32, 1951
32 Gross, L. Pathologic properties, and vertical transmission of the mouse leukemia agent. Proc. Soc. Exptl. Biol. Med. 78: 342-348, 195133 Gross, L. 'Vertical' transmission of passa A leukemic virus from inoculated $\mathrm{C}^{2} \mathrm{H}$ mice to their untreated offspring. Proc. Soc. Exptl. Biol. Med., 107: 90-93, 1961
34 Herbst, A.L., Ulfelder, H., and Poskanzer, D.C. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. New Engl. J. Med., 284: 878-881, 1971
35 Herbst, A.L., Ulfelder, H., and Poskanzer, D.C. Registry of clear-cell carcinoma of genital tract in young women. New Engl. J. Med., 285: 407, 1971a
36 Huebner, R.J., Kelloff, G.J., Sarma, P.S. et al. Group-specific antigen expression during embryogenesis of the genome of C-type RNA tumor virus: Implications for ontogenesis and oncogenesis. Proc. Natl. Acad. Sci., 67: 366-376, 1970
37 Huebner, R.J., Todaro, G.J., Sarma, P.S., Hartley, J.W., Freeman, A.E., Peters, R.L., Whitmire, C.E., Meier, H., and Gilden, R.V. 'Switched-off' vertically transmitted C-type RNA tumor viruses as determinants of spontaneous and-induced cancer: A new hypothesis of viral carcinogenesis. In Second International Symposium on Tumor Viruses: 33-57, Ed. Ctr. Nat. de la Recherche Scient., Paris, 1970
38 Huebner, R.J., Sarma, P.S., Kelloff, G.J., Gilden, R.V., Meier, H., Meyers, D.D., and Peters, R.L. Immunological tolerance to RNA tumor virus genome expressions: Significance of tolerance and prenatal expressions in embryogenesis and tumorigenesis. Ann. N.Y. Acad. Sci., 181: 246-268, 1971
39 Huth, E.F. Krebs im Kindesalter. Ärztl. Wschr., 13: 990-995, 1958
40 Ida, N., Moloney, J.B., and Taylor, G. Vertical transmission of Moloney leukemia virus in A/LN and BALB/c strains of mice. Gann., 56: 239-249, 1965
41 Ida, N., Fukuhara, A., and Ohba, Y. Several aspects of vertical transmission of Moloney virus. Natl. Cancer Inst. Monogr., 22: 287-311, 1966
42 Ivankovic, S., Druckrey, H., and Preussmann, R. Erzeugung neurogener Tumoren bei den Nachkommen nach einmaliger Injektion von Äthylnitrosoharnstoff an schwangeren Ratten. Naturwissenschaften, 53: 410, 1966
43 Ivankovic, S. and Druckrey, H. Transplazentare Erzeugung maligner Tumoren des Nervensystems. I. Äthyl-nitroso-harnstoff ( $\overline{\mathrm{A}} \mathrm{NH}$ ) an BD IX-Ratten. Z. Krebsforsch., 71: $320-360,1968$
44 Jarrett, W.F.H., Crawford, E.M., Martin, W.B., and Davie, F. Virus-like particle associated with leukemia (lymphosarcoma). Nature, 202: 567-569, 1964
45 Jänisch, W. and Schreiber, D. Experimentelle Geschwülste des Zentralnervensystems. Jena: Gustav Fischer, 1969
46 Jänisch, W., Schreiber, D., Warzok, R., and Schneider, J. Die transplazentare Induktion von Geschwülsten des Nervensystems. Vergleichende Untersuchung der Wirksamkeit von Methyl-und Äthylnitrosoharnstoff. Arch. Geschwulstforsch., 39: 99-106, 1972
47 Kalter, H. and Warkany, J. Experimental production of congenital malformation in mammals by metabolic procedures. Physiol. Rev., 39: 69-115, 1959
48 Kawakami, T.G., Theilen, G.H., Dungworth, D.L., et al. 'C-type' viral particles in plasma of cats with feline leukemia. Science, 158: 1049-1050, 1967
49 Kleihues, P., Matsumoto, S., Wechsler, W., and Zülch, K.J. Morphologie und Wachstum der mit Äthylnitrosoharnstoff transplazentar erzeugten Tumoren des Nervensystems. Verh. Deutsch. Ges. Path., 3: 372-380, 1968
50 Kleihues, P., Mennel, H.D., and Koestner, A. Alkylierung ven Nukleinsäuren in HeLa Zellen durch N-Methyl-N-nitrosoharnstoff und Hibwelse für eine RepairSynthese. Verhandel. Deutsch. Gesellschaft Pathol., 54: 654-655, 1970
51 Kleihues, P., Mende, Chr., and Reucher, W. Tumours of the peripheral and centralnervous system induced in BD-rats by prenatal application of methylmethanesulfonate. Europ. J. Cancer, 8: 641-645, 1972
52 Klein, M. Induction of lung adenomas following exposure of pregnant, newborn and immature male mice to urethane. Cancer Research, 14: 438-440, 1954
53 Koestner, A., Swenberg, J.A., and Wechsler, W. Transplacental production with ethylnitrosourea of neoplasms of the nervous system in Sprague-Dawley rats. Am. J. Pathol., 63: 37-56, 1970

54 Koestner, A., Swenberg, J.A., and Wechsler, W. Experimental tumors of the nervous system induced by resorptive N -nitrosourea compounds. In Recent Advances in Brain Tumor Research. Progress in Experimental Tumor Research. Hormburger, ed. vol. 17, pp. 9-30, 1972
55 Larsen, C.D. Pulmonary-tumor induction by transplacental exposure to urethane. J. Natl. Cancer Inst., 8: 63-69, 1947

56 Law, L.W. and Moloney, J.B. Studies of congenital transmission of a leukemia virus in mice. Proc. Soc. Exptl. Biol. Med., 108: 715-724, 1961
57 Law, L.W. Transmission studies of a leukemogenic virus, MLV, in mice. Natl. Cancer Inst. Monogr. No., 22: 267-285, 1966
58 Magee, P.N. and Barnes, J.M. The production of malignant primary hepatic tumors in the rat by feeding dimethylnitrosamine. Brit. J. Cancer, 10: 114-122, 1956
59 Meir, H., Myers, D.D., and Huebner, R.J. Genetic control by the hr-locus of susceptibility and resistance to leukemia. Proc. Natl. Acad. Sci. 63: 759-766, 1969
60 Mennel, H.D. and Zülch, K.J. Zur Morphologie transplacentar exzeugter neurogener Tumoren beim Goldhamster. Acta neuropath., 21: 194-203, 1972
61 Migaki, G., Nelson, L.W., and Todd, G.C. Prevalence of embryonal nephroma in slaughtered swine. J. Am. Vet. Med. Assoc., 159: 441-442, 1971
62 Miller, R.W., Fraumeni, J.F., and Manning, M.D. Association of Wilms's tumor with aniridia, hemihypertrophy, and other congenital malformations. New Engl. J. Med., 270: 922-927, 1964

63 Miller, R.W. Relation between cancer and congenital defects: An epidemiologic evaluation. J. Natl. Cancer Inst., 40: 1079-1085, 1968
64 Miller, R.W. Transplacental chemical carcinogenesis in man. J. Natl. Cancer Inst., 47: 1169-1171, 1971
65 Mohr, U. and Althoff, J. Mögliche diaplacentar-carcinogene Wirkung von Diäthylnitrosamin beim Goldhamster. Naturwissenschaften, 16: 515, 1964
66 Mohr, U., Althoff, J., and Wrba, H. Diaplacentare Wirkung des Carcinogens Diäthylnitrosamin beim Goldhamster. Z. Krebsforsch., 66: 536-540, 1965
67 Mohr, U. and Althoff, J. Die diaplacentare Wirkung des Cancerogens Diäthylnitrosamin bei der Maus. Z. Krebsforsch., 67: 152-155, 1965
68 Mohr, U. Diaplacentare Cancerogenese im Experiment. Langenbecks Arch. klin. Chir., 231: 273-279, 1968
69 Napalkov, N.P. Sequences of exposure to chemical carcinogens during pregnancy. Bull. Cancer, 7: 3-4, 1969
70 Olsen, R.G. and Yohn, D.S. Demonstration of antibody in cat sera to feline oncornavirus by complement-fixation inhibition. J. Natl. Cancer Inst., 49: 395-403, 1972
71 Oroszlan, S., Bova, D., Huebner, R.J., and Gilden, R.V. Major group-specific protein of rat type C viruses. J. Virol., 10: 746-750, 1972
72 Osske, G., Warzok, R., and Schneider, J. Diaplazentare Tumorinduktion durch endogen gebildeten N -Äthyl-N-nitrosoharnstoff bei Ratten. Arch. Geschwulstforsch., 40: 244-247, 197273 Payne, L.M. and Chubb, R.C. Studies on the nature of genetic control of an antigen in normal chick embryos which reacts on the COFAL test. J. Gen. Virol., 3: 379-391, 1968
74 Pielsticker, K., Wieser, O., Mohr, U., and Wrba, H. Diaplacentar induzierte Nierentumoren bei der Ratte. Z. Krebsforsch., 69: 345-350, 1967
75 Rickard, C.G., Barr, L.M., Noronha, F. et al. C-type virus particles in spontaneous lymphocytic leukemia in a cat. Cornell Vet., 57: 302-307, 1967
76 Rickard, C.G., Post, J.E., Noronha, F., and Barr, L.M. A transmissible virus-induced lymphocytic leukemia of the cat. J. Natl. Cancer Inst., 42: 987-1014, 1969
77 Rubin, H., Fanshier, L., Cornelius, A., and Hughes, W.F. Tolerance and immunity in chickens after congenital and contact infection with an avian leukosis virus. Virology, 17: 143-156, 1962
78 Smith, W.E. and Rous, P. The neoplastic potentialities of mouse embryo tissues. iv. Lung adenomas in baby mice as a result of prenatal exposure to urethane. J. Exptl. Med., 88: 529-555, 1948
79 Spatz, M., and Lagueur, G.L. Transplacental induction of tumors in Sprague-Dawley rats with crude cycad material. J. Natl. Cancer Inst., 38: 233-245, 1967
80 Swenberg, J.A., Koestner, A., Wechsler, W., and Denlinger, R.H. Quantitative aspects of transplacental tumor induction with ethylnitrosourea in rats. Cancer Research, 32: 2656-2660, 1972
81 Swenberg, J.A., Wechsler, W., and Koestner, A. The sequential development of transplacetally induced neuroectodermal tumors. J. Neuropathol. Exptl. Neurol., 31: 202-203, 1972
82 Tennant, J.R. and Snell, G.D. The H-2 locus and viral leukemogenesis as studied in congenic strains of mice. J. Natl. Cancer Inst., 41: 597-604, 1968
83 Tomatis, L., Turusov, V., Guibbert, D., Dupperray, B., Malaveille, C., and Pacheco, H. Transplacental carcinogenic effect of 3-methylcholanthrene in mice and its quantitation in fetal tissues. J. Natl. Cancer Inst., 47: 645-651, 1971
84 Warkany, J. and Schraffenberger, E. Congenital malformations induced in rats by maternal vitamin A deficiency. I. Defects of the eye. Arch. Ophthalmol., 35: $150-169,1946$
85 Wechsler, W., Ivankovic, S., Kleihues, P., Matsumoto, S., Preussman, R., Druckrey, H., and Zülch, K.J. Pathology of experimental neurogenic tumors chemically induced during pre- and postnatal life. Ann. N.Y. Acad. Sci., 159: 360-408, 1969
86 Wechsler, W. Oncogenic, teratogenic and mutagenic effects of methyl- and ethylnitrosourea. Proc. Sixth Internat. Congress Neuropath., pp. 128-129, Paris: Masson et Cie., 1970
87 Wechsler, W. Carcinogenic and teratogenic effects of ethylnitrosourea and methylnitrosourea during pregnancy in experimental rats. In W.H.O. Eurotox, pp. 230-256, Conference, Hannover, 1971
88 Wechsler, W. Teratogenic and oncogenic effects of ethylnitrosourea on the developing nervous system of rats. In The Brain in Unclassified Mental Retardation. J.B. Cavanagh (ed.) Churchill Livingstone, pp. 133-145, 1972
89 Weinstein, I.B., Gebert, R., Stadler, U.C., Orenstein, J.M., and Axel, R. Type C virus from cell cultures of chemically induced rat hepatomas. Science, 178: $1098-1100,1972$
90 Wells, H.G. Occurrence and significance of congenital malignant neoplasms. Arch. Path., 30: 535-601, 1940
91 Wilson, J.G. and Warkany, J. Malformations in the genitourinary tract induced by maternal vitamin A deficinecy in the rat. Am. J. Anat., 83: 357-407, 194892 Wrba, H., Pielsticker, K., and Mohr, N. Die diaplacentar-carcinogene Wirkung von Diaethylnitrosamin bei Ratten. Naturwissenschaften, 54: 47, 1967
93 Zülch, K.J. Gibt es Beziehungen in den Befunden der experimentellen und spontanen neurogenen Tumoren. Arzneimittel. Forsch. (Drug Res.), 19: 1503-1508, 1969
94 Zülch, K.J. and Mennel, H.D. Recent results on chemically induced tumors of the nervous system. Proceedings of the Sixth International Congress of Neuropathology. Paris: Masson, et Cie, 1970, pp. 60-63# The use of DNA repair in the identification of carcinogens, precarcinogens, and target tissue 

H.F. STICH, D. KIESER, B.A. LAISHES, and R.H.C. SAN<br>Cancer Research Centre, University of British Columbia, Vancouver, B.C.

| 4NQO | 4-Nitroquinoline 1-oxide |
| :--: | :--: |
| 3-Me-4NPO | 3-Methyl-4-nitropyridine 1-oxide |
| 3-Me-4HAPO | 3-Methyl-4-hydroxyaminopyridine 1-oxide |
| 2,3-diMe-4NPO | 2,3-Dimethyl-4-nitropyridine 1-oxide |
| 3-Et-4NPO | 3-Ethyl-4NPO |
| MNNG | $N$-Methyl- $N^{\prime}$-nitro- $N$-nitrosoguanidine |
| MMS | Methylmethanesulfonate |
| EMS | Ethyl methane sulfonate |
| NMU | Nitrosomethylurea |
| $\mathrm{HN}_{2}$ | Nitrogen mustard |
| AAF | 2-Acetylaminofluorene |
| $N$-OH-AAF | $N$-Hydroxy-2-acetylaminofluorene |
| $N$-Ac-AAF | $N$-Acetoxy-2-acetylaminofluorene |
| AS | Aminostilbene |
| AAS | Acetylaminostilbene |
| AAP | Acetylaminophenanthrene |
| AABP | Acetylaminobiphenyl |
| ABP | Aminobiphenyl |
| DMBA | 7,12-Dimethylbenz( $\alpha$ ) anthracene |
| BA | Benzanthracene |
| DBA | Dibenzanthracene |
| BP | Benzpyrene |
| MCA | Methylcholanthrene |
| DMN | Dimethylnitrosamine |
| FANFT | $N$-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide |Our understanding of DNA repair and its genetic control has led to a reappraisal of many cherished concepts of radiobiology, cell biology, and molecular genetics. The level and fidelity of DNA repair seem to play a more central role than the type and extent of DNA alterations following physical or chemical mutagens. Cell death, delayed lethality, loss of proliferative capacity, and mutagenesis are expressions of unrepaired DNA changes, misrepaired nucleotide sequences, delayed repair, or copying errors during the semi-conservative DNA replication in the cell cycles following the application of a mutagenic agent. Considering the crucial role of DNA repair in the maintenance of a stable genome, it is not surprising to find an elaborate repair system already present in the most primitive organisms (e.g. PPLO) and the early discovery of an optimal repair mechanism which seems to have changed little throughout evolution. In this paper, we restrain ourselves to a discourse about possible practical uses of DNA repair in the field of environmental carcinogenesis. This self-imposed restriction may help in focusing on a topic which does not attract the attention it seems to merit.

# METHODOLOGY 

Several methods are now available to estimate DNA repair in eukaryotic cells. However, only few of them could be adapted for the identification of carcinogens or mutagens in a large-scale prescreening or screening program. With this view in mind we present a short summary of the common approaches.
1 Repair of altered DNA molecules can be measured by the rate of disappearance of the changed nucleotides, e.g. thymidine dimers following UV-irradiation; ${ }^{51}$ alkylated DNA bases following exposure to an alkylating agent. ${ }^{33}$ This approach usually requires the isolation of DNA, and hydrolysis and chromatographic separation of the abnormal nucleotides. Although this procedure reveals the type of molecular changes which were induced by a carcinogen, it is too cumbersome to be suitable for large-scale experiments. 2 Another sophisticated, sensitive, but still unproven method, makes use of the observations that following X-irradiation, new groups, such as phosphate groups, become available to enzymatic attack upon breakage of a DNA strand. ${ }^{4}$ This procedure may be exploited in the assessment of repair of a chemically induced DNA damage. The more single-strand breaks that occur in a given DNA sample, the more exposed ends exist. The rate of disappearance of the exposed DNA end-groups, which can be monitored at various times post-treatment with a carcinogen, will reveal the rate of DNA repair.
3 Sedimentation of DNA through alkaline sucrose gradients provides a direct measure of single-stranded DNA breakage. It can also be employedin DNA repair studies. Although many modifications exist, the original technique introduced by McGrath and Williams, ${ }^{37}$ whereby intact cells are lysed directly on top of the alkaline sucrose gradient, is most often followed. ${ }^{6}$ In this manner, mechanical shearing of DNA is kept to a minimum. The idea is based on the assumption that DNA with carcinogen-induced single-strand breaks will not sediment as fast as intact DNA strands and that the return of the broken DNA strands to the original molecular weight following a carcinogen application is a measure of DNA repair (Figs. 1,2). Although the essential function of the alkaline medium is to destroy interstrand hydrogen bonding and base-stacking, it can also function to mediate hydrolytic chain fission of DNA initiated by DNA alkylation. Therefore one must be careful in defining such alkaline gradient measurements of DNA repair following challenge by alkylating agents. ${ }^{31}$ Considerable success in measuring DNA damage and repair in vivo has also been obtained with alkaline sucrose gradient analysis of DNA extracted from rat liver ${ }^{17}$ and DNA released from liver cell suspensions that were lysed directly on top of alkaline gradients. ${ }^{9}$ 4 The most widely used methods of monitoring DNA repair synthesis involve the 'resynthesis' of short sections of the DNA molecule which were eliminated by endo- and exonuclease enzymes following exposure to exogenous DNA-damaging agents. ${ }^{48}$ Common techniques that utilize the phenomencn of 'unschdduled DNA synthesis' or 'DNA repair synthesis' track the incorporation of 5 -bromodeoxyuridine (BrdU) or tritiated thymidine ( ${ }^{3} \mathrm{HTdR}$ ), into nuclear DNA of repairing cells, although other purine and pyrimidine precursors can also be successfully employed. ${ }^{8}$
![img-5.jpeg](img-5.jpeg)

Figure 1 DNA repair as measured by shifts in DNA sedimentation profiles (alkaline sucrose gradients) of cultured human fibroblasts exposed for 30 min to $5 \times 10^{-6} \mathrm{M}$ 4 NQO and sampled immediately after 4 NQO treatment (left graph) and after 12.5 hours of repair incubation. 4 NQO treated cells ( $\square$ ); control cells ( $\square$ ).![img-6.jpeg](img-6.jpeg)

Figure 2 DNA repair synthesis in cultured human fibroblasts following short term exposure to 4 NQO and measured as unscheduled incorporation of ${ }^{3} \mathrm{HTdR}$ (autoradiography, $\nabla$ ) or as a shift in the sedimentation rate in an alkaline sucrose gradient ( $\square$ ). By about 12 hours, post-treatment DNA repair synthesis ceases and the sedimentation profile approaches the original pattern.

Bouyant density cesium chloride gradients were repeatedly used to separate newly synthesized DNA from parental DNA and to measure the incorporation of BrdU into non-replicating, yet repairing DNA strands. ${ }^{6}$ This is quite an elegant procedure of distinguishing DNA replication from DNA repair, but is hardly applicable as a rapid analytical method to screen hundreds of carcinogenic agents.

Incorporation of BrdU into DNA also renders the position of incorporation labile to the effect of long-wave ultraviolet radiation. ${ }^{54}$ This photosensitizing procedure has been successfully applied to estimate the extent of DNA repair. ${ }^{49}$ Cultured mammalian cells were UV irradiated or treated with a chemical carcinogen; thereafter, they were allowed to undergo repair replication in the presence of BrdU and exposed to a pulse of 313 nm light. Repair-replicated regions containing BrdU are rendered alkaline-labile by the irradiation. The extent of DNA breakage and repair is deduced by the degree of shift in the DNA peak following centrifugation in an alkaline sucrose gradient. Only recently introduced, this approach is not yet popular.

The technique of choice appears to be the autoradiographic detection of radioactive precursors applied during the period of DNA repair synthesis. By exposing non-proliferating cells to exogenous physical ${ }^{6}$ or chemical ${ }^{8,58,62,63}$ agents and then allowing them to engage in DNA repair synthesis in the presence of ${ }^{3} \mathrm{HTdR}$, a measure of unscheduled repair synthesis can be readily obtained. ${ }^{58}$ Furthermore, the autoradiographic preparations providea record of the cytological location of the incorporated thymidine, the identification of the cell type engaged in DNA repair synthesis, the proportion of cells involved in DNA repair, and the variation of DNA repair levels within a cell population. ${ }^{58}$ Since hundreds of preparations can be handled simultaneously, and the evaluation of the autoradiographic preparations can be semi-mechanized, this procedure can be applied in large-scale screening tests. ${ }^{1}$

DNA REPAIR AND IDENTIFICATION
OF CARCINOGENS - BIOASSAYS

Several new factors contribute to what may be considered a critical period in screening programs for carcinogens. The yearly input of new compounds into man's environment occurs at an unprecedented rate. The present drugoriented society tries to solve its organic and psychic ills by consuming vast quantities of compounds in all imaginable permutations and combinations. The needs of the new megalopolis demand the long-term preservation of virtually all food products, which in turn requires the large-scale use of effective preservatives. The rapidly increasing trade between nations leads to a worldwide spread of new compounds which are either man-made or appear as naturally occurring contaminants in the imported products. The standard 'rodent painting and feeding tests' for carcinogenicity can hardly cope with this newly evolved situation. The cost ${ }^{45}$ of these experiments is prohibitive (up to $\$ 30,000$ for testing a single compound on 200 mice), and the completion of these tests requires a relatively long time (up to 2 years). These facts are not readily acceptable to the highly competitive business community. Moreover, the logistics of handling and screening millions of mice or rats would be staggering. Thus there is an urgent demand for an economic, rapid, and relevant screening procedure, or at least for a bioassay, which could be used in a prescreening program.

In this paper we should like to discuss the pros and cons of using DNA repair synthesis of mammalian cells as an indicator for a carcinogenic and/or mutagenic activity of a compound. The idea is based on the assumption that chemical carcinogens interact with DNA and that the ensuing DNA changes will result in a DNA repair synthesis. This working hypothesis was examined by comparing the extent of DNA repair in hamster and human cells after their exposure: (1) to several key agents belonging to different groups of carcinogens (Table I); (2) to highly, weakly, and non-oncogenic compounds ${ }^{61}$ (Fig. 3); and (3) to precarcinogens and their active proximate metabolites (Fig. 4). ${ }^{60,62} \mathrm{~A}$ short exposure of cultured mammalian cells to several key carcinogens results in a DNA repair synthesis whereas the application of non-oncogenic agents (e.g., 3 NQO, 5 NQO ), precarcinogensTABLE I
DNA repair synthesis as a bioassay for chemical carcinogens

| Unscheduled ${ }^{3} \mathrm{HTdR}$ (uptake detected) | Unscheduled ${ }^{3} \mathrm{HTdR}$ uptake (not detected) |
| :--: | :--: |
| 4NQO ( $\& 16$ carcinogenic derivatives) | DMBA <br> BP <br> MCA, MCA-DIOL <br> DBA, DBA-DIOL |
| 3-Me-4NPO | BA, BA-DIOL |
| 3-Me-4HAPO |  |
| 2,3-diMe-4NPO | DMN |
| 2,3-diMe-4HAPO | n-amyl-nitrite |
| 2-Me-4NPO | Cyclophosphamide |
| 3-Et-4NPO |  |
| 2,3-diEt-4NPO |  |
| Rugulosin | Aflatoxin $B_{1}$ |
| MNNG |  |
| MMS |  |
| EMS | Daunomycin |
| NMU | Acriflavine neutral |
| $\mathrm{HN}_{2}$ | Ethidium bromide |
| t-Butyl-hydroperoxide |  |
| ICR-191 |  |
| $N$-OH-AAF |  |
| $N$-Ac-AAF | AAF |
| $N$-OH-AAS | AS |
| $N$-Ac-AAS | AAS |
| $N$-OH-AAP |  |
| $N$-Ac-AAP | AAP |
| $N$-Ac-AABP | AABP |
| $N$-Ac-3-AAF | ABP |
| $N$-Myristoyloxy-AAF |  |
|  | Cycadin |
| BA-epoxide | 3-OH-xanthine guanine-n-oxide |
|  | 3-OH-guanine |

(e.g., AAF, AAS) and non-oncogenic metabolic products (e.g., diols of benz $(\alpha)$ anthracene; $4 \mathrm{AQO}^{25}$ a metabolite of the carcinogen 4 HAQO ) did not elisit a detectable level of unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation.

A correlation between the oncogenicity of a compound and the level of DNA repair synthesis is particularly evident within a group of related carcinogens. For example, cells respond to the highly and weakly oncogenic derivatives of $4 \mathrm{NQO}^{26}$ with a high and low level of unscheduled DNA synthesis respectively. The non-oncogenic 4 NQO derivatives lack the capacity to evoke a detectable DNA repair synthesis. The K -region epoxide of benz $(\alpha)$ anthracene, which is a potent transforming ${ }^{18}$ and mutagenic ${ }^{24}$ compound and probably represents the proximate carcinogen, ${ }^{20}$ is a highly active inducer of DNA repair, as compared to the parental benz( $\alpha$ ) anthracene or the BA-cis-5,6-dihydrodiol which is a further metabolic product. ${ }^{60}$ The application of $N$-hydroxy and $N$-acetoxy derivatives ${ }^{38,39}$ of AAF, AS,![img-7.jpeg](img-7.jpeg)

Figure 3 DNA repair synthesis in cultured human fibroblasts exposed to highly (group I), weakly (group II) and non-oncogenic (group III) derivatives of 4 NQO and 4 NPO.

GRAINS / NUCLEUS
![img-8.jpeg](img-8.jpeg)

BA
BA-EPDXIDE
BA-DIOL

MCA
MCA-EPDXIDE
MCA-DIOL
Figure 4 DNA repair synthesis in cultured human fibroblasts exposed for 5 hours to benz $(\alpha)$ anthracene (BA), BA-5,6-epoxide, BA-cis,5,6-dihydrodiol; methylcholanthrene (MCA); and the epoxide and dihydrodiol of MCA. Autoradiography.AAS results in cells responding with a DNA repair synthesis, whereas the non-activated AAF, AS, AAS at equimolar concentrations lack the capacity to elicit a detectable level of DNA repair in cultured human or hamster fibroblasts. However, there are two groups among the compounds listed in Table I which deserve a closer examination. Several potent mutagens including acridines, daunomycin, and ethidium bromide lacked the capacity to evoke a detectable level of DNA repair synthesis although they can affect DNA molecules. Although these agents seem to intercalate between the nucleotides of DNA and lead to frameshift mutations, they do not fall into the category of carcinogens. The postulated relationship between oncogenicity of a compound and its capacity to elicit DNA lesions which result in a DNA repair synthesis seems to apply to the intercalating type of agents. In this connection it is of interest to note that quinacrine-mustard (ICRI91), which has an alkylating activity apart from its intercalating capacity, induces a low but definite level of DNA repair synthesis.

As can be seen from Table I there are several so called 'false negatives.' These compounds are definitely carcinogenic, but they do not lead to a DNA repair which is detectable by an unscheduled incorporation of ${ }^{3} \mathrm{HTdR}$. Several factors may be responsible for this exceptional behaviour. Low solubility in water, DMSO, or ethanol is one of the simplest reasons for a 'false negative.' For example, lipophilic derivatives of 4 NQO (e.g., benzylsulfonylquinoline 1-oxide) are good representatives of this type of compound. A second set of carcinogenic agents may affect cells without acting directly on DNA or they may produce DNA alterations, which are not recognizable and repairable by the 'cut and patch' repair mechanism. For example, the oncogenic human adenovirus type 12 and 18 and the Simian adenovirus SA7 neither induced a measurable DNA repair synthesis nor inhibited a DNA repair synthesis elicited by single UV dose in Syrian hamster cells in which the viruses do not replicate but induce neoplastic transformation (Table II). Finally the cultured fibroblast may not represent the proper target cells for those carcinogens which need activation by an organ-specific enzyme.system. This topic is discussed in the following section.

# DNA REPAIR AND IDENTIFICATION OF PRECARCINOGENS 

Many of the proposed in vitro test systems which rely on bacteria, yeast. fungi, or cultured mammalian cells appear to be highly sensitive indicates for activated carcinogens and mutagens, but they seem to miss precarcinogens and premutagens that require activation to potent metabolites. Unfortunately, many noxious compounds in man's environment belong in this latter category. The ubiquitous nitrosamines, the widely spread polycyclicTABLE II
DNA repair synthesis in $\mathrm{XP}_{\mathrm{E}}$ and control cells infected with inactivated human adenovirus type 12 and exposed to UV-radiation

|  | Grain per nucleus |  |
| :-- | :--: | :--: |
|  | Normal | XP |
| UV $^{1}\left(900 \mathrm{erg} / \mathrm{mm}^{2}\right)$ | 62 | 13 |
| AD12 50 PFU $^{2}$ | 0 | 0 |
| AD12 10 PFU | 0 | 0 |
| AD12 50 PFU plus UV | 57 | 11 |
| AD12 10 PFU plus UV | 56 | 12 |

${ }^{1}$ The cited samples were taken 12 hours postinfection ( 3 hours absorption time). Comparable results were obtained when the infected fibroblast cultures were sampled at 4,24 , and 36 hours postinfection with the UV inactivated AD12.
aromatic hydrocarbons, and the naturally occurring hepatocarcinogens of fungal origin (e.g., aflatoxins, sterigmatocystin) typify this category of compounds. Thus, a successful utilization of any in vitro system - including DNA repair synthesis of human fibroblasts - will depend to a large extent on the introduction of effective and reliable activation procedures for a wide array of precarcinogens.

For one example - dimethylnitrosamine (DMN) - we should like to illustrate the combined application of DNA repair synthesis and in vitro activation as a procedure that may be suitable in the massive screening of exogenous precarcinogens. The activation preparation ${ }^{30,36}$ consists of a post3nitochondrial supernatant fraction resulting from a $9000 \times \mathrm{g}$ centrifugation ( 10 minutes) of a mouse liver homogenate. The microsome fraction (200800 mg liver-equivalents per cell culture contained in a Leighton tube) is then fortified with $8.5 \mu$ moles NADPH, $25 \mu$ moles magnesium chloride, and $20 \mu$ moles glucose-6-phosphate to allow for possible regeneration of NADPH via the phosphogluconate pathway during the course of the incubation. ${ }^{13}$ DMN was mixed into the fortified microsome preparation and the mixture was then added to non-proliferating cells. The cultures were flushed with $\mathrm{O}_{2}$ and left without further agitation at $37^{\circ}$ for the required incubation period. For analysis of DNA repair synthesis, the cell cultures were processed in the usual way to assess the level of unscheduled ${ }^{3} \mathrm{H}-\mathrm{TdR}$ uptake by the autoradiographic analysis. For an analysis of the changes in molecular weight of DNA, a modified version of the McGrath and Williams technique was employed. ${ }^{9}$ The results, which are given in Figure 5 show a relatively high level of unscheduled ${ }^{3} \mathrm{H}-\mathrm{TdR}$ incorporation in cultured human fibroblasts exposed to DMN plus the complete activation mixture, whereas DMN alone induces just a trace of DNA repair synthesis. Similarly, the alkaline![img-9.jpeg](img-9.jpeg)

Figure 5 DNA repair synthesis in cultured human fibroblasts following exposure to non-activated DMN ( $\bigcirc$ and $\square$ ) and DMN activated by a postmitochondrial liver mixture for different time periods ( $\boldsymbol{\sim}$ and $\boldsymbol{\square}$ ). Unscheduled incorporation of 2 HTdR combined with autoradiography.
sucrose profiles indicate a considerable shift in molecular weight following treatment with the activated DMN, but show virtually no effect when DMN is incubated with an inactivated post-mitochondrial supernatant fraction (Fig. 6). ${ }^{90}$ Comparable results were also obtained with aflatoxin B1 which elicits a DNA repair synthesis and mutations ${ }^{18}$ only when activated by the liver microsomal fraction. This result suggests that the liver post-mitochondrial supernatant may contain the proper activation enzymes for a variety of precarcinogens, and a combined application of DNA repair and activation enzymes may prove useful as a bioassay.

DNA REPAIR AND IDENTIFICATION OF SENSITIVE CELLS - XERODERMA PIGMENTOSUM

Numerous studies on microbial systems have revealed that an elevated sensitivity to UV-irradiation is due to mutations affecting one of the steps in the DNA excision-repair synthesis or 'cut and patch' procedure. ${ }^{19,23,50,54,75}$ The Exc- bacterial mutants and UV-yeast cells (Figs. 7, 8) also show an![img-10.jpeg](img-10.jpeg)

Figure 6 Changes in MW of DNA of cultured human fibroblasts treated with nonactivated and activated DMN for 30 min . A, sedimentation profile (alkaline sucrose gradient) of DNA of untreated cells; B, activation system only; C, DMN ( $5 \times 10^{-2} \mathrm{M}$ ) plus inactivated ( $10-\mathrm{min}$ boiling) activation system; D, DMN ( $5 \times 10^{-2} \mathrm{M}$ ) plus complete activation system.
increased sensitivity to the lethal action of exogenous chemicals and an elevated mutation rate when exposed to UV-radiation or challenged with several chemical mutagens. ${ }^{18,29}$ These microbial systems have proven to be excellent models for normal and repair-deficient human cells in which the role of DNA repair and its genetic control are only now being slowly unravelled. We shall concentrate briefly on the more practical and clinical implications of DNA repair rather than getting bogged down in a sophisticated speculation of various biochemical aspects of mammalian repair mechanisms.

The first question we were seeking to answer concerned the capacity of![img-11.jpeg](img-11.jpeg)

Figures 7, 8 Frequency of mutations (resistance to the antibiotic actidione) of different yeast strains (wild type; UV- = UV sensitive; $\mathrm{X}^{-}=\mathrm{X}$-ray sensitive; UV- $\mathrm{X}^{-}=$double mutant) following 4 NQO and MNNG.

Xeroderma pigmentosum cells to repair DNA changes which were induced by several chemical carcinogens. The homozygous recessive XP cells are known to be deficient in correcting UV-induced thymine dimers and possibly cytosine dimers in DNA molecules. ${ }^{5,6,52}$ However the response of XP cells towards chemical or viral carcinogens remained unknown until recently. ${ }^{7,53,55,59,62,63}$ To gain information on this important question, key carcinogens of diverse molecular structures were selected and cultured XP fibroblasts and normal human cells were exposed to them for short time periods ( $1.5-3$ hours). The unscheduled incorporation of ${ }^{3} \mathrm{HTdR}$ into nuclear DNA of non-dividing cells was then estimated by the regular autoradiographic technique. Diligent work, painstaking grain counts, and the loss of several technicians resulted in Figure 9 and Table III and the conclusion that XP cells show a considerably reduced DNA repair synthesis when exposed to some but not all chemical carcinogens. Thus, it is misleading to refer to XP cells as deficient in DNA repair without mentioning the 'agent provocateur.' As can be seen from Figure 9, XP cells can cope normally with a DNA damage induced by typical alkylating mutagens and carcinogens, including MNNG, MMS, and NMU.

A second point of general interest is the wide spectrum of DNA repair deficiencies found in cultured cells which were obtained from several unrelated persons. ${ }^{57}$ Among more than 40 XP patients examined the DNA repair synthesis varies from an undetectable level to about 80 per cent of that found in cells of non-afflicted control persons. ${ }^{1,3,6,29,63}$ Complementation studies (somatic cell hybridization between cells of two unrelated XP![img-12.jpeg](img-12.jpeg)

Figure 9 Unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation in cultured fibroblasts of Xeroderma pigmentosum patients ( $\square$ ) and control persons ( $\bigcirc$ ) following short ierm exposures to carcinogens and mutagens. Autoradiography.
patients) suggest the presence of different gene mutations among XP patients. ${ }^{72}$ At this stage the question was raised whether XP cells, which greatly differ in their capacity to repair UV-induced DNA changes, also differ in their response to chemically induced DNA alterations. Cell cultures of five XP patients were available to us and were chosen for this study. The results clearly show that the level of DNA repair synthesis is to a large extent independent of the type of DNA damaging agent (Table IV). ${ }^{62}$ The human population seems to contain an array of mutations which reduce to different levels the efficiency of repairing DNA changes induced by physical or chemicul carcinogens. Aflatoxins, dimethylnitrosamine, and the ubiquitous poly-TABLE III
Response of xeroderma pigmentosum cells to chemical carcinogens and mutagens

| Normal repair capacity | Reduced repair capacity |
| :--: | :--: |
| MNNG | 4NQO \& carcinogenic derivatives |
| MMS | 3-Me-4NPO |
| EMS | MCA-epoxide (K-region) |
| NMU | BA-epoxide (K-region) |
| $\mathrm{HN}_{3}$ | $N$-acetoxy-AAF |
| BHP | $N$-hydroxy-AAF |
| ICR-191 | $N$-acetoxy-AAS |
|  | $N$-hydroxy-AAS |
|  | $N$-acetoxy-4-AABP |
|  | $N$-acetoxy-2-AAP |
|  | $N$-hydroxy-2-AAP |
|  | $N$-myristoyloxy-2-AAF |
|  | $N$-acetoxy-3-AAF |
|  | DMN, activated |
|  | Aflatoxin $\mathrm{B}_{1}$, activated |
| X-ray | UV |

TABLE IV
Comparative levels of DNA repair synthesis in XP cells exposed to ultraviolet light, 4 NQO, $N$-acetoxy-AAF and Aflatoxin $B_{1}$ (activated by a post-mitochondrial liver fraction)

| Patient | Sex | Ultraviolet <br> $1000$ <br> $\mathrm{erg} / \mathrm{mm}^{2}$ | $\begin{aligned} & 4 \mathrm{NQO} \\ & 2 \times 10^{-6} \mathrm{M} \\ & 90 \mathrm{~min} \end{aligned}$ | $\begin{aligned} & \hline N \text {-acetoxy- } \\ & \text { AAF } \\ & 5 \times 10^{-5} \mathrm{M} \\ & 5 \mathrm{~h} \end{aligned}$ | Aflatoxin <br> $\mathrm{B}_{1}$ |
| :--: | :--: | :--: | :--: | :--: | :--: |
| XPH $_{1}$ | F | 9.8 | 10.3 | 10.2 |  |
| $\mathrm{XPH}_{2}$ | M | 12.1 | 13.1 | 16.0 |  |
| $\mathrm{XP}_{\mathrm{E}}$ | F | 21.5 | 20.2 | 22.9 | 19.7 |
| $\mathrm{XP}_{\mathrm{V}}$ | F | 36.0 | 33.6 | 29.1 |  |
| $\mathrm{XP}_{\mathrm{E}}$ | M | 56.6 | 55.7 | 60.8 | 61.1 |
| HETEROZYGOTES |  |  |  |  |  |
| $\mathrm{XP}_{\mathrm{E}}$ | Mother | 102 | 121 | 116 | - |
| $\mathrm{XP}_{\mathrm{V}}$ | Mother | 101 | 108.5 | 100 | - |
| $\mathrm{XP}_{\mathrm{E}}$ | Father | 123.5 | 94.2 | - | - |
| $\mathrm{XP}_{\mathrm{E}}$ | Mother | 116.1 | 95.2 | - | - |
| CONTROL | $\mathrm{M}+\mathrm{F}$ | $100 \%$ | $100 \%$ | $100 \%$ | $100 \%$ |

cyclic aromatic hydrocarbons, which have been implicated as cause of human neoplasms, are among the group of compounds that induce unrepairable DNA changes in XP cells.

Finally we turned our attention to the behaviour of cells which carry only one XP gene. These heterozygous XP cells were obtained from skin biopsies of parents of two XP patients. The DNA repair capacity of the XP heterozygous cells was compared with that found in XP homozygous fibroblasts and control cells. Even though we challenged the XP heterozygous cell with different UV doses, different chemical carcinogens, short-term andlong-term exposures to chemicals and various combinations of carcinogens, we were hitherto unable to distinguish XP heterozygous cells from normal ones (Table IV).

# DNA REPAIR AND IDENTIFICATION OF TARGET TISSUE 

In the preceding sections we tried to demonstrate the potential of DNA repair as a bioassay for carcinogens. In this section we should like to illustrate the use of DNA repair synthesis in the detection of those tissues and organs from which malignant sarcomas or carcinomas arise. This idea is based on the assumptions that DNA alterations are directly (as mutants) or indirectly (as sites of viral DNA integration) involved in neoplastic transformation, that proximate forms of chemical carcinogens are responsible for these DNA changes and that cells will attempt to correct these DNA anomalies by a DNA repair synthesis. The latter occurs only in cells of tissues and organs which were affected by a chemical carcinogen. Thus, by screening various organs for a DNA repair synthesis, we should be able to identify the target tissues of organotropic carcinogens.

To prove or disprove this hypothesis we designed a novel experimental procedure to examine DNA damage in various tissues following the administration of oncogenic compounds. The carcinogens or precarcinogens are injected into adult mice, biopsies are taken from various organs, the biopsy samples are dissected into small pieces (less than 0.5 mm in diameter) and are incubated for 180 min in a standard tissue culture medium containing ${ }^{3} \mathrm{HTdR}\left(10 \mu \mathrm{C} / \mathrm{ml}\right)$, then fixed, squashed between coverslips and slide, stained with a 2 per cent orcein-solution and covered with a photographic emulsion. The unscheduled incorporation of ${ }^{3} \mathrm{HTdR}$ into nondividing cells and its autoradiographic detection was employed to reveal the presence or absence of a DNA repair synthesis. Since this procedure permits the visualization of DNA repair in individual nuclei, it is possible to count the number of cells in DNA repair and to identify the type of cells and tissues which is engaged in DNA repair synthesis. The presence of heavily labelled S-phase nuclei throughout the biopsy samples indicate a good penetration of ${ }^{3} \mathrm{HTdR}$.

This method was used to examine the effect of 4 NQO and DMN. The two carcinogens were selected because they differ in their organotropic action. Mice injected with a single dose of 4 NQO developed lung adenomas and lung carcinomas but formed no hepatomas, ${ }^{41,42}$ whereas mice injected with DMN developed hepatomas, lung carcinomas, and occasionally kidney carcinomas. ${ }^{68,71}$

According to our previous postulation, the injected 4 NQO should induce only in the lung a DNA damage which results in a measurable DNA repairsynthesis, whereas DMN should evoke DNA changes and DNA repair in parenchymal cells of the liver, lung cells, and to a smaller degree in kidney cells. The actual results substantiate this prediction (Table IV). Cells in an active DNA repair synthesis were only seen in those tissues in which neoplasms arise after a single administration of 4 NQO or DMN. In this connection it is of interest to note the metabolic behaviour of the two carcinogens employed. ${ }^{27}$ Following a single injection, 4 NQO accumulates in the lung and is metabolized there into the proximate carcinogen 4 HAQO . On the other hand the liver of these mice contained only traces of the highly oncogenic 4 HAQO , but harboured considerable quantities of the non-oncogenic metabolites $4 \mathrm{NH}_{2}$-quinoline 1 -oxide and $4 \mathrm{NH}_{2}$-quinoline. Unfortunately no corresponding data are available on the metabolism of DMN in various organs of mice. However, the liver of rodents seems to be the main organ of DMN metabolism as shown in vitro on organ slices. ${ }^{34,46}$

The simplest interpretation of these data is to assume an organ specific activation of precarcinogens into the proximate carcinogens resulting in these organs in DNA changes which in turn are followed by a DNA repair synthesis. Thus an estimation of a DNA repair synthesis which can be accomplished within a few days does reveal the tissues affected by carcinogens and identifies the site of later tumor formation. Furthermore the method proposed above will detect the action of organotropic precarcinogen.s which become activated in one particular tissue and thus could be missed by in vitro screening procedures.

DNA REPAIR, CHROMOSOME ABERRATION AND CELL SURVIVAL

Copy errors during repair synthesis, unrepaired DNA changes, and mistakes during a semi-conservative DNA replication of unrepaired DNA lesions should result in changes detectable at the cellular level. In bacteria, lethality and mutagenesis are two biological parameters which are strongly affected by the level of DNA repair capacity. Considering the similarity between $\mathrm{Exc}^{-}$bacterial mutants and XP cells, ${ }^{6}$ one should expect that survival rate and mutation frequency will be good indicators for revealing the influence of a deficient DNA repair mechanism in mammalian cells. ${ }^{10,52,60,62,67}$

The clone-forming capacity of XP cells was compared with that of control cells following short term exposures to various chemical carcinogens (Fig. 10). A comparative investigation of 16 compounds revealed a certain pattern: the XP cells are highly sensitive to those carcinogens which elicit in them a lower than normal level of DNA repair synthesis (e.g., 4 NQO , N -acetoxy-AAS, DBA-Epoxide). On the other hand, carcinogens which evoke a comparable DNA repair synthesis in normal cells and XP cells (Fig. 9) exert a similar lethal effect (e.g., MNNG [Fig. 10]). Furthermore,![img-13.jpeg](img-13.jpeg)

Figure 10 Clone-forming capacity of cultured fibroblasts of Xeroderma pigmentosum patients ( $\square$ ) and control persons ( $\bigcirc$ ) following short term exposure to various carcinogens and mutagens.TABLE V
DNA repair synthesis in various tissues following a single injection of the organotropic carcinogens 4 NQO and DMN

| Tissue | Average grain number ${ }^{2}$ 4NQO $(200 \mathrm{mg} / \mathrm{kg})$ | DMN $(150 \mathrm{mg} / \mathrm{kg})$ |
| :--: | :--: | :--: |
| Lung ${ }^{1}$ | $11.5(\sim 90 \%)$ | $5.7(\sim 30-50 \%)$ |
| Liver, parenchymal cells | 0 | $13.2^{3}$ |
| endothelial cells | 0 | 0 |
| Kidney, glomeruli | 0 | 0 |
| loops of Henle | 0 | $4.8^{3}$ |
| Spleen | 0 | 0 |
| Salivary gland | 0 | 0 |
| Thymus | 0 | 0 |
| Stomach, epithelial cells | 0 | 0 |
| Large intestine, epithelial cells | 0 | 0 |

${ }^{1}$ At present we did not distinguish between epithelial and non-epithelial cell types.
${ }^{2}$ Average grain number of cells which showed unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation, S-phase nuclei were excluded from the counts.
${ }^{3}$ Cells showing unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation occur in groups.
precarcinogens which seem to lack the capacity to interfere with DNA molecules and thus do not trigger any DNA repair do not reduce even at very high concentration the clone-forming capacity of normal or XP cells (Fig. 10).

An accurate estimation of the mutation frequency in cultured normal cells and XP cells has proven so far to be an unrewarding venture. The test system of forward mutations to 8 -azaguanine resistance is difficult to quantitate when the cloning efficiency is low and when two cell types (normal and XP cells) which are to be compared differ greatly in their lethality towards active carcinogens. We, therefore, decided to estimate accurately the frequency of chromosome aberrations rather than to measure inaccurately point mutations.

In a series of experiments, we compared the chromosome damaging effect of three groups of compounds: (1) carcinogens which produce unrepairable DNA changes in XP cells (e.g., $N$-acetoxy AAF, activated aflatoxin B1, 4 NQO ); (2) carcinogens which induce repairable DNA changes in XP cells (e.g., MNNG); and (3) mutagens which induce chromosome anomalies, but apparently lack the capacity to evoke a DNA repair synthesis in normal and XP cells (e.g., daunomycin). The results are summarized in Table VI. The frequency of chromosome aberrations in XP cells differs from that in control cells following the application of agents belonging in group 1. All the other compounds examined induce at equimolar concentrations a similar frequency of chromosome aberrations in cells with a normal DNA repair synthesis and in cells with an impaired repair mechanism.TABLE VI
Frequency of Xeroderma pigmentosum and control cells with chromosome aberrations following exposure to different carcinogens

|  |  | Metaphase plates with chromosome aberrations (\%) |  |
| :--: | :--: | :--: | :--: |
| Carcinogens | Concentration | $\mathrm{XP}_{\mathrm{E}}$ | Control (Do) |
| 4NQO | $1.2 \times 10^{-7} \mathrm{M}$ ( 90 min ) | 40.8 | 0.5 |
| N -acetoxy-AAF | $1.0 \times 10^{-5} \mathrm{M}$ ( 5 hours) | 44.0 | 4.7 |
| N -hydroxy-AAP | $1.0 \times 10^{-5} \mathrm{M}$ ( 5 hours) | 28.5 | 0.7 |
| BA-epoxide | $3 \mu \mathrm{~g} / \mathrm{ml}$ | ( 5 hours) | 45.3 | 0.5 |
| Aflatoxin $B_{1}$ | $60 \mu \mathrm{~g} / \mathrm{ml}$ | ( 30 min ) | 100.0 | 16.6 |
| MNNG | $1.2 \times 10^{-3} \mathrm{M}$ ( 3 hours) | 48.3 | 50.0 |
| Daunomycin | $0.35 \mu \mathrm{~g} / \mathrm{ml}$. ( 3 hours) | $93: 3$ | 83.3 |
| Adenovirus $12^{1}$ | 50 PFU | 51.7 | 58.9 |

${ }^{1}$ AD12 preparations were inactivated by UV-irradiation ( $3.600 \mathrm{erg} / \mathrm{mm}^{2}$ ).

In a second set of experiments, we tried to answer the question whether XP cells of different DNA repair capacities will show different sensitivities towards the chromosome damaging action of carcinogens. Cultured fibroblasts of $\mathrm{XP}_{\mathrm{H}}$ ( 12 per cent repair deficient compared to control), $\mathrm{XP}_{\mathrm{E}}$ ( 21 per cent), and $\mathrm{XP}_{\mathrm{K}}$ ( 56 per cent), and of two non-affected controls were exposed to 4 NQO and the chromosome aberrations were scored at the metaphase plate of the first cell division following the application of the carcinogens. There seems to be a good correlation between degree of repair deficiency and sensitivity towards the chromosome damage effect of chemicals: the more severe the repair deficiency, the higher the frequency of chromosome aberration.

Furthermore, we exposed XP cells and normal ones to UV-inactivated human adenovirus type 12 (AD12) which is capable of inducing a relatively high frequency of chromosome aberrations in human and hamster cells. ${ }^{56,64}$ The UV-irradiation of the virus preparation was necessary to block virus replication and its cytolytic effect. There was no obvious difference between the frequency of chromosome breakage in XP cells and normal cells at the first mitosis post-infection with the UV-inactivated AD12 (Table VI). In this connection it is of interest to note that XP cells show no elevated transformation rate when exposed to SV40. ${ }^{2,47}$

These few preliminary studies have already revealed the presence of gene mutations among the human population which affect the sensitivity of cells towards the lethal effect and chromosome damaging action of several but not all chemical carcinogens. The degree of sensitivity seems to be related to the level of deficiency in the DNA repair mechanism. If the Xeroderma pigmentosum case represents only one 'sensitizing' gene complex amongmany possible ones, then one must expect a considerable variation in the response of human beings towards the same noxious agent as well as a variation in the reactions towards different carcinogens.

# TEMPORARY INHIBITION OF DNA REPAIR 

There is a plethora of evidence showing that a genetically impaired DNA repair mechanism increases the sensitivity of bacterial and mammalian ce!ls towards the lethal and mutagenic effect of physical and chemical agents. The questions must be raised whether a DNA repair synthesis can be temporarily reduced or blocked by chemicals, whether such a treatment would sensitize cells towards chemotherapeutic agents or carcinogens, and whether an interference with the repair processes is reversible.

Since a discussion of all these problems is beyond the main aim of this paper, we wish to restrict ourselves to describing a dual action of carcinogens: namely their capacity to induce DNA lesions and their capacity to affect a normal DNA repair synthesis. The following experimental protocol was used: non-dividing human cells were either UV-irradiated and thereafter exposed to chemical carcinogens, or treated with the chemical carcinogen prior to, as well as after, UV-irradiation. Following this combined application of UV-radiation and a chemical carcinogen, the cells were placed into culture medium with ${ }^{3} \mathrm{HTdR}$ to measure DNA repair synthesis or seeded into new plates to estimate the clone-forming capacity (Fig. 11).

The results show that all the active chemical carcinogens examined inhibit DNA repair synthesis and that various carcinogenic compounds greatly differ in their capacity to induce DNA lesions and to inhibit DNA repair. Unfortunately, it is somewhat difficult to assess the results of the combination experiments, because the chemical carcinogens add new DNA lesions to those induced by UV-irradiation. Thus the ensuing unscheduled DNA synthesis is a product of the DNA lesions induced by UV, DNA lesions induced by the chemical, and the extent to which DNA repair synthesis is adversely affected by UV and the chemical carcinogen. In spite of these technical restrictions, one can grade carcinogens as strong or weak inducers of DNA lesions and strong or weak inhibitors of DNA repair. The absence of a DNA repair synthesis following the administration of a compound

Figure 11 Inhibition of DNA repair synthesis in cultured human fibroblasts following the combined application of UV and chemical compounds. $\square=$ unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation following 90 min of $N$-acetoxy-AAS, nitrogen mustard, or FANFT; - unscheduled ${ }^{3} \mathrm{HTdR}$ incorporation following UV irradiation ( $900 \mathrm{erg} / \mathrm{mm}^{2}$ ) and the three compounds. $\Delta=$ theoretical curves showing a strict additive effect of UV and the three compounds (an additive effect occurs at the lowest concentrations employed).![img-14.jpeg](img-14.jpeg)![img-15.jpeg](img-15.jpeg)

Figure 12 Effect of a combined treatment (UV $16 \mathrm{erg} / \mathrm{mm}^{2}$ and 4 NQO or $N$-acetoxyAAS of various concentrations) on clone-forming capacity of cultured human fibroblasts.
could be due to the lack of its interaction with DNA (non-oncogenic compounds) or due to a blockage of repair processes by a carcinogen with a strong inhibitory property.

The intriguing question must be raised whether a chemical could have a carcinogenic effect by merely inhibiting DNA repair of 'spontaneously' occurring DNA lesions and in this manner contribute to genetic anomalies and neoplastic transformation. We have no answer to offer at present to this question. However an extensive study of Gaudin et al. ${ }^{14}$ has revealed that all co-carcinogens examined inhibit DNA repair synthesis.

If one wished to speculate about the properties of the most effective carcinogen, one would predict that an 'ideal carcinogen' is a relatively weak inducer of DNA breaks and a weak inhibitor of DNA repair. This double action may lead to unrepaired DNA lesions and mutations without producing a strong lethal effect or permitting a complete repair of the induced DNA lesion.

# A LOOKOUT FOR AN OUTLOOK 

If the reader is somewhat confused about the significance of all the preceding data we would apologize by saying that he is by no means alone in thispredicament. We, ourselves, can only offer a kind of Chinese brush painting which demands that the beholder complete the details according to his own imagination and free association.

It has been claimed that at least 80 per cent of all human neoplasms have an environmental etiology and are thus theoretically preventable. ${ }^{11,21,46}$ Why then has this promising prediction not been at least partly implemented? In answering this question one must immediately confess to a lack of information about the large number of factors involved in the interaction between a complex, largely unknown environment, and an equally complex and unknown set of cell responses. Probably the most disturbing observation is the highly elevated sensitivity of Xeroderma pigmentosum cells towards some, but not all, chemical or physical carcinogens. If this type of selective response also occurs in cells carrying other cancer predisposing genes, then the human population must consist of a virtually uncountable number of groups, subgroups, and families, each of them sensitive to a different set of carcinogenic agents. There is evidence in support of such an assumption. For example, cultured fibroblasts of patients with Klinefelter's syndrome, ${ }^{43}$ Fanconi's anemia, ${ }^{74}$ Down's syndrome, ${ }^{70,75}$ and XY-gonadal dysgenesis ${ }^{44}$ are highly susceptible to viral (SV40) induced transformation whereas the XP cells do not show this phenomenon. ${ }^{2,47}$ Thus, in order to determine the type and spectrum of sensitivity, one is forced to test the response towards a large series of chemical compounds, various oncogenic viruses, and physical carcinogens. This, indeed, is a herculean task.

The search for cancer predisposed persons is complicated further by the genetic heterogeneity within a particular defect, as is the case for Xeroderma pigmentosum. Patients with clinical symptoms may have a DNA repair level which is reduced by $20-100$ per cent as compared to non-afflicted control persons of comparable age and sex. Persons with only a slightly reduced repair capacity ( $1-19$ per cent) have not been found as yet. They are probably missed because they may not show any of the typical XP symptoms. Nevertheless, it is conceivable that their sensitivity towards UV-irradiation and other DNA-damaging agents is elevated. At present this population group, if it exists at all, remains unrecognized, thus escaping any possible preventive measures. A second serious gap in our knowledge is the inability to recognize individuals who are heterozygous for the XP gene. Thus, it is unknown whether or not these XP heterozygous persons show a higher than normal incidence of tumors. In this connection it is of interest to note that the recessive autosomal gene of Fanconi's anemia (FA) increases (threefold) the risk of a heterozygote dying from malignancy. ${ }^{66}$ As in the case of Xeroderma pigmentosum, the FA heterozygote shows none of the clinical symptoms of the homozygous patient.

Critics of studies on rare tumor predisposing genes tend to forget theseheterozygous carriers. Their number is by no means negligible. There should be about $650,000 \mathrm{FA}$ carriers among the $200 \times 10^{6}$ North Americans. If they all show an elevated cancer risk, then, according to Swift, the FA heterozygous persons could comprise about 1 per cent of all patients dying of cancer and leukemia. At present we cannot apply a similar calculation for the XP heterozygous (about 200,000 in North America), because we cannot access their cancer risk. If these estimations are extended to other gene mutants and chromosome anomalies, then the proportion of persons carrying at least one cancer predisposing genetic defect must be considerable. Thus, by looking to relatively small numbers of homozygous patients, one may erroneously consider the genetic predisposition for cancer a rare phenomenon.

Turning to environmental carcinogens, we face an equally complex situation. There is the unsolved problem of deciding on relevant screening and prescreening procedures. The use of rodents for testing yearly hundreds of new compounds is logistically difficult and would become a serious financial burden to society. On the other hand, many in vitro bioassays on mammalian or microbial cells are economic and rapid but easily miss precarcinogens which need metabolic activation by an enzyme system restricted to one or the other mammalian tissue. The solution of this dilemma is at present one of the key issues in the field of environmental carcinogenesis. The proposed method of applying a compound in vivo and measuring the induced DNA alterations as DNA repair in vitro has a very good chance of fulfilling all requirements for a bioassay applicable in a large-scale creening program. This method is economic, can be completed within one week, and would hopefully detect not only precarcinogens but also the organs and tissues from which neoplasms will arise following the application of organotropic carcinogens and precarcinogens.

# REFERENCES 

1 Bootsma, D., Mulder, M.P., Pot, F., and Cohen, J.A. Different inherited levels of DNA repair replication in Xeroderma pigmentosum cell strains after exposure to ultraviolet light. Mutation Research, 9: 507-516, 1970
2 Bowen, J.M., Mukerjee, D., Scanlon, M.D., Bettinger, J., Trujillo, J.M., and Domochowski, L. Interaction of SV40 with skin fibroblasts from patients with Xeroderma pigmentosum. Proc. Am. Assoc. Cancer Research, 13: 99, 1972
3 Burk, P.G., Lutzner, M.A., Clarke, D.D., and Robbins, J.H. Ultraviolet-stimulated thymidine incorporation in Xeroderma pigmentosum lymphocytes. J. Lab. Clin. Me 1., 77: 759-767, 1971
4 Chu, E.H.Y. and Malling, H.V. Mammalian cell genetics, in. Chemical induction of specific locus mutations in Chinese hamster cells in vitro. Proc. Natl. Acad. Sci., 61: 1306-1312, 19685 Cleaver, J.E. DNA repair and radiation sensitivity in human (Xeroderma pigmentosum) cells. Intern. J. Radiat. Biol., 18: 557-565, 1970
6 Cleaver, J.E. Repair of damages in human and other eukaryotic cells. In Nucleic Acid-Protein Interactions. D.W. Ribbons, J.F. Woessner, and J. Schultz, eds. pp. 7-111. Amsterdam: North-Holland Publishing Co., 1970
7 Cleaver, J.E. Repair of alkylation damage in ultraviolet-sensitive (Xeroderma pigmentosum) human cells. Mutation Research, 12: 453-462, 1971
8 Cleaver, J.E. DNA repair with purines and pyrimidines in radiation- and carcinogendamaged normal and Xeroderma pigmentosum human cells. Cancer Research, 33: $362-369,1972$
9 Cox, R., Damjanov, I., Abanobi, S.E., and Sarma, D.S.R. A method for measuring DNA damage and repair in the liver in vivo. Cancer Res., 33: 2114-2121, 1973
10 Creech, H.J. Thirteenth Annual Report. Inst. for Cancer Research (Philadelphia), Scientific Rept. 97, 1964-1966
11 Davies, J.N.P. Cancer and the internal and external environment. In Proc. Ninth Canadian Cancer Research Conf., P.G. Scholefield, ed. pp. 10-12, Toronto: University of Toronto Press, 1971
12 Dalrymple, G.V., Sanders, J.L., Moss, A.J., Baker, L.M., and Wilkinson, K.P. Radiation produces breaks in L-cells and mouse liver DNA characterized by $5^{\prime}$ phosphoryl termini. Biochem. Biophys. Res. Commun., 35: 300-305, 1969
13 Garner, R.C., Miller, E.C., and Miller, J.A. Liver microsomal metabolism of aflatoxin $\mathrm{B}_{1}$ to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Research, 32: 2058-2066, 1972
14 Gaudin, D., Gregg, R.S., and Yielding, K.L. DNA repair inhibition: A possible mechanism of action of co-carcinogens. Biochem. Biophys. Res. Commun., 45: 630-636, 1971
15 German, J., Archibald, R., and Bloom, D. Chromosomal breakage in a rare and probably genetically determined syndrome of man: Science, 148: 506-507, 1965
16 Goldstein, S. The role of DNA repair in aging of cultured fibroblasts from Xeroderma pigmentosum and normals. Proc. Soc. Exptl. Biol. Med., 137: 730-734, 1971
17 Goodman, J.I. and Potter, V.R. Evidence for DNA repair synthesis and turnover in rat liver following ingestion of $3^{\prime}$-methyl-4-dimethyl-aminoazobenzene. Cancer Research, 32: 766-775, 1972
18 Grover, P.L., Sims, P., Huberman, E., Marquardt, H., Kuroki, T., and Heidelberger, C. In vitro transformation of rodent cells by K-region derivatives of polycyclic hydrocarbons. Proc. Natl. Acad. Sci. u.s., 68: 1098-1101, 1971
19 Haynes, R.H., Baker, R.M., and Jones, G.E. Genetic implications of DNA repair. In Energetics and Mechanisms in Radiation Biology, G. Phillips, ed. London: Academic Press, 1968
20 Heidelberger, C. In vitro studies on the role of epoxides in carcinogenic hydrocarbon activation. In Topics in Chemical Carcinogenesis, W Nakahara, S. Takayama, T. Sugimura, and S. Odashima, eds., pp. 371-386. Baltimore: University Park Press, 1972
21 Higginson, J. Present trends in cancer epidemiology'. Proc. Eighth Canadian Cancer Conference, ed. pp. 40-75. The University of Toronto Press, 1969
22 Horikawa, M., Nikaido, O., Tanaka, T., Nagata, H., and Sugahara, T. Carcinogenesis in tissue culture, X. Rejoining of single-strand breaks in DNA of mammalian cells induced by chemical carcinogens (4-nitroquinoline 1-oxide and its derivatives) in vitro. Exptl. Cell Research, 59: 147-152, 197023 Howard-Flanders, P. DNA repair. Ann. Rev. Biochem., 37: 175-200, 1968
24 Huberman, E., Aspiras, L., Heidelberger, C., Grover, P.L., and Sims, P. Mutagenicity to mammalian cells of epoxides and other derivatives of polycyclic hydrocarbons. Proc. Natl. Acad. Sci. u.s., 68: 3195-3199, 1971
25 Kawazoe, Y., Tachibana, M., Aoki, K., and Nakahara, W. The structurecarcinogenicity relationship among derivatives of 4 -nitro and 4 -hydroxyaminoquinoline 1-oxides. Biochem. Pharmacol. 16: 631-636, 1967
26 Kawazoe, Y. and Araki, M. Chemical problems in 4NQO carcinogenesis. In Chemical Tumour Problems. W. Nakahara, ed. pp. 45-104. Tokyo: Gaitame, 1970
27 Kawazoe, Y., Uehara, N., and Araki, M. Studies on chemical carcinogens. xi. Metabolism of tritiated carcinogenic 4-nitroquinoline 1 -oxide and distribution of its metabolites in mouse. Gann, 60: 617-629, 1969
28 Kleijer, W.J., Lohman, P.H.M., Mulder, M.P., and Bootsma, D. Repair of X-ray damage in DNA of cultivated cells from patients having Xeroderma pigmentosum. Mutation Research, 9: 517-523, 1970
29 Kondo, S. and Kato, T. Photoreactivation of mutation and killing in Escherichia Coli. In Advances in Biological and Medical Physics, Vol.12, J.H. Lawrence and J.W. Goffman, eds., pp. 283-298. New York: Academic Press, 1968

30 Laishes, B.A. and Stich, H.F. Repair synthesis and sedimentation analysis of DNA of human cells exposed to dimethylnitrosamine and activated dimethylnitrosamine. Biochem. Biophys. Res. Commun., 52: 827-833, 1973
31 Laishes, B.A. and Stich, H.F. Relative DNA damage induced in cultured human skin fibroblasts by exposure to the precarcinogen 2-acetylaminofluorene, the proximate carcinogen N-hydroxy-2-acetylaminofluorene, and the ultimate carcinogen N -acetoxy-2-acetylaminofluorene. Can. J. Biochem., 51: 990-994, 1973
32 Lieberman, M.W., Baney, R.N., Lee, R.E., Sell, S., and Farber, E. Studies on DNA repair in human lymphocytes treated with proximate carcinogens and alkylating agents. Cancer Research, 31: 1297-1306, 1971
33 Lieberman, M.W. and Dipple, A. Removal of bound carcinogen during DNA repair in nondividing human lymphocytes. Cancer Research, 32: 1855-1860, 1972
34 Magee, P.N. Possible mechanisms of carcinogenesis and mutagenesis by nitrosamines. In Topics in Chemical Carcinogenesis. W. Nakahara, S. Takayama, T. Sugimura, and S. Odashima, eds., pp. 259-275. Baltimore: University Park Press, 1972
35 Maher, V.M., Miller, E.C., Miller, J.A., and Szybalski, W. Mutations and decreases in density of transforming DNA produced by derivatives of the carcinogens 2-acetylaminofluorene and N -methyl-4-aminoazobenzene. Molec. Pharmacol., 4: $411-425,1968$
36 Malling, H.V. Dimethylnitrosamine: Formation of mutagenic compounds by interaction with mouse liver microsomes. Mutation Research, 13: 425-429, 1971
37 McGrath, R.A. and Williams, R.W. Reconstruction in vivo of irradiated E. Coli deoxyribonucleic acid: The rejoining of broken pieces. Nature, 212: 534-535, 1966
38 Miller, J.A. Carcinogenesis by chemicals: an overview. Cancer Research, 30: 559-576, 1970
39 Miller, J.A. and Miller, E.C. Metabolic activation of carcinogenic amines and amides via N-hydroxylation and N -hydroxy-esterification and its relationship to ultimate carcinogens as electrophilic reactants. In Jerusalem Symposia on Quantum Chemistry and Biochemistry. Physico-chemical Mechanisms of Carcinogenesis. Vol. 1, p. 237. E.D. Bergman and B. Pullman, eds. Jerusalem, Israel Academy of Sciences and Humanities, 196940 Montesano, R. and Magee, P.N. Metabolism of nitrosamines by rat and hamster tissue slices in vitro. Proc. Am. Assoc. Cancer Research, 12: 14, 1971
41 Mori, K. Induction of pulmonary and uterine cancers, and leukemia in mice by injection of 4-nitroquinoline 1-oxide. Gann, 56: 513-518, 1965
42 Mori, K. and Kondo, M. Induction of pulmonary tumors by a single dose of 4-nitroquinoline 1 -oxide injected in newborn mice. (A consideration on renewal of tissue cells in carcinogenesis.) Gann, 57: 543-548, 1966
43 Mukerjee, D., Bowen, J., and Anderson, D.E. Simian papovavirus 40 transformation of cells from cancer patient with XY/XXY mosaic Klinefelter's Syndrome. Cancer Research, 30: 1769-1772, 1970
44 Mukerjee, D., Bowen, J.M., Trujillo, J.M., and Cork, A. Increased susceptibility of cells from cancer patients with XY-gonadal dysgenesis to simian papovavirus 40 transformation. Cancer Research, 32: 1518-1520, 1972
45 National Program for the Conquest of Cancer. Document No. 92-9, u.s. Government Printing Office, Washington, 1971
46 Oettle, A.G. Cancer in Africa: Especially in regions south of the Sahara. J. Natl. Cancer Inst., 33: 383-439, 1964
47 Parrington, J.M., Delhanty, J.D.A., and Baden, H.P. Unscheduled DNA synthesis, UV-induced chromosome aberrations and SV40 transformation in cultured cells from Xeroderma pigmentosum. Ann. Hum. Genet. (London), 35: 149-160, 1971
48 Rasmussen, R.E. and Painter, R.B. Radiation-stimulated DNA synthesis in cultured mammalian cells. J. Cell Biol. 9: 11-19, 1966
49 Regan, J.D., Setlow, R.B., and Ley, R.D. Normal and defective repair of damaged DNA in human cells: A sensitive assay utilizing photolysis of Bromodeoxyuridine. Proc. Natl. Acad. Sci. u.s., 68: 708-712, 1971
50 Setlow, R.B. Steps in the repair of DNA: Fact and fancy. Brookhaven Symp. Biol., 20: 1-12, 1967
51 Setlow, R.B. and Carrier, W.L. The disappearance of thymine dimers from DNA: An error-correcting mechanism. Proc. Natl. Acad. Sci. u.s., 51: 226-231, 1964
52 Setlow, R.B., Regan, J.D., German, J., and Carrier, W.L. Evidence that Xeroderma pigmentosum cells do not perform the first step in the repair of ultraviolet damase to their DNA. Proc. Natl. Acad. Sci. u.s., 64: 1035-1041, 1969
53 Setlow, R.B. and Regan, J.D. Defective repair of N-acetoxy-2-acetylamino-fluoreneinduced Lesions in the DNA of Xeroderma pigmentosum cells. Biochem. Biophys. Res. Commun., 46: 1019-1024, 1972
54 Smith, K.C. and Hanawalt, P.C. Molecular Photobiology, Inactivation and Recovery. New York: Academic Press, 1969
55 Stich, H.F. The link between oncogenicity of 4 NQO and 4 NPO derivatives, Induction of DNA lesions and enhancement of viral transformation. In Topics in Chemical Carcinogenesis, W., Nakahara, S. Takayama, T. Sugimura, and S. Odashima, eds., pp. 17-28. Baltimore: University Park Press, 1972

56 Stich, H.F., Avila, L., and Yohn, D.S. Viruses and mammalian chromosomes. IX. The capacity of UV-impaired adenovirus type 18 to induce chromosome aberrations. Exptl. Cell Research, 53: 44-54, 1968
57 Stich, H.F. and Laishes, B.A. DNA repair and chemical carcinogens. In Pathobiology Annual, 1973, H.L. Joachim, ed. New York: Appleton-CenturyCrofts, pp. 341-376, 1973
58 Stich, H.F. and San, R.H.C. DNA repair and chromatid anomalies in mammalian cells exposed to 4-nitroquinoline 1-oxide. Mutation Research, 10: 389-404, 1970
59 Stich, H.F. and San, R.H.C. Reduced DNA repair synthesis in Xerodermapigmentosum cells exposed to 4 NQO and 4 HAQO . Mutation Research, 13: $379-404,1971$
60 Stich, H.F. and San, R.H.C. DNA repair synthesis and survival of repair deficient human cells exposed to the K-region epoxide of benz( $\alpha$ ) anthracene. Proc. Soc. Exptl. Biol. Med. 142: 155-158, 1973
61 Stich, H.F., San, R.H.C., and Kawazoe, Y. DNA repair synthesis in mammalian cells exposed to a series of oncogenic and non-oncogenic derivatives of 4 -nitroquinoline 1-oxide. Nature, 229: 416-419, 1970
62 Stich, H.F., San, R.H.C., and Kawazoe, Y. Increased sensitivity of Xeroderma pigmentosum cells to some chemical carcinogens and mutagens. Mutation Research, 17: 127-137, 1973
63 Stich, H.F., San, R.H.C., Miller, J., and Miller, E. Various levels of DNA repair synthesis in Xeroderma pigmentosum cells exposed to N -hydroxy- and N -acetoxy-2acetylaminofluorene, Nature, New Biology., 238: 9-10, 1972
64 Stich, H.F., Stich, W., and San, R.H.C. Chromosome aberrations in Xeroderma pigmentosum cells exposed to the carcinogens, 4-nitroquinoline-1-oxide and N-methyl-N'-nitro-nitrosoguanidine. Proc. Soc. Exptl. Biol. Med., 142: $1141-1144,1973$
65 Stich, H.F. and Yohn, D.S. Mutagenic capacity of adenoviruses for mammalian cells. Nature, 216: 1292-1294, 1967
66 Swift, M. Fanconi's anaemia in the genetics of neoplasia. Nature, 230: 370-373, 1971
67 Takebe, H., Furuyama, J., Miki, Y., and Kondo, S. High sensitivity of Xeroderma pigmentosum cells to the carcinogen 4-nitroquinoline 1-oxide. Mutation Research, 15: 98-100, 1972
68 Terracini, B., Palestro, G., Gigliardi, M.R., and Montesano, R. Carcinogenicity of dimethylnitrosamine in Swiss mice. Brit. J. Cancer, 20: 871-876, 1966
69 Todaro, G.J., Green, H., and Swift, M.R. Susceptibility of human diploid fibroblast strains to transformation by SV40. Science, 153: 1252-1254, 1966
70 Todaro, G.J. and Martin, G.M. Increased susceptibility of Down's syndrome fibroblasts to transformation by SV40. Proc. Soc. Exptl. Biol. Med., 124: 1232-1236, 1967
71 Toth, B., Magee, P.N., and Shubik, P. Carcinogenesis study with dimethylnitrosamine administered orally to adult and subcutaneously to newborn BALB/c mice. Cancer Research, 24: 1712-1721, 1964
72 de Weerd-Kastelein, E.A., Keijzer, W., and Bootsma, D. Genetic heterogeneity of Xeroderma pigmentosum demonstrated by somatic cell hybridization. Nature, New Biology, 238: 80-83, 1972
73 Witkin, E.M. Ultraviolet-induced mutation and DNA repair. Ann. Rev. Genetics, 3: $525-552,1969$
74 Young, D. SV40 transformation of cells from patients with Fanconi's anaemia. Lancet, 1: 294-295, 1971
75 Young, D. The susceptibility to SV40 virus transformation of fibroblasts obtained from patients with Down's syndrome. European J. Cancer, 7: 337-339, 1971TUMOR IMMUNOLOGY$\cdot$
$\cdot$# Mechanisms of humoral tumor immunity in malignant melanoma 

M.G. LEWIS<br>Director, McGill Cancer Research Unit, McIntyre Medical Science Building, Montreal 109, Quebec

The fact that growing tumors produce in the hosts bearing them a variety of forms of immune response against the tumors is now beyond reasonable doubt. The subject has developed rapidly over the past fifteen to twenty years and evidence both in experimental animals and in man is available and has been extensively reviewed in the literature. ${ }^{1,2,3}$ I wish to confine my remarks in this presentation to certain aspects of immune reactions against human tumors, namely the role played by circulating antibodies against a number of tumor antigens, particularly in human malignant melanoma. This particular human neoplasm, which characteristically arises from melanocytic cells in the epidermis of the skin or from the choroidal melanocytes of the eye and rarely from certain other mucous membranes, represents a group with a number of features that lend themselves to the particular studies to be outlined.

CLINICALOBSERVATIONS
The advantage of studying a tumor which arises usually in an easily visible site and therefore can be detected at an early stage and yet can go through a somewhat varied and very wide spectrum of biological activity is obvious. Malignant melanoma certainly fits most of these criteria, in addition to which it is one of the most important of the groups of human tumors that have been recorded as undergoing spontaneous regression. ${ }^{4,5}$ For many years, clinicians and pathologists studying this tumor have been intrigued by its varied natural history and its ability, for instance, to remain localized for relatively long periods of time at all stages of its development, even in the later widespread metastatic phase. ${ }^{6}$ The difficulty of comparing groups of patients where the tumor may arise at almost any point on the body surface with the variety of lymphatic drainage limited the scope of detailed studies relating to the host's effect on the tumor. The situation in the African, however, led to some clarification of this. Malignant melanoma in the Negroraces of Africa characteristically arises on the soles of the feet in approximately seventy per cent of patients, with initial spread to the draining lymph nodes of the groin and then subsequent dissemination in the characteristic way seen also in the European races. ${ }^{7}$ It was possible, therefore, to compare groups of patients with an identical primary site of tumor and with an identical secondary spread prior to dissemination. During this study, three types of patient-tumor relationship were seen: ${ }^{8}$ group one, in which the tumor remained localized on the soles of the feet for many months or years with no spread to the draining lymph node until late; group two, in which the tumor spread rapidly within a matter of weeks or months from the sole of the foot to the groin and beyond; and group three, in which the primary tumor regressed, leaving secondary deposits in the lymph node, thus giving the impression that the tumor had presented as lymph node metastases. ${ }^{9,10}$

The usual clinical criteria of age, sex, tribe showed no difference between the groups, and histopathological analysis of tumors in over three hundred patients representing these three groups showed again that the tumor type was not responsible for the difference.

# LABORATORY INVESTIGATIONS 

It was decided to investigate the possibility that other host factors might be responsible and tumors were therefore prepared freshly from the patient in tissue culture medium and placed in Pulvertaft culture chambers consisting of a Teflon ring attached to a glass slide by silicone grease with a coverslip attached to the top. ${ }^{11}$ The tumor cells were then placed in these culture chambers and mixed with volumes of the patient's own serum and various control serums. The sera from patients in group one, with the long-delayed metastatic disease, caused the autologous tumor cells to round up and fall away from the glass coverslip and cease to grow. The sera from group two and group three showed no such reaction and were identical with the control sera. ${ }^{12}$ Subsequent studies demonstrated that the component in the serum was in fact an immunoglobulin, usually IgG, and that the reaction could be abolished by inactivating complement. This technique has been subsequently described as a complement-dependent cytotoxicity. An attempt to quantitate this by incorporation of radioactive uridine into the cells, although somewhat tedious, confirmed the test and showed that it could be quantitated. ${ }^{13}$

## FLUORESCENTANTIBODYTECHNIQUES

In addition to cytotoxicitis, sera were tested against autologous melanoma cells by the indirect immunofluorescent technique in two ways: (1) against snap frozen melanoma cells prepared in a mixture of liquid nitrogen andisopentane, ${ }^{14}$ allowing the cytoplasmic contents to react with the serum (Fig. 1); and (2) against the surface membrane of viable tumor cells (Fig. 2). In both cases, specific fluorescence was seen. ${ }^{15}$ Similar results have also been obtained by a number of other groups using both immunofluorescence ${ }^{16,17,18}$ and a number of other tests for antibodies including complement fixation and immunodiffusion. ${ }^{19}$

# THE SPECIFICITY OF THE REACTIONS 

It is obviously essential to demonstrate as nearly as possible that these reactions are in fact tumor specific, and this was carried out in a number of ways.

Initially, an indirect approach was taken. Positive sera were absorbed with a number of tissue extracts which can be seen in Table I. These included pigmented skin, non-pigmented skin, the patient's own skin, and the patient's tumor and other patients' tumors. The only materials which could absorb out and reduce completely the positive sera were the autologous and allogeneic tumor extracts. Positive sera demonstrated by the techniques have also been used both by cytotoxic test and by immunofluorescence against a number of other cell types, including normal human fibroblasts and, more recently, normal choroidal melanocytes, in the case of ocular melanomas. ${ }^{20}$ In no cases so far have significant positive results been obtained against these other cell types. ${ }^{21}$

Regarding the patient's specificity, two types of reaction have been demonstrated. The cytotoxic test and the membrane fluorescence appear to be matched consistently when performed on the same sera and the same cells, but cross reaction with other melanoma cells is either at a very low level or non-existent. ${ }^{13}$ If the sera are routinely diluted one in four, most cross cractivity can be reduced below the base line of the tests concerned. ${ }^{15}$ The reaction, however, against the cytoplasmic antigens appears to have a multiple cross-section pattern which will be described in more detail later in this paper. Other investigations using somewhat different criteria and test yystems have indicated cross reactivity with membrane immunofluorescence. ${ }^{22,23}$

## RELATIONSHIP WITH STAGE OF DISEASE

Having obtained considerable laboratory data and established the reasonable tumor specificity and the differing patient specificities of these anibody reactions, the next stage was the rather important one of re-establishing that these antibodies bore some relation to the natural history of the disease concerned. The subsequent studies were carried out in Britain and Canada,![img-16.jpeg](img-16.jpeg)

Figure 1 Immunofluorescent antibody antigen reaction in cytoplasm of snap frozen melanoma cells.
![img-17.jpeg](img-17.jpeg)

Figure 2 Surface membrane immunofluorescence on viable tumor cells.TABLE I
Tests for tumor specificity by prior absorption of sera with a variety of tissues and tumor

| Materials used in absorption | Maximum titres of antibody following absorption |  |  |  |  |
| :--: | :--: | :--: | :--: | :--: | :--: |
|  | Mel 1 | Mel 2 | Mel 3 | Mel 4 | Mel 5 |
| Bovine liver | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Rat liver | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Melanin granules | $1 / 32$ | $1 / 64$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Human skin (non-pigmented) | $1 / 32$ | $1 / 64$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Human skin (heavily pigmented) | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Human skin (pooled) | $1 / 32$ | $1 / 64$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Autologous skin | $1 / 32$ | $1 / 64$ | $1 / 32$ | $1 / 32$ | $1 / 32$ |
| Allogeneic melanoma extract | $1 / 8$ | $1 / 8$ | $1 / 16$ | $1 / 8$ | $1 / 16$ |
| Autologous melanoma extract | $1 / 2$ | $0 / 0$ | $0 / 0$ | $0 / 0$ | $0 / 0$ |

Note: With permission of J. B. Lippincott Co., from Lewis, 1973 (a).
![img-18.jpeg](img-18.jpeg)

Figure 3 Diagrammatic summary of the stages in the natural history of cutaneous malignant melanoma. (With permission Springer-Verlag, Heidelberg - Lewis 1973(a)
and have been performed on more than two hundred individual patients with benign and malignant melanomas. The patients were divided into three stages (summarized in Fig. 3) : stage one, primary tumor only; stage two, tumor still confined within the regional draining lymph nodes and the area drained by these lymph nodes; and stage three, dissemination of tumor beyond the regional lymph nodes. The majority of patients in this series with primary tumors only showed positive antibody in their sera, whereas among the patients with disseminated tumor practically none had any detectable antibody. Stage two showed a mixed picture, with somepatients still having antibody present and others not (Table II). To dissect out this stage between primary and dissemination, more detailed sequential studies were needed. Patients were followed through the stages of their disease, as they progressed from primary tumor to dissemination, and the sera tested against autologous tumor cells. The pattern that emerged is that of a fall in antibody as the disease progresses from primary to dissemination. Again, several other groups have found similar relationships between serum antibody and staging of human melanoma. ${ }^{22}$

If one follows individuals in more detail, it is possible to show that in a number of patients the antibody levels fall prior to clinical manifestation of disseminated tumor. The evidence, therefore, strongly suggests that circulating antibodies may well play a rather important role in the localization or spread of this particular tumor. If this is the case, it poses the question of why the antibodies disappear.

# THE FAILURE OF HUMORALIMMUNITY 

There are a number of possible theoretical reasons for this failure which can be summarized as follows:
1 There may be a loss of antigenicity of tumor cells in metastatic disease.
2 The immune system may fail to produce antibodies.
3 There may be a soaking up of antibody by excess antigen represented by the large amount of disseminated tumor.
4 There may be substances liberated into the serum or present in the serum which effectively block the action of the circulating antibody.
In an attempt to investigate these possible mechanisms the following series of experiments were carried out.

## AUTOIMMUNIZATION

A number of patients were immunized by means of multiple intracutaneous and subcutaneous injection of the irradiated autologous melanoma cells. ${ }^{24}$ The remaining tumor cells not used for the immunization were then protected with dimethylsulphoxide (DMSO) and controlled frozen in liquid nitrogen, and then stored for a period of fourteen to twenty-eight days, depending on the individual patient. Sera were collected and also stored in vapour-phase liquid nitrogen. At the end of the time period, each sera was reacted with cells removed from liquid nitrogen. Tests including cytotoxic anitibody, membrane and cytoplasmic fluorescence were performed. A total of thirty-nine patients with malignant melanoma have so far been investigated in this way. Thirty-one of them produced a clear rise of antibody characteristic of a secondary type of response lasting for periods up to![img-19.jpeg](img-19.jpeg)

Figure 4 An example of the response to autoimmunization with irradiated tumor cells of a patient with malignant melanoma. (From Lewis 1972)
three weeks, but in most instances falling to undetectable levels again (Fig. 4). The eight patients who failed to respond were either in advanced stages of malignancy and died before the investigation was completed or were given less than $10^{7}$ cells in the immunization procedure. The result of this study would indicate that the first two mechanisms are unlikely since the tumor cells in many of the cases were metastatic and yet still gave rise to a rapid secondary type of response. Secondly, the immune system in the majority of cases was capable of responding and responding actively. The next factor to be considered was the ability of metastases to soak up antibody as fast as it was produced. If this was the case, then one would expect to find appreciable quantities of such antibody present on tumor cells in remaining tumor nodules. Although this has been reported by some observers, ${ }^{25}$ most of the tumors they studied were either in lymph nodes or from bone or pleural or ascitic diffusions. In the present series, subcutaneous nodules were examined and found not to have any measurable quantities of immunoglobulin on the tumors. This was performed by direct immunofluorescence and by eluting cell preparations with subsequent concentration and application to cellulose acetate membrane immunodiffusion and im-TABLE II
amor antibody levels in patients with malignant melanoma related to stage of disease

| Serum antibody in human malignant melanoma |  |  |
| :-- | :--: | :--: |
| Clinical appearance | Antibody +VE | Antibody -VE |
| Primary tumor only | 17 | 2 |
| Localized or regional lymph nodes | 28 | 10 |
| Disseminated beyond regional lymph nodes | 1 | 72 |

munoelectrophoresis. In addition, no increase or appreciable numbers of lymphoid cells were seen infiltrating the tumor nodules. At this time, a patient at Westminster Hospital in London with multiple subcutaneous and cutaneous malignant melanoma was treated with intravenous phytohemagglutinin. On the eighth day, all the tumor nodules became hot, swollen, and painful and over the next few days were reduced in size. During the shrinking of the tumor, repeat biopsy was performed. Following the PHA administration, the tumors were found to be infiltrated with lymphoid cells. By direct immunofluorescence, they were heavily coated with immunoglobulin and appreciable quantities of IgG could be eluted from the surface of these cells. ${ }^{26}$ None of these features were present in the biopsy prior to PHA administration. As a result of this finding, a series of patients was given combinations of PHA and autoimmunization or PHA alone. Again, only those given PHA showed antibody coating of the tumor cells in the subcutaneous tissue and lymphoid infiltration. ${ }^{27}$ The mechanisms responsible for this are not understood, and the subject is under further study. It does, however, illustrate that there are methods for allowing antibody to become available to tumors outside the vasculature but that these are not normally present even when antibody may be present at high levels in the serum. It adds a certain conviction to the previous negative results and makes the idea of antibody being soaked up less likely. In addition, it has been shown clearly that antibody is related not to the volume or mass of tumor present, but to the degree of localization or dissemination in that patients whose tumors are confined to one limb, for instance, may have masses of tumor and still have antibody in the circulation, whereas those with minute deposits of tumor beyond the draining regional lymph node have been shown to have no detectable antibody. ${ }^{28}$ Moreover, the fall of antibody prior to dissemination, although its timing is difficult to pinpoint, again adds further support to the idea that a simple soaking of antibody by tumor cells is less likely. Evidence has also been suggested that under normal circumstances relatively high molecular weight substances do not readily leave the vasculature and that the pressure at the centre of even small tumor nodules may exceed the arteriolar pressure, all of which makes antibody normally available to extravascular nodules extremely unlikely. Conse-quently, the fourth mechanism was investigated, namely the possibility of blocking substances. Again, patients who had been autoimmunized were chosen and the positive serum obtained at the height of the antibody response was mixed with a variety of control sera, including sera from other melanoma patients, and then applied by surface membrane immunofluorescence or cytotoxicity to the autologous tumor cells from that patient with no appreciable reduction in titre or fluorescent index. On the other hand, in three patients where the positive sera were mixed with the autologous preimmunized negative sera, the effect both by fluorescence and cytotoxicity was abolished completely. The negative serum could not produce this blocking if applied to the tumor cells prior to the positive serum, but only if mixed with the positive serum in vitro first. The negative sera only blocked the autologous positive sera. When the negative serum and the positive serum were separated in gamma and non-gamma fractions, it was shown that the gamma fraction reacted with the gamma fraction, and subsequently an IgG separated from the negative serum by DEAE cellulose column reacted with a line of diffusion against the positive gamma fraction on cellulose acetate membrane. ${ }^{29}$ Attempts to further separate any potential antigen linked to this IgG by immunoelectrophoresis failed to demonstrate any other substance. It is, of course, possible that this negative serum blocking effect is due to an antibody-antigen complex in which the antigen is very firmly bound and of such small molecular weight as not to alter the mobility of the IgG of the negative serum. But this does reduce the likelihood. The unique patient-specific reaction raises the possibility of an alternative explanation, i.e., an anti-idiotype or anti-antibody. These have been described in other situations ${ }^{30}$ and would explain why it is that patients with normal intact immunity suddenly cease to produce effective antibody. This aspect of the study is still under investigation. In view of the results so far outlined, our attention has been focused on the types of antigen concerned, since circulating soluble antigen could also be responsible for blocking immunity in a number of ways.

# NEPHROTIC SYNDROME AND MALIGNANCY 

In addition, another interesting phenomenon is worth mentioning. It has been known for some time that the nephrotic syndrome can be associated with malignancy. ${ }^{31}$ In some recent studies, a patient with carcinoma of the lung which had been present for many years developed a nephrotic syndrome, and it was possible to elute immunoglobulin from the basement membrane of the glomeruli of the kidney (Fig. 5). This reacted specifically with the surface of the lung carcinoma cells, and not with normal lung tissue, suggesting that in this particular case and possibly in others, the nephrotic![img-20.jpeg](img-20.jpeg)

Figure 5 Direct immunofluorescent identification of immune complexes in renal glomerules in a patient with nephrotic syndrome and long-standing malignancy.
syndrome was due to the deposition of antibody-antigen complexes against tumor antigens. ${ }^{32}$ This raises several possible avenues of future research. It could be the means of obtaining tumor-specific antigen in a pure form, since the kidney under these circumstances could be acting as a rather specific 'bio-absorption column.' In addition, tumor antigens could be used as models for understanding the production of the nephrotic syndrome and other forms of immune complex damage of the kidney. These studies also point towards a potential danger, since a number of investigators have used and advocated the use of passive immunization in the form of transfusions of plasma or serum from patients with regressing tumors to those with socalled progressing tumors. ${ }^{33}$ The possibility exists that under these circumstances antibody-antigen complexes of the type capable of being deposited in the kidney may occur and result in further disease.# THE EARLY STAGES OF MALIGNANT MELANOMA 

Although so far I have concentrated on studies related to the prevention of metastases and the development of tumors in the later stages of the disease, one of the most interesting aspects of malignant melanoma is the early change from a benign mole or naevus to malignant melanoma and the factors that determine the rapidity of spread of these early lesions. The main technical difficulties have revolved around the obtaining of suitable cell preparations in these small cutaneous tumors. Cell suspensions are almost impossible and sections of tumor are also difficult to handle. Quite often the pathologist needs most of the tumor to make the diagnosis. It was decided, therefore, to investigate the usefulness of the cross-reacting cytoplasmic antigen mentioned earlier. A series of patients were examined, the sera tested against snap frozen smears of melanoma cells, and the histological diagnosis then compared on a double-blind basis. The study has revealed that a number of other skin tumors do not have, antibodies cross reacting with melanoma, adding further support to the specificity of previous reactions mentioned, but with one very important exception. Eleven patients with the so-called halo naevus syndrome were included in this series. In ten of these, the sera showed positive antibody against cytoplasm of allogeneic melanoma cells. ${ }^{34}$ The halo naevus is of some considerable interest in that it represents a pigmented mole or pigmented tumor which develops a symmetrical halo of depigmentation around it and gradually disappears. ${ }^{35}$ Some patients have multiple such halo naevi. In one of the patients mentioned in this study, the serum prior to the development of the halo was negative, the serum changed to positive at the height of the halo and some weeks or months following regression, the serum was again negative. One of the characteristic histological features of the halo naevus is the dense lymphocytic infiltration that occurs in and around these lesions. It is thus very suggestive that this might represent the early recognition and rejection of a developing malignant melanoma. It is also of some considerable interest that halo naevi may well be commoner than previously considered, particularly on areas of the body which are not easily visible. Certainly moles of a variety of types appear and disappear during life. The question also arises why it is that moles are so common and melanoma so rare. ${ }^{36}$ The further study of this particular phenomena might well be rewarding.

## THE ANTIGENS OF MELANOMA CELLS

Another facet which arose from this approach was the awareness that even the cytoplasmic antigens may be multiple. This emerged from the study of a large number of patients with melanoma at various stages and examinationof the sera for antibodies, not against the autologous cells as previously described, but against allogeneic melanoma cells. In these preliminary studies, it looks very much as if the antibody against allogeneic cytoplasmic antigen arises or is present at different stages in the disease from that described in the autologous situation. In some very recent and as yet unpublished studies and investigations we have also been examining melanoma cells for the possible presence of fetal-type antigens. An anti-human-fetal serum has been raised in rabbits against 12 -week-old human fetuses, and by subsequent absorptions with normal human serum proteins and tissues, reacts with the surface membrane of human fetal cells, but not with human adult cells of a variety of types. It has, however, reacted with a number of human tumors including some cells of malignant melanoma. ${ }^{37}$ The fetal antigen, however, is not related, or does not appear to be related, to the tumorspecific antigens of the surface membrane in that a positive patient's serum against the surface of the autologous cells does not block the effect of the anti-fetal serum or vice versa. The main surface membrane tumor described earlier has been investigated further in terms of its patient specificity, and by means of cross-absorption techniques it has been possible to show that, if a number of positive sera are absorbed with autologous cells and allogeneic cells and re-reacted with the autologous cells, it is only the latter which can absorb out the reaction. ${ }^{38}$ If, in addition, one uses neat serum instead of that diluted one in four, it is possible to get some cross reaction. As previously stated, this can be abolished easily by diluting the serum.

Summarizing the antigens so far determined, it would seem that there are six types (Fig. 6). The next question relates to the relative importance of the antigens in the complex interrelationship between tumor and host. Which are responsible for invoking protective immunity, particularly in the circulation, and which give rise to antibody, which is really an epiphenomenon occurring as the disease progresses. Figure 7 is a hypothetical relationship between the time sequence of the natural history of the disease and the presence in the serum of antibodies against the antigens concerned. Another possibility is that cells at different parts of the cycle may well express different antigens in different strengths and that the proportion of antigen will be related to the degree of heterogeneity of the tumor at any one moment in time.

QUANTIFICATION OF FLUORESCENCEANTIBODY
Recently we have been engaged in attempts at a quantification approach to this problem. An epi-illumination microscope fitted with a photometric device has enabled us to measure the fluorescent emission over a specific narrow wavelength so that individual cells can be examined and the quantity![img-21.jpeg](img-21.jpeg)

SURFACE MEMBRANE AUTOLOGOUS
![img-22.jpeg](img-22.jpeg)

CYTOPLASMIC AUTOLOGOUS
![img-23.jpeg](img-23.jpeg)

SURFACE MEMBRANE ALLOGENEIC
![img-24.jpeg](img-24.jpeg)

CYTOPLASMIC ALLOGENEIC
![img-25.jpeg](img-25.jpeg)

SURFACE MEMBRANE FOETAL
![img-26.jpeg](img-26.jpeg)

NUCLEAR I NUCLEOLAR ALLOGENEIC

Figure 6 Diagrammatic summary of antigens in human malignant melanoma cells. (With the permission of the Yale Journal of Biology and Medicine.)
![img-27.jpeg](img-27.jpeg)

Figure 7 Relationship between antibodies and various antigens and stages of the disease.of fluorescence measured. In the preliminary studies so far carried out there is a clear difference between the controls and the test but, of more importance, a positive serum against a fresh preparation of tumor cells often indicates a wide range of quantitation and possibly therefore expression of the antigen. If, on the other hand, a cell line of melanoma is used, the fluorescent emission range is much narrower. Studies will be undertaken to relate the quantity of antigen under varying circumstances of cell types and possibly this will be another useful method for dissecting out differences in antigen and antibody under these conditions.

THE POSSIBLE ROLE OF ANTIBODY AND
OTHER MANIFESTATIONS OF IMMUNITY IN THE
NATURAL HISTORY OF MELANOMA
Finally, I should like to mention briefly the way in which these studies on tumor antibodies in the circulation fit into the overall picture of the host/ tumor relationship. It is extremely important that we relate all our laboratory data to the natural history of the disease being studied. The staging, the type of tumor, the individual patient, are all of considerable importance. Figure 8 summarizes the sort of situation that can be seen in patients with malignant melanoma studied at various stages of the disease. There is much evidence
![img-28.jpeg](img-28.jpeg)

Figure 8 Diagrammatic summary of relation between immune mechanisms and natural history of malignant melanoma.to suggest that cellular immunity plays its most important role early in th natural history of melanoma, and that this is the time when cellular im. munity is most strongly expresesed. ${ }^{39}$ On the other hand, humoral immunity appears to have its most important role later in the disease, and particularly at the stage prior to dissemination of tumor via the blood stream. There is other experimental evidence to suggest that humoral immunity may play an important role in protecting the blood stream against circulating cells and thus subsequently metastases. ${ }^{40}$ It is, after all, metastases which usually kill patients in this disease as in many other human tumors, and the control of metastases is the key to the understanding and the mastery of human cancer. To be able to reach this point, we need to be able to understand the step-bystep sequences and the interrelationships between humoral and cellular immunity and maybe other yet undefined host factors which play their part in the complex interplay between tumor and host. Our final goal in understanding the relationship between immunity and malignancy is to be able to manipulate the immune system in such a way as to bring the host-tumor balance on the side of host and thus to be able to control the malignant process to the benefit of the patient.

# REFERENCES 

1 Fisher, B. The present status of tumour immuuology. Advances in Surgery, 5: $189-254,1971$
2 Piessons, W. Evidence for human cancer immunity. A review. Cancer, 26: $1212-1220,1970$
3 Kopf, A.W. Host defenses against malignant melanoma. Hospital Practice, 116-124, Oct. 1971
4 Smithers, D.W. Spontaneous regression of cancer. Ann. Roy. Coll. Surg. Engl. 41: 160,1967
5 Everson, J.C. and Cole, W.H. Spontaneous regression of cancer. Philadelphia \& London: W.B. Saunders Co., 1966
6 Bodenham, D.C. A study of 650 observed malignant melanomas in the South West Region. Ann. Roy. Coll. Surg. Engl. 43: 218, 1968
7 Lewis, M.G. Malignant melanoma of the sole of the foot in Uganda. The role of pigmentation. Brit. J. Cancer, Sept. 1967
8 Lewis, M.G. and Kiryabwire, J.W.M. Malignant melanoma in Uganda - aspects of behaviour and natural history. Cancer, 21: 876, 1968
9 Das Gupta, T. and Brasefield, R. Metastatic melanoma - a clinicopathological study. Cancer, 17: 1323-1339, 1964
10 Cochran, A.J., Diehl, V., and Stjernswäard, J. Regression of primary malignant melanoma associated with a good prognosis despite metastasis to lymph nodes. Europ. J. Clin. Biol. Res., XV: 969-972, 1970
11 Pulvertaft, R.J.V. The examination of pathological tissues in a fresh state. In Modern Trends in Pathology, pp. 19-44. D.H. Collins, ed. London: Butterworth. 195912 Lewis, M.G. Possible immunological factors in human malignant melanoma. Lancet, 2: 921-922, 1967
13 Lewis, M.G., Ikonopisov, R.L., Nairn, R.C., Phillips, T.M., Hamilton-Fairley, G., Bodenham, D.C., and Alexander, P. Tumour specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Brit. Med. J., 3: 547-552, 1969
14 Nairn, R.C. Fluorescent protein tracing. 3rd ed. London: E.\&S. Livingstone \& Co. Ltd., 1969
15 Phillips, T.M. and Lewis, M.G. A system of immunofluorescence in the study of tumour cells. Rev. Europ. etudes Clin. \& Biol., XV: 1016-1020, 1970
16 Morton, D.L., Malmgren, R.A., Holmes, E.C., and Ketcham, A.S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery, 64: $233-240,1968$
17 Muna, N.M., Marcus, S., and Smart, C. Detection by immunofluorescence of antibodies specific for human malignant melanoma. Cancer, 23: 88-93, 1969
18 Rhomsdahl, M.M. and Cox, I.S. Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch. Surg., 100: 491-497, 1970
19 Czajowski, N.P., Rosenblatt, M., Wolf, P.L., and Vas Quaz, J. A new method for active immunization to autologous human tumour tissue. Lancet, 2: 905, 1967
20 Fedderman, J.L., Lewis, M.G., Clark, W.H., Egerer, I., and Sarifn, L.K. Tumour associated antibodies in the serum of ocular melanoma patients. J. Natl. Cancer Inst. In press
21 Lewis, M.G. Tumour specific antigens in melanoma. Proc. Seventh Cancer Conf. Philadelphia: P.J.B. Lippincott Co., in press, 1973(a)
22 Morton, D.L., Eilber, F.R., and Malmgren, R.A. Immune factors in cancer: Malignant melanomas; Skeletal and soft tissue sarcomas. Prog. Exptl. Tumour Res., 14: $25-42,1971$
23 Hellstrom, I., Hellstrom, K.E., Pierce, G.E., and Yang, J.P.S. Cellular and humoral immunity in different types of human neoplasm. Nature (Lond.), 220: 1352-1354, 1968
24 Ikonopisov, R.L., Lewis, M.G., Hunter-Craig, I.D., Bodenham, D.C., Phillips, T.M., Cooling, I.C., Proctor, J., Hamilton-Fairley, G., and Alexander, P. Autoimmunization with iradiated tumour cells in human malignant melanoma. Brit. Med. J., 2: 752, 1970
25 Hellstrom, I. and Hellstrom, K.E. Some recent studies on cellular immunity to human melanomas. Fed. Proc. In press, 1973
26 Lewis, M.G., Humble, J.G., Lee, E. Stanley, and Phillips, T.M. The effects of intravenous phytohaemagglutinin in a patient with disseminated malignant melanoma. Europ. J. Clin. Biol. Res., 16: 924-927, 1971
27 Lewis, M.G., McCloy, E., Blake, J., and Phillips, T.M. The production and fate of antibody following autoimmunisation in human malignant melanoma (paper in preparation).
28 Lewis, M.G., McCloy, E., and Blake, J. The significance of circulating antibody in the localisation of human malignant melanoma. Brit. J. Surg., 60, 443-446, 1973
29 Lewis, M.G., Phillips, T.M., Cook, K.B., and Blake, J. Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma. Nature (Lond.), 232: 52-54, 1971
30 Drew, R.L., Thompson, S., and Pardoe, G.I. The immunogenicity of Proteus Vulgaris OX19 in the rabbit. Pathol. Microbiol. (Basel), 38: 184-91, 197231 Loughbridge, L.W. and Lewis, M.G. Nephrotic syndrome in malignant disease of non-renal origin. Lancet, 1: 256, 1971
32 Lewis, M.G., Loughridge, L.W., and Phillips, T.M. Immunological studies on a patient with the nephrotic syndrome associated with malignancy of non-renal origin. Lancet, 2: 134, 1971
33 Horn, L. and Horn, H.L. An immunological approach to the therapy of cancer? Lancet, 2: 466-69, 1971
34 Lewis, M.G. and Copeman, P. Halo Naevus - a frustrated malignant melanoma? Brit. Med. J., 2: 47-48, 1972
35 Sutton, R.L. An unusual variety of vitiligo; Leucoderma acquisitium centrifugium. J. Cutan. Dis., 34: 797-800, 1916

36 Pack, G.T. A clinical study of pigmented nevi and melanomas. The biology of melanoma. N.Y. Acad. Sci., IV: 52-81, 1948
37 Avis, P. and Lewis, M.G. Tumour associated fetal antigens in human malignant melanoma. J. Natl. Cancer Inst., 51, 1063-1066
38 Lewis, M.G. and Phillips, T.M. The specificity of surface membrane immunofluorescence in human malignant melanoma. Intern. J. Cancer, 10: 105-11, 1972(a)
39 Hellstrom, I., Hellstrom, K.E., Sjogren, H.O., and Warner, G.A. Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American ;$\cdot$egro) donors. Intern. J. Cancer, 11: 116-122, 1973
40 Proctor, J.W., Rudenstram, C.M., and Alexander, P. A factor preventing the development of lung metastases in rats with sarcoma. Nature (Lond.), 242, 29, 1973# Immunotherapy for acute myelogenous leukemia* 

RAY POWLES<br>I.C.R.F. Senior Scientific Officer, Department Medical Oncology, St. Bartholomew's Hospital, London, E.C.I, England

A new problem has arisen for controlling acute myeloblastic leukemia in man following recent marked improvement in producing remission in this disease ${ }^{1,2,3}$ and many patients who previously would have died early in this disease now require treatment for maintenance of their remission. Recent reports ${ }^{4}$ show that conventional chemotherapeutic maintenance of this disease gives poor results and so we decided to examine the possibility of using an immunological approach to manage the problem.

We consider it important to be guided by the principles discovered in the animal experiments to determine if myeloblastic leukemia is a disease suitable for treatment and, if so, how best to do it. Many studies have shown that successful immunotherapy in animals is only effective when the quantity of tumor tissue is very small in the host. ${ }^{5,6,7}$ Leukemia, unlike most other malignant diseases in man, mimics this situation because chemotherapy can often be given until no detectable disease remains, but after a variable diseasefree period of remission the leukemia inevitably recurs. It is during this period of remission that immunotherapy is most likely to be effective. A study involving myeloblastic leukemia has definite advantages over the lymphoblastic variety because the patients are adults and so tolerate repeated injections better than children, and conventional treatment gives such poor results that improved methods quickly become apparent. The method of immunotherapy we decided to use included injections of cells (and BCG), and is based upon experiments by Haddow and Alexander ${ }^{8}$ in which a powerful systemic immune response could be generated in rats with primary sarcomata by inoculation at distant sites with irradiated tumor cells. Similar immunological studies in our Institute, involving autoimmunization using tumor cells of patients with either malignant melanoma ${ }^{9}$ or leukemia, ${ }^{10}$

[^0]
[^0]:    * This study was conducted by the following workers: P. Alexander, D. Crowther, T. McElwain, G. Hamilton Fairley, H.E.M. Kay, and many others. We are indebted for financial support to the Imperial Cancer Research Fund, the Leukaemia Research Fund, and the Medical Research Council; and we thank Sir Ronald Bodley Scott and Dr P.E. Thompson Hancock for their advice and help.have shown that specific host-immune responses similar to the animal experiments could be detected, but the number of irradiated cells required was large, i.e., approximately $1 \times 10^{9}$ cells, and since the effects were transient, the injections needed to be frequent. In most malignant diseases in man a long-term immunotherapy program involving such numbers of cells would be impossible, but leukemia seems unique in that techniques are now available whereby very large numbers of cells may be collected and stored (see below). We decided to use allogeneic tumor cells rather than autologous cells for several reasons. Animal experiments have shown that antibodies ${ }^{11}$ and cytotoxic lymphoid cells ${ }^{12}$ directed against tumor-specific antigens are produced more effectively if immunogen is allogeneic rather than a syngeneic leukemia cell; but the main advantage of using allogeneic cells was a logistic one. If it were possible to use only autologous cells, then only patients with high initial white-cell counts suitable for leukophoresis could be included in the trial; the number of immunizing doses for any one patient would be clearly finite; there could be risk of accidentally giving back viable autologous leukemia cells; and cells from patients who do not go into remission would be wasted. These factors would severely limit the nature and extent of the trial. However, if allogeneic cells are used, then a single suitable high-count donor (who may die without going into remission) may easily provide enough cells for the long-term treatment of several other patients. A large bank of cells may be collected very rapidly for use in all patients in the trial. While the principal component of the immunotherapy regime we used was tumor cells, we decided to give, in addition, frequent percutaneous injections of BCG. This was based on the original observations of Halpern, ${ }^{13}$ later widely confirmed, that BCG stimulated immune reactivity in a non-specific way with an increased capacity of the recipient to resist bacteria particularly but also tumor cells. The anti-tumor effect of BCG in animals, although inconsistent and not pronounced ${ }^{14,15}$ acts as a useful adjunct because it is additive to the therapeutic effect of irradiated tumor cells even when the two materials are administered separately. ${ }^{7}$

Because of the anecdotal nature of all previous claims of 'successful' immunotherapy in man, we decided that this study must be a carefully controlled randomized trial. At present we feel that patients in remission with myeloblastic leukemia cannot ethically be left without any form of treatment. Consequently, the only way we could conduct a controlled trial was to compare a group of patients receiving only chemotherapy with an identical group of patients receiving the same chemotherapy plus immunotherapy. Currie and Bagshawe ${ }^{16}$ have shown in animals that under certain circumstances the anti-tumor effects of chemotherapy and immunotherapy may be synergic and it was with the intermittent nature of their chemotherapy in mind that we designed our maintenance protocol.

The control trial described in this paper is a comparison of a group ofpatients with myeloblastic leukemia in the remission phase receiving maintenance chemotherapy in widely spread intermittent bursts with a similar group also receiving large numbers of allogeneic stored myeloblastic leukemia cells killed by irradiation and BCG, at separate sites weekly.

# PATIENTS 

This study included all patients with acute myeloblastic leukemia wio passed into full remission at St Bartholomew's Hospital between October 1970 and 1 February 1973, all of whom had remission induced with daunorubicin and cytosine arabinoside. There were three subgroups (Trials II, III, and IV) because of slight differences in the schedule of the drugs used. Trial IV is at present still accepting new patients, but II and III are complete.

The essential part of this study was to determine the effect of immunotherapy on the maintenance of remission in these patients.

All remission patients received identical maintenance chemotherapy consisting of pulses of five-day courses of cytosine arabinoside and daunorubicin, alternating with five days of cytosine arabinoside and 6-Thioguanine. Between every five days of treatment there was a twenty-three day gap. These forty-five patients were randomized into two groups, one received maintenance chemotherapy, and the other immunotherapy in addition to the chemotherapy.

## IMMUNOTHERAPY

As soon as full remission was obtained, all immunotherapy patients received weekly BCG, and irradiated allogeneic myeloblastic leukemia cells. The injections were timed deliberately to straddle the five days of chemotherapy given every month.

## B C G

The BCG given was a freeze-dried percutaneous preparation obtained from Glaxo and when reconstituted contained 10 mg of organisms per ml , of which approximately 20 per cent were viable. Forty needle punctures in the skin to a depth of 2 mm using a Heaf gun gave an approximate dose of $1 \times 10^{6}$ live organisms. The limb that received the BCG vaccine varied from week to week.

## CELLS

The cells used for immunotherapy were irradiated allogeneic myeloblastic leukemia cells and were injected into the three limbs not receiving the BCG.These cells were collected from the peripheral blood of all suitable patients with acute myeloblastic leukemia using a NCI/IBM cell separator. The leukemia cells are mixed with 10 per cent Dimethylsulphoxide, frozen slowly at $1^{\circ} / \mathrm{min}$ to $-30^{\circ} \mathrm{C}$ using a Planer Ltd. Gas Phase Programmed Freezer and stored in liquid nitrogen.

Each ampoule contains approximately $1 \times 10^{9}$ cells. When required the cells are rapidly thawed at $37^{\circ} \mathrm{C}$, washed, and resuspended in medium 199 at $4^{\circ} \mathrm{C}$. This process is found to damage only a small fraction of the cells. ${ }^{17}$ The cells are then thawed, washed, and irradiated to 10,000 rads using a $\gamma$-source, then immediately injected into the three limbs, both intradermally and subcutaneously. Approximately $1 \times 10^{9}$ cells are injected each week.

# RESULTS 

The total entry of new patients with myeloblastic leukemia to Trials II, III, and IV was 107 ( 1 February 1973) and 45 of these have so far passed into full remission. They were then included in the controlled immunotherapy section of the trial. Nineteen of these patients received only maintenance chemotherapy and 23 received immunotherapy also. Three immunotherapy patients have been excluded - two because they have only just passed into remission, and one because he died of infection immediately following remission induction, before immunotherapy was started.

## REMISSION LENGTH

In the two groups that are now accepting no new patients (Trials II and III), only three of the fifteen patients receiving chemotherapy alone remain in remission and the median remission length is 30 weeks, whereas in the chemotherapy plus immunotherapy group four of the fifteen remain in remission with a median remission length of 53 weeks. Actuarial analysis of all three trials (including Trial iv which still takes new patients) shows the median remission length for the nineteen chemotherapy patients will be 26 weeks and for the twenty-three chemotherapy plus immunotherapy patients 45 weeks. At present, in these groups 8 of the 23 immunotherapy patients remain in remission, compared with 5 of the 19 chemotherapy patients.

## SURVIVAL

Similar analysis for the survival of the same group of patients in Trials II and III shows nine of the fifteen chemotherapy plus immunotherapy patients remain alive, so a median has not yet been reached. However, only four of the fifteen chemotherapy alone patients remain alive, with the median, atpresent, for this group 35 weeks. Actuarial analysis (including Trial iv) gives a median survival time after attaining remission of 78 weeks for the immunotherapy patients ( 16 of 23 survive) compared with 43 weeks for the chemotherapy alone group ( 7 of 19 survive).

# DISCUSSION 

The results presented in this paper show that immunological manoeuvres conducted in the way have a significant beneficial effect upon the natural history of remission patients with myeloblastic leukemia, and this has not been described previously.

Mathe ${ }^{18}$ in a partially controlled study found evidence that weekly injections of BCG given to children with acute lymphoblastic leukemia prolonged the duration of remission. Subsequently the Medical Research Council ${ }^{19}$ in a large multicentred prospective trial failed to confirm this result, but certain subtle features of this latter trial such as the type and mode of administration of the BCG varied, and this may account for the discrepancy. In addition, Mathe gave some of his patients especially, in the later stages, small numbers of irradiated formalized cells in addition to the BCG, and this may have been important. The clear-cut results obtained in our study may have two causes: first, the constant use of large numbers of cells for immunotherapy, and secondly the type of leukemia treated. Lymphoblastic leukemia, which by its very nature affects the immune system, may make the host, even in remission, defective in taking advantage of immunological procedures.

Although the results obtained by the methods we have described are of great interest, clearly they are not the answer to this disease - patients relapse and they die and, although both remission length and survival in these patients is doubled, the likelihood of cure in any but a few seems remote. Obviously we should attempt to assess our procedures in an effort to develop a rationale for better methods of treatment. We are doing so and have described preliminary results of such methods. ${ }^{20,21}$

The overall place of experimental procedures in the treatment of cancer must always be considered in the light of the best available conventional methods, since we consider that denying patients good conventional treatment for untried experimental methods can never be justified. With this in mind, we observe with interest the results using intensive chemotherapy obtained by both the South Western and Sloan-Kettering groups. ${ }^{2,3}$ Although their results are not as good as those of our chemotherapy plus immunotherapy group, and it is our impression that the quality of life of patients treated with intensive chemotherapy is far from satisfactory, we feel that chemotherapy must always play the dominant role in the overall management of these diseases. Perhaps the final role of immunology for thesediseases, as occurred in tubercule, will not be for treatment but for the much more important if less spectacular role of immunodiagnosis and immunoprophylaxis, and the sort of study we have described in this paper may pave the way for these aims by giving a better understanding of the specific immunological mechanisms involved in leukemia.

Finally, a word of caution about designing future immunotherapeutic programs or undue zeal in applying theoretical arguments for devising better methods; there is not a scrap of evidence either in our study or in that of others that the effector mechanism following this type of treatment is in any way immunological in nature.

# REFERENCES 

1 Crowther et al. Brit. Med. J., 4: 513, 1970
2 Clarkson, B.D. Cancer, 6: 1572, 1972
3 Whitecar, J.P., Bodey, G.P., Freireich, E.J., McCredie, K.B., and Hart, J.S. Cancer Chemotherapy Repts., 56: 543, 1972
4 Crowther et al. Brit. Med. J., 1: 131, 1973
5 Alexander, P., Bensted, J., Delorme, E.J., Hall, J.G., and Hodgett, J. Proc. Roy. Soc., B, 174: 237, 1967
6 Oettgen, H.F., Old, L.T., and Boyce, E.A. Med. Clin. N. Am., 55: 761, 1971
7 Parr, I. Brit. J. Cancer, 26: 174, 1972
8 Haddow, A. and Alexander, P. Lancet, 1: 452, 1964
9 Ikonopisov, R.L. et al. Brit. Med. J., 2: 752, 1971
10 Powles, R.L., Balchin, L.A., Hamilton Fairley, G., and Alexander, P. Brit. Med. J., I: 486, 1971
11 Gorer, P.A. and Amos, D.B. Cancer Research, 16: 338, 1956
12 Alexander, P. and Hall, J.G. Advances in Cancer Research, 13: 1, 1970
13 Halpern, B.N., Biozzi, G., Stiffel, C., and Mouton, D.I. Am. Inst. Pasteur, 153: 919, 1959
14 Old, L.J., Benacerra, B., Clarke, D.A., Carswell, E.A., and Stockert, E. Cancer Research, 21: 1281, 1961
15 Mathe, G., Pouillart, P., and Lapeyraque, F. Brit. J. Cancer, 23: 814, 1969
16 Currie, G.A. and Bagshawe, K.D. Lancet, 1: 514, 1970
17 Powles, R.L. and Grant, C. Cryobiology. In press, 1973
18 Mathe, G. Brit. Med. J. 4: 7, 1969
19 Brit. Med. J. 4: 189, 1971
20 Alexander, P. and Powles, R.L. Published in Birth Defects, Original Article Series Long term lymphocyte cultures in human genetics. Vol. IX, No. 1, National Foundation - March of Dimes
21 Powles, R.L. et al. Brit. J. Cancer. In press, 1973# Pitfalls in tumor immunology * 

RICHMOND T. PREHN<br>The Institute for Cancer Research, Fox Chase Center for Cancer and Medical Sciences, Philadelphia, Pa.<br>Department of Pathology, University of Pennsylvania, Philadelphia, Pa.

HISTORICAL INTRODUCTION

Acceptance of the fact that most and perhaps all tumors possess antigens capable of inducing an immunological reaction in the autologous host occurred gradually following papers by Baldwin, ${ }^{1}$ Klein et al., ${ }^{8}$ and Prehn and Main. ${ }^{15}$ The paper by Prehn and Main ${ }^{15}$ contained the suggestion that an important facet of hydrocarbon oncogenesis might be the immunological depression that hydrocarbon oncogens produce. It was thus implied that the immune mechanism served, in the absence of such depression, to prevent the development of clones of neoplastically transformed cells. It remained for Thomas ${ }^{17}$ to suggest that the entire allograft immune reaction had evolved primarily as a defence against incipient neoplastic disease. This suggestion was adopted and developed by Burnet, ${ }^{4}$ who coined the term 'immunological surveillance.' During the past decade the theory of immunological surveillance has received wide publicity and quite general acceptance. As conceived by Burnet ${ }^{4}$ and by Good and Finstad, ${ }^{5}$ the immune reaction, of the allograft type, is visualized as the primary and most important line of defence against neoplasia. The argument is made that neoplastic transformation must be a frequent accident of somatic cell replication; however, since the transformed neoplastic variants are antigenic, they are eliminated rapidly by the immune response. Only rarely, and for unknown reasons, can a neoplastic clone escape this defence mechanism and develop into a clinically recognizable malignancy. Thus, the vast majority of neoplasms are thought to be eliminated by the immunological surveillance mechanism at a very early stage in their evolution.

At the present time, the concept of immunological surveillance is accepted by the majority of oncologists as established fact. A vast amount of clinical

[^0]
[^0]:    * This investigation was supported by Public Health Service Research Grant Nos. CA-08856, CA-06927, CA-05255, RR-05539 from the National Institutes of Health, and by an appropriation from the Commonwealth of Pennsylvania.observation and experimental evidence has been marshalled in support of the concept. To challenge its essential validity has become something of a heresy and indeed it requires some temerity to do so. Nonetheless, in the past few years some 'Thomas doubters' have begun to appear and some serious challenges to the theory of immunological surveillance are now being made. It is the purpose of this paper to assess the evidence, both pro and con, and to try to place the role of the immune reaction, during incipient neoplasia, in better perspective.

The evidence in favour of the theory of immunological surveillance, as developed primarily by Thomas, ${ }^{17}$ Burnet, ${ }^{4}$ and Good and Finstad, ${ }^{6}$ rests upon the following points:
1 Most tumors possess demonstrable antigens - antigens capable of arousing a cytotoxic immune reaction in the autologous host.
2 Measures which interfere with the function of the immune system, such as newborn thymectomy, whole-body X-radiation, or the administration of immunosuppressive drugs, render an animal more subject to the induction of neoplasia.
3 Those clinical syndromes characterized by deficient immune reactions (i.e., ataxia-telangiectasia, Wiskott-Aldrich syndrome, etc.) are also characterized by a higher than normal tumor incidence.
4 Measures which stimulate the immune mechanism non-specifically, such as immunization with bacillus Calmette-Guérin, may make animals unusually resistant to the induction of neoplasia.
5 Aging is associated with an increasing risk of neoplasia and a declining immunocompetence.
6 Caloric restriction can reduce the incidence of neoplasia - it also increases the efficacy of cellular immunity, the type of immunity of greatest import in resistance to solid tumors.
7 In any information transfer system, such as somatic cell replication, there is inevitably some noise; neoplastic transformation must therefore be frequent. The argument is sometimes made that immunological surveillance must be efficacious or overt clinical neoplasia would necessarily be much more frequent than it actually is. Although this is a very weak and circular argument, it is encountered with surprising frequency.
8 Very early neoplasms, especially in skin where these lesions can be readily examined, are usually associated with a dense lymphocytic infiltration - presumably the histological evidence of surveillance at work.
9 The fact that overt malignancies sometimes regress suggests the existence of an immunological resistance. If this can occur in the case of large overt lesions, it is probable that regression is the virtual rule in the case of microscopic, nascent tumors.10 Neoplasia is, according to Burnet, ${ }^{4}$ a vertebrate disease. The lack of neoplasia in invertebrates and its presence in vertebrates accounts for the fact that the allograft type of immune response is also a vertebrate attribute. It was in the vertebrates that the challenge of a new type of disease, neoplasia, necessitated the evolution of a new specific defence system, the allograft response.
It is evident that the above arguments rest largely upon correlations between varying levels of immune competency and the incidence of neoplasia. Although such arguments may be incapable of rigorously establishing a casual link between tumor susceptibility and immunocompetence, if the correlations are very strong, a causal connection can be reasonably presumed. It will, therefore, be necessary to examine the evidence in some detail in order to determine just how strong the case really is for immunological surveillance.

# TUMOR IMMUNOGENICITY 

The first correlation that requires. detailed examination is that between neoplastic transformation and the appearance in the transformed cells of tumor regression antigens or TRAs. The presence of such antigens, and their ability to arouse a cytotoxic immune response, appears to be a prerequisite for the surveillance concept.

## Induced tumors

When sarcomas are induced with a hydrocarbon such as 3-methylcholanthrene, the tumors can readily be shown to be immunogenic upon transplantation to syngeneic animals. ${ }^{15}$ However, the quantitative response varies widely from tumor to tumor and an occasional lesion will induce little or perhaps even no immunological resistance. It has been shown that a lack of an immune resistance reaction can often be accounted for by the presence in the serum of the immunized animal of specific factors which block lymphocyte cytotoxicity. ${ }^{6}$ However, some tumors have been described in which no new surface antigens can be detected by any known techniques. ${ }^{2}$ Thus, there is a strong presumption that tumor-regression antigens are not inevitably present on neoplastically transformed cells. Even when present, they may be ineffective because of blocking activity in the serum. Nevertheless, a cytotoxic immune reaction is certainly the usual result of immunization of syngeneic animals with those tumors that result from the action of strong chemical oncogens, radiation, or the potent viruses that are used in the laboratory. Presumably, these tumors escape the surveillance mechanism by virtue of the immunological depression caused by the oncogen. ${ }^{11}$ Thus, inthese laboratory systems the necessary prerequisite for immunological surveillance, namely tumor immunogenicity, appears to be met.

# Spontaneous tumors 

The situation in so-called 'spontaneous' tumors is rather different. These tumors commonly fail to elicit a specific immunological resistance in transplantation tests in syngeneic animals. ${ }^{15}$ When a resistance reaction is found, it is almost invariably weak. Whether the lack of immune resistance is due to a lack of antigens or to blocking factors is not clear in all cases, but this question appears irrelevant in the present context. If a tumor fails to induce an immunological resistance, for whatever reason, it does not seem a likely subject for immunological surveillance. The common lack of immunological resistance to spontaneous tumors can be seen in mouse sarcomas, mouse lung adenomas, and mouse mammary tumors, and can, I think, be regarded as a general phenomenon.

The usual failure of spontaneous tumors to arouse an immunological resistance is not necessarily a potent argument against the efficacy of immunological surveillance. The argument can be turned around and the very lack of immunogenicity of spontaneous tumors can be used as evidence in favour of the immunological surveillance hypothesis. The reasoning is that the spontaneous tumors available for study represent a very small minority of transformed clones - a small minority that escape the surveillance mechanism by virtue of a lack of immunogenicity. They are thus highly selected and their lack of immunogenicity tells us nothing about the immunogenicity of the vast bulk of neoplastically transformed cells which never grow into clones of testable size. In fact, if immunological surveillance were not highly efficacious, would not many of the spontaneous tumors we see be highly immunogenic?

If, indeed, spontaneous tumors lack immunogenicity because of immunoselection, we can predict that spontaneous tumors arising in immune-free environments would, like chemically induced lesions, be highly antigenic and immunogenic. Recently my colleagues and I have put this question to the test by examining the immunogenicities of a series of tumors that arose by 'spontaneous' transformation in vitro in tissue cultures of mouse nearterm fetal cells or in similar cultures grown in vivo within the protecting confines of diffusion chambers. ${ }^{12}$ Rather to our surprise, such tumors proved to have no more immunogenicity in transplantation tests than do spontaneous tumors that arise in normal environments. It would appear that the usual lack of immunogenicity of spontaneous tumors cannot be accounted for by immunoselection, nor is the lack of such immunogenicity an argument in favour of the existence of an efficacious immunological surveillance.# EFFECTS OF MINIMALIMMUNITY <br> ON NASCENT TUMORS 

Despite the lack of much immunogenicity in spontaneous tumors, immunological surveillance might still be operative. There does not seem to be a total lack of immunogenicity in spontaneous tumors and it could be argued that very little is required for the purposes of surveillance. Perhaps a very minimal even subliminal, immunoresistance might be adequate to eliminate very small foci of nascent tumor cells. It has been demonstrated in many systems that an immune response that can cope with small numbers of neoplastic cells may be overwhelmed by larger numbers. However, three separate lines of evidence argue against the possibility that minimal immune resistance is all that is necessary to cope with incipient neoplasms.

## Sneaking through

The first piece of evidence against the efficacy of minimal immunity towards nascent tumors is the so-called 'sneaking through' phenomenon. This phenomenon was first described in connection with hydrocarbon-induced mouse sarcomas. During the course of transplantation studies in syugeneic mice it was found that some tumors exhibited an unexpected behaviour. These tumors, in common with the rest, overcame host resistance when inoculated in high cell dosage, but failed to grow when fewer cells were used. Additionally, however, these tumors did sometimes grow when exceedingly small tumor cell inocula were utilized. The dose response curve upon transplantation was thus biphasic; very low as well as high numbers of cells produced growth while intermediate numbers were inhibited, presumably by the immune response. This curious phenomenon has been confirmed by a number of investigators and can be demonstrated even when previously immanized animals are challenged with varying dosages of tumor cells. ${ }^{14}$ It has been suggested that the explanation may be that a very few tumor cells fail to signal effectively the immune response of their presence. A delay in this signal may allow the inoculated cells to establish themselves and begin to grow. It is known that grafts of tumors or, for that matter, of normal allogeneic tissue are much less vulnerable to the immune response after they have established a blood supply. Although the explanation of the phenomenon is still obscure, the facts are clear. A very small tumor cell inoculum, which can be thought to simulate a nascent in situ tumor, may survive when a larger inoculum is immunologically destroyed. Thus the 'sneaking through' phenomenon argues that the nascent tumor, far from being more vulnerable to immune attack, may actually be relatively resistant. Since the phenom-enon is demonstrable with highly immunogenic hydrocarbon-induced sarcomas, it seems unlikely that the immune response could 'survey' minimally immunogenic, nascent, spontaneous tumors. In rebuttal, it should be pointed out that 'sneaking through' may not be a general phenomenon. It is demonstrable with only some tumors and is a rather subtle process. Whether its falure to be seen with all tumors is merely a technological problem or alternatively represents a real qualitative difference is not known.

# Mammary hyperplastic nodules 

The second argument against the possible efficacy of immunological resistance to nascent tumors of minimal immunogenicity arises from a consideration of the biology of hydrocarbon-induced mammary tumors in mice. These tumors, in common with most other hydrocarbon-induced neoplasms, are highly immunogenic. The system has the advantage that benign premalignant precursor lesions can be studied. One of my colleagues, Dr Glenn Slemmer, has been able to show that these benign tumors, while potentially immunogenic, do not in fact signal the immune mechanism of their presence as long as they are small in situ lesions. ${ }^{16}$ The lesions can, in this system, achieve a considerable mass while completely ignored by the immune mechanism. Thus, it seems that immune surveillance is, in the mouse mammary tumor system, not possible at the level of the nascent tumor. Immune resistance is a late - often too late - development. Of course, the model of the mouse mammary tumor may not be applicable to other systems. However, there is a considerable probability that other sites of epithelial tumor formation may also be immunologically privileged, i.e., these sites may, like the breast, by virtue of anatomical peculiarities, be endowed with defects in the afferent limb of the immune response. In such sites, if this is true, even those tumors of high potential immunogenicity could not be immunologically surveyed at early stages of their evolution. The skin may represent such a site, since Billingham and Silvers ${ }^{8}$ have shown that carefully made allografts of melanocytes can survive as intra-epithelial grafts due to an afferent limb defect. Thus, tumors arising in this site should also fail to immunize at early stages of their development.

## Immunological stimulation

The third argument against the proposal that a minimal level of immune reactivity may be adequate to control a nascent lesion arises from recent work of mine. This work suggests that a weak immune reaction, rather than being inhibitory to target tumor cells, may actually stimulate them to growbetter. ${ }^{13}$ The experimental design was based upon Winn-type tests. Varying numbers of spleen cells from tumor-immune mice were mixed with constant, near-threshold, numbers of target tumor cells and the mixtures inoculated subcutaneously into test mice. The recipient mice had been immunocrippled previously by adult thymectomy followed with whole-body X-radiation. In this fashion it was hoped that the recipient mice would make little or no contribution to the immune reaction. The growths of tumor at the site of inoculation were compared with the growths produced by mixtures of tumor with non-immune spleen cells or with mixtures composed of tumor and spleen cells sensitized to an extraneous antigen. In these experiments it was found that large proportions of specifically immune spleen cells inhibited tumor growth. However, non-immunized spleen cells, in large proportions, produced greater growth than occurred when tumor alone was the inoculum. In addition, at low levels of admixed spleen cells, the specifically immune stimulated tumor growth as compared with the non-sensitized or as compared with no spleen cells at all.

The explanation for this tuitor stimulation is not yet clear. It is unlikely to be caused by classical blocking factors; rather it appears to be an absolute stimulation. Whether it is a purely quantitative phenomenon is uncertain since the possibility of the presence in the spleen cell population of more than one cell type (thymus-dependent and thymus-independent as well as macrophages) raises the possibility that the stimulatory effect might be the result of a qualitatively different mechanism than is the inhibitory. The apparent quantitative aspect could be explained if separate stimulatory and inhibitory cells in the inoculum were present in differing amounts and possibly had differing thresholds of reactivity. Whatever the explanation, it seems clear that under circumstances in which tumor immunogenicity is weak and/or the response for any reason minimal, stimulation of tumor growth rather than inhibition may result. These facts suggest that the minimal immune response, which must apparently be the initial reaction to nascent spontaneous tumors, rather than being a defence, may be the actual means by which a tumor that might otherwise be dormant is stimulated to grow. ${ }^{14}$

It can be concluded that the first correlation upon which the argument for immunological surveillance is based, namely the almost universal presence on the tumor cells of immunity-producing antigens, is not good. The correlation is adequate in connection with chemically and some virally induced lesions, but seems to break down completely in the case of most spontaneous tumors. In fact, far from being inhibitory, the hypothesis must be entertained that the immune response to spontaneously transformed nascent clones may be stimulatory. At present, the extreme hypothesis that a weak immune response may be necessary to the growth of nascent tumors in vivo cannot be ruled out.EXPERIMENTAL ALTERATION OF THE
IMMUNE RESPONSE

# Animal experiments 

The second correlation upon which the argument in favour of immunological surveillance is based is the correlation between experimental manipulations that interfere with allograft immunity and the susceptibility to tumor induction. How good is this correlation? The experimental data are now very extensive and certainly enough success has been achieved to say that a correlation exists, but it is far from perfect. ${ }^{14}$ Newborn thymectomy was shown to increase the susceptibility to hydrocarbon oncogenesis in mice, but the results, while significant, were not dramatic. Anti-lymphocyte serum also increases this type of oncogenesis. However, it must be remembered that success in these systems is of small magnitude, and negative experiments tend not to be published. Perhaps the most dramatic results have been achieved in relation to oncogenesis by polyoma virus.

When one looks at the picture in relation to spontaneous tumors the correlation becomes very poor indeed. Lifetime administration of antithymocyte serum accompanied by proven interference with allograft reactions failed to alter the incidence of spontaneous neoplasms. ${ }^{9}$ In the mouse mammary tumor system, measures that ordinarily depress allograft reactions regularly result in fewer rather than in more tumors! ${ }^{14}$ The only convincing success in a spontaneous tumor system has been reported by Trainin in connection with spontaneous lung adenomas in mice. ${ }^{14}$ In that system immunodepression results in a marked increment of tumors, despite the fact that the tumors have very little immunogenicity. One probable explanation, which I favour as a working hypothesis, is that true immunological surveillance may really occur in the lung much more than in other sites. The lung has an unusually high degree of immunological sensitivity. Thus, it is possible to sensitize by inhalation against bacillus CalmetteGuérin with approximately tenfold fewer organisms than by a cutaneous route. Of course, while highly suggestive, the correlation in the lung adenoma system does not prove the immunological surveillance hypothesis even for that organ. Other explanations of the data are possible.

## Observations in man

One other claimed correlation between immunosuppression and spontaneous tumor formation merits detailed discussion. Penn and Starzl ${ }^{10}$ have collected data showing a very high incidence of neoplasia in patients treated with immunosuppressive therapy for the purpose of kidney transplantation.The obvious conclusion is that this is another evidence of the ordinary efficacy of immunological surveillance. This conclusion is rather doubtful. Nearly half of the reported neoplasms are reticulum cell sarcomas or other lymphomas. If tumor formation were occurring because of an absence of a normal immunological surveillance, all types of neoplasms would be increased. It is not proper to produce as evidence tumors composed of cells involved in the immune mechanism itself. Damage to the immunological organ by immunosuppressive drugs can be expected to lead to attempts at compensation and to resultant neoplasia in that organ. While the claims based upon the reticulum cell sarcomas can be disallowed, Penn and Starzl ${ }^{10}$ also believe that kidney transplant patients have a higher than expected incidence of tumors of other types. This may be true, but as of now, the data ate not entirely convincing. The problem lies in a proper control population. The kidney patients were observed closely for periods ranging up to ten years. Many of the tumors seen were in situ cervical lesions or were skin tumors which may be under reported in control registry data. Under these circumstances, while the data seem suggestive, it may still be premature to conclude that the incidence of epithelial tumors is really increased. Judgment must be reserved.

# EXPERIMENTS OF NATURE 

The third correlation upon which claims concerning the importance of immunological surveillance have been based concerns the tumor incidence in patients with naturally occurring immunodeficiency syndromes. As in the kidney graft patients, there is an excess of neoplasia, but it seems to be largely lymphosarcoma or lymphoma. ${ }^{5}$ Again, as in the case of the kidney graft patients, increments in these tumors do not constitute good evidence for failure of a normal surveillance mechanism.

## MISCELLANEOUS CORRELATIONS

It is true that non-specific stimulation of the immune response by bacillus Calmette-Guérin has a demonstrated anti-tumor therapeutic effect and can also lower the incidence of neoplasia. ${ }^{4}$ However, the results, at least as far as tumor incidence is concerned, are rather feeble. Perhaps, rather than demonstrating the efficacy of immunological surveillance, these results show that what is ordinarily an ineffective defence mechanism can be improved by artificial means.

Aging and caloric restriction obviously have manifold effects other than those upon the immune mechanism. Consequently, I think that it is difficult to draw firm conclusions about immunological surveillance from these evi-dences. The data are, however, consistent with the immunological survelllance hypothesis and highly suggestive. ${ }^{4,7}$

The lymphoid infiltration often observed in early neoplasms could be a manifestation of immunological surveillance. However, it might also be evidence of immunostimulation of tumor growth. More information is needed before firm conclusions can be reached.

TUMORSUSCEPTIBILITY AND PHYLOGENY
One of the most interesting correlations that has been drawn in support of the immunological surveillance hypothesis concerns the lack of neoplasia and of an allograft type of immune reaction in the invertebrate part of the phylogenetic tree. It is far from certain that this correlation really exists. Some tumors that fulfil any reasonable definition of neoplasia have been described in invertebrates and it may well be that their apparent paucity is due to lack of adequate observation. However, if we assume for the moment that the correlation really does exist, its interpretation may not be that advanced by the supporters of the surveillance hypothesis. They would have us believe that the allograft reaction evolved to meet a new threat in the vertebrates. No explanation is offered of the lack of neoplasia in the supposedly defenceless invertebrates. A far more direct explanation of the supposed facts, now that it has been shown that the immune reaction can be stimulatory to tumor cells, would be that invertebrates have a paucity of neoplasia precisely because they lack an anti-allograft reactivity. ${ }^{13}$

# GENERAL CONCLUSIONS 

In reviewing the correlations that have been made or not made relative to immunological surveillance, can any general conclusions be reached? I think the following may be satisfactory:
1 There is an immune defence mechanism in cancer biology. However, in most systems it is ineffective and late acting rather than a surveillance mechanism against incipient tumors. It is seldom efficacious in spontaneous tumor systems, with the possible exception of lung tumors, where true surveillance may be operative because of the unusual efficiency of the lung as a site for immunization. There is evidence for surveillance in some chemically induced and in some viral tumor systems, in both of which the tumors are unusually immunogenic. These systems may be laboratory artifacts that have little to say about the naturally occurring disease.
2 The interaction of the immune mechanism with the nascent spontaneous neoplasm is more likely to be stimulatory than inhibitory. It is thereforehighly unlikely that the allograft type of immune reaction evolved as a response to neoplasia.
Thus, the evidence overall seems to suggest that immunological surveillance of nascent tumors, as originally conceived, may not exist in most tumor systems. On the other hand, there is a late-acting and inefficient immunological defence mechanism. Hopefully, this mechanism may be subject to augmentation for purposes of immunotherapy. If the surveillance mechanism were more efficient, the chances of effective immunotherapy might be much less than they probably are. I think that the usual failure of immunological defence offers the opportunity to improve artificially upon what nature has imperfectly wrought.

# REFERENCES 

1 Baldwin, R.W. Brit. J. Cancer, 9: 652-657, 1955
2 Baldwin, R.W. and Embleton, M.J. Intern. J. Cancer, 4: 47-53, 1969
3 Billingham, R.E. and Silvers, W.K. J. Exptl. Med., 131: 101-117, 1970
4 Burnet, F.M. Immunological Surveillance. Oxford: Pergamon Press, 1970
5 Good, R.A. and Finstad, J. Natl. Cancer Inst. Monogr., 31: 41-58, 1969
6 Hellström, I., Hellström, K.E., Evans, C.A., Heppner, G.H., Pierce, G.E., and Yang, J.P.S. Proc. Natl. Acad. Sci., 62: 362-368, 1969

7 Jose, D.G. and Good, R.A. Nature, 231: 323-325, 1971
8 Klein, G., Sjögren, H.O., Klein, E., and Hellström, K.E. Cancer Research, 20: 1561-1572, 1960
9 Nehlsen, S.L. Clin. Exptl. Immunol., 9: 63-77, 1971
10 Penn, I. and Starzl, T.E. Transplantation, 14: 407-417, 1972
11 Prehn, R.T. J. Natl. Cancer Inst., 31: 791-805, 1963
12 Prehn, R.T. In Immune Surveillance (R.T. Smith and M. Landy, eds.). New York: Academic Press, 1970
13 Prehn, R.T. Science, 176: 170-171, 1972
14 Prehn, R.T. and Lappé, M.A. Transplant. Rev., 7: 26-54, 1971
15 Prehn, R.T. and Main, J.M. J. Natl. Cancer Inst., 18: 769-778, 1957
16 Slemmer, G.L. Natl. Cancer Inst. Monogr., 35. In press
17 Thomas, L. In Cellular and Humoral Aspects of the Hypersensitive States (H.S. Lawrence, ed.), pp. 529-532. New York: P.B. Hoeber, 1959# CHEMOTHERAPY$\cdot$
$\cdot$# Selection of regimens for clinical chemotherapy 

THOMAS C. HALL<br>American Cancer Society Research Professor RP-42,<br>LAC/USC Cancer Center, Los Angeles, California 90033

There are important differences between predicting responses to new agents and selecting the components for a therapeutic regimen for a specific patient at a specific point in time. Predicting response can be done statistically by epidemiologic studies; for example, one can show that patients who have slow-growing disease will respond more frequently to cancer therapy. ${ }^{1,2}$ Patients who have poor nutrition ${ }^{3}$ and impaired immunologic statuses will do less well. ${ }^{4,5}$ During the early stages of drug development, it is usually possible to predict response of an animal tumor to a new drug by in vivo studies of drug effect on tumor cell metabolism ${ }^{6}$ or even to define which tumor types will respond to a new drug. However, the selection of specific drugs for human trial requires a higher order of precision, based upon detailed study of the tumor, and, when possible the normal host cells of the particular patient at the specific time. This involves a knowledge of the details of specific metabolic relationship between the tumor, each of a number of drugs, and of the host's normal tissues. These are costly investigations, and those in charge of large national programs in cancer therapy have shown a remarkable unwillingness to undertake studies of the mode of action of drugs, feeling that such studies divert funds from the empirical development of superior new drugs and combinations. What arguments can be raised to justify attempts to develop clinical predicting systems for individualization of patient therapy?

First, in a number of rapidly fatal malignancies such as acute myelogenous leukemia, for which there are a large number of drugs, each of which has only a moderate (i.e. $20-30$ per cent) response rate, there is usually only time for one drug or combination to be tried, and if the one chosen is ineffective, the patient will be dead before another can be tried.

Second, with the current increased interest in therapeutic combinations, each agent chosen has some host toxicity, whereas not all agents will have anti-tumor toxicity. Hence, identification of drugs good for the patient could possibly limit the number of drugs needed in a proposed combination, whilepre-identification of ineffective drugs should permit them to be excluded from the regimen, and thus lessen host toxicity.

Third, new drugs with unknown response rates could be preselected for use in certain patients and groups only, thus increasing the simplicity, speed, and effectiveness of phase in trials.

Finally, virtually all patients treated with the most effective current anticancer drugs relapse in time. At the time of relapse, there are usually a large number of new drugs which might be effective, and resistance to the previous drugs may be incomplete, or due to different biochemical pathways from these characterizing initial resistance. ${ }^{7}$ Therapy for the relapsed patient could be more effective were we able to 'cone down' on the few most likely next alternatives, from among all the possibilities, by some form of drug sensitivity pretesting.

# INEFFECTIVE METHODS 

In the past, a number of methods for preselection of best therapies have proven ineffective. The simplest and most familiar, because of its use in bacterial sensitivity was the treatment of the patient's tumor by proposed drugs in vitro. Methods for measuring cytoxicity to the tumor included loss of tetrazolium dye reducing capacity, ${ }^{8}$ increased stainability with dyes excluded from living cells, ${ }^{9}$ and inspection for cytopathogenicity. ${ }^{10}$ The problems encountered included lack of in vivo host-tissue effects on activation (cyclophosphamide), detoxification ( 5 fluorouracil), or excretion (methotrexate) of the drug. In addition, human tumors virtually never continue to grow and divide in cell culture, thus rendering it difficult to measure the possible in vivo effects of antimetabolites or antimitotic agents.

Other problems included persistence of drugs in high concentrations in the cultures for longer than would occur in vivo, absence from the cell culture of needed hormones, and lack of knowledge of the proper pool sizes of competing nucleosides and bases.

The growth of differentiated human tumors in immunosuppressed or tolerant animal hosts represented an attempt to overcome some of the restrictions of the in vitro systems. Again, very few tumors grew, the drugs had to be given to hamsters or rats which had metabolic pathways different from man, and the few human clones which persisted seemed to be composed of cells that were not representative of the types or proportions of cells found in, and needing treatment in, the patient.

Most commonly at present, new drugs are tested against a few transplantable mouse tumors, such as L1210, Sa 180, and melanoma B-19, which are stated to be comparable to certain human tumors. However, it is now recognized that these mouse tumors are most similar to each other andquite different from almost all human tumors in respect to growth rates, daughter cell death rates, and drug handling characteristics. They only have a certain predictability for childhood acute lymphoblastic leukemia. It was hoped that the host's pattern of drug handling might be different between drug-sensitive and resistant patients; this was a will-o-the-wisp pursued most intently by those interested in the determinants of steroid sensitivity. However, neither plasma protein binding, steroid sulfurylation, ${ }^{11}$ nor urinary excretion ${ }^{12}$ have been of help in selecting drugs for the treatment of a particular patient with cancer of the secondary sex organs. This is an expected finding, in view of the fact that the doses of steroids given are usually 50 to 100 -fold higher than those produced physiologically, and this amount of steroid should, and does, overwhelm individual differences seen in the handing of small doses. Paradoxically, such studies have emphasized the importance of avoiding overuse of animal models for the human situation because of large species differences: for example, the anabolism of methotrexate by the rabbit, ${ }^{13}$ the extensive deamination of cytarabine by certain rodents, ${ }^{14}$ and the extensive plasma binding and inactivation of some antifols ${ }^{15}$ by rodents.

It was hoped that pharmacokinetic differences between patients or between groups of patients with different tumors, or in different age, sex, and racial groups, might be found to explain and hence predict the sensitivity of certain tumors or patients to drugs. Although this has been helpful in decreasing the dose frequency of certain drugs such as adriamycin with long plasma half-lives, ${ }^{16}$ it has not been shown that the 25 per cent of patients who are adriamycin sensitive differ in any conventional pharmacokinetic fasion from the 75 per cent who do not respond, the plasma half-times, urinary excretion, and body-compartment distribution all being identical.

Finally, even examination of the cells kinetics of growth has not been helpful in selecting which drugs might be effective against classes of tumors, or individuals with tumors. Thus we see that rapidly growing tumors such as melanoma respond to 'non-cycle-specific' agents such as dimethyltriazenoimidazocarboxamide, while slower growing colon and breast cancers respond better to 's-phase' antimetabolites such a fluorouracil. Cycle sensitive 6-mercaptopurine which inhibits acute lymphoblastic leukemia is virtually ineffective (as are vincristine and methotrexate) against equally rapidly growing myeloblastic leukemia. Lastly, as resistance to an effective drug develops, all cytokinetic studies have shown that the resistant and the sensitive clones have similar kinetics. ${ }^{17}$

At the present time, the only useful determinants of drug responsiveness are to be found by analysis of drug effects in the target tumor cell itself, and the fashion and extent to which a sensitive tumor cell differs biochemically from a resistant tumor cell and from the tissues of the tumor-bearing host.This is reasonable, in view of the fact that there are many different biochemical stages traversed by each normal cell in its ontogeny, and tumors appear to be blocked at many different and individual points along the ontogenic path. In addition, the mutability of cancer cells suggests that resistant clones will emerge with still different patterns of metabolism. Hence, prediction needs to determine which of these many possible relationships actually operates between a particular drug and the tumor of a patient at the point in time that treatment is contemplated. The host's cells, having undergone the uniform ontogeny that characterizes normal differentiation, and lacking the genetic instability of the tumor, are predictable in their drug handling and responsiveness; examination of a few normal tissues may determine normal tissue responses for the whole species, but each tumor needs individual analysis. Hence, individualization of anti-cancer therapy requires individualization of tumor analysis, and repeated analysis of the specific tumor over a period of time.

In recent years, we have been able to remove some normal organs completely without compromising the survival of the host; and life can proceed in the absence of thyroid, parathyroid and thymus, pancreas, adrenal, primary and secondary sex organs, colon, bladder, esophagus, etc. We use this concept as the background for a largely unrecognized form of anticancer therapy based upon the similarities between organs and the tumors which arise from them. ${ }^{18}$ Using this concept, op ${ }^{1}$ DDD, an insecticide causing adrenal necrosis, was deliberately chosen for use in adrenal cortical cancer. Corticoids, mustards, and 1-asparaginase, which lyse normal lymphocytes, have been used to lyse malignant lymphocytes. Streptozotocin, which causes diabetes, has been used to treat islet cell cancer. In such instances, instead of analysing tumors for these drug characteristics which differ from the normal host counterpart, selection of suitable patients may require that the tumor have diffentiated to a point comparable to that of the host. Similar considerations also underlie the use of sex steroids in breast cancer, since only those tumors which have differentiated enough to resemble normal breast tissue in respect to the presence of Barr bodies, or estrogen-binding proteins, seem to respond by further differentiation towards normality, and cessation of unrestrained growth.

# PREDICTION FOR SPECIFIC DRUGS 

Several steps are involved in development of a valid screening test: first, the identification of critical biochemical determinants for activation of and activity by a drug - for example, deoxycytidine kinase phosphorylation of cytarabine, and the inhibition of DNA polymerase by cytarabine nucleotides. It is useless to measure an important pathway if the drug is not directlyinvolved. ${ }^{19}$ The second step is the elucidation of the variations from the above which are involved in drug resistance. This should be done separately for 'native,' 'acquired,' and 'collateral' resistance. Both steps one and two can often be done using animal tumors, cell cultures, and even microbiological assays.

The next steps are to determine that these pathways are also present in some human tissues, both normal rapidly growing tissues, and tumors, and to relate clinically observed drug sensitivity or resistance to the presence or absence of the specific pathways. Finally, the selection test can be applied to specific patients prior to treatment in order better to select effective drugs and combinations.

# ALKYLATINGAGENTS 

These agents were amongst the earliest anti-cancer agents introduced, and after several decades relatively little is known about the determinants of selective toxicity. In animals, it is clear that a sensitive tumor will take up and retain more drug than a resistant tumor of similar histologic type, in the same animal. ${ }^{20}$ This may result from differences in transmembrane transport, since nitrogen mustard has been shown to be carried across the plasma membrane of mouse ascites tumors by a mechanism similar to that used for the transport of amino acids. ${ }^{21}$ However, the existence of this transport in human cells has not been demonstrated, and its relevance to differential human drug sensitivity is not yet clear. In addition, there is evidence that retention intracellularly following transport may correlate with binding to an intracellular site. ${ }^{22}$ We have yet to see data in which these two variables are examined together and in relationship to differential net drug retention by tumors.

After the mustard is retained by the tumor, there must be a highly selective cytotoxic action on certain cell types, such as lymphocytes, probably through an as yet undescribed but inhibitable target mechanism in $\mathrm{G}_{1}$ cells. In addition, specific patients' tumors within certain histologic types, e.g. breast adenocarcinoma, are mustard sensitive, while most tumors are not. Whether this is because a few breast cancers share the sensitive target of lymphocytes is not clear. Mustards inhibit equally rapidly dividing tissues, such as normal bone marrow and acute leukemia blasts, but since there is little differential toxicity, there is also little therapeutic advantage. It is not clear if the same mechanism is involved in the much greater differential toxicity occasionally seen following mustard treatment of breast cancer. On the whole, the best current clinical procedures for sensitivity testing for alkylating agents would seem to be: (a) study of the differential uptake of trace doses of isotopically labelled drug in normal and tumor tissue of the involved patient and (b)observation of the serial short-term changes in nucleic acid synthesis in the tumor following a single treatment dose of stable drug. ${ }^{23}$

# STEROIDS 

The pioneering studies of Jensen ${ }^{24}$ suggested that the effects of estrogen on cells depended upon the presence of specific cytoplasmic binding proteins. Recent work with corticoids ${ }^{25}$ and progrestins ${ }^{26}$ have suggested that these steroids also require specific intracellular ligands in order to affect target cells. The presence of estrogen-binding proteins within breast cancer cells from humans and animals has been reported by several laboratories to correlate well with response to hormonal ablation, including oophorectomy ${ }^{27}$ and adrenalectomy, ${ }^{28}$ as well as to steroid administration. ${ }^{29}$ Such bind:ng may be responsible for the apparent prognostic significance of estrogen uptake in vivo by human breast cancer tissue. ${ }^{30}$ However, not all patients who have good levels of cytoplasmic estrogen-binding protein respond to hormone therapy, and indeed some patients with high estradiol uptakes in vivo did not respond. This may be due to the fact that most reported studies have concerned the cytoplasmic or $8-\mathrm{S}$ receptor, and not the nuclear $5-\mathrm{S}$ receptor, which is present in much smaller amounts. Adequate amounts of cytoplasmic receptor would permit, but not guarantee, response. Response would ultimately require the presence of both cytoplasmic and nuclear receptor, and Shyamala has described just this phenomenon in mouse breast cancer. ${ }^{31}$ Studies of human tissues so far have clearly demonstrated the binding protein, ${ }^{32-37}$ have related it to response, ${ }^{38}$ and suggested that there may be qualitative differences between the receptors in normal and neoplastic breast tissues, as well as quantitative differences between different cancer nodules in the same patient. Lemon et al. suggested further that the therapeutic effect of weak estrogens might be related to their affinity for such cytoplasmic ligands. ${ }^{39}$

As was mentioned earlier, studies of steroid metabolism by the whole host were not predictive of specific responses; Dao, however, suggested that steroid sulfurylation by tumor tissue itself might be of help. ${ }^{40}$ However, at least one recent study casts doubt upon this method of prediction. ${ }^{38}$

Available evidence suggests that estradiol is the main active physiologic human estrogen, and is potent in very small doses. Testosterone, on the other hand, required vastly larger doses, and for this and other reasons was suspected not to be the actual androgen acting at the cellular level. The work of Wilson suggested that in prostate, and possibly other male secondary sex organs, reduction of testosterone was required for physiologic activity. ${ }^{41}$ The presence of testosterone reductase permits a tissue to become androgen sensitive, and studies are badly needed to explore the possibility that the anti-tumor activity of testosterone against breast and some prostate and renal cancers may relate to the selective occurrence of androgen reductases in such tumors. Since breast cancers which respond to estrogen usually respond later to androgen, and vice versa, the suggestion seems logical that there may be relations between the ligands, either structurally, or closely related on the genome.

The progestins have been studied even less extensively than the androgens, but there are reports of specific progestin-binding proteins, and it is conceivable that tissue examination for these could form the basis for preselection of drug-sensitive patients with adenocarcinoma of the endometrium, breast, prostate, and kidney.

Recently Tomkins, ${ }^{42}$ Rosen, ${ }^{43}$ and others have demonstrated selective retention of corticoids by some cells of lymphoid origin. Tonkins has correlated corticoid uptake with anti-tumor effect in a mouse lymphosarcoma. Such examinations may be very helpful in predicting which malignant lymphocytes or related cells of chronic leukemia, lymphoblastic leukemia, myeloma, and lymphoma will respond to corticoid treatment. The lympholytic effect of corticoids is dramatic, but short-lived, and it would be of great interest to examine cells with drug-induced resistance for changes in ligand concentration, structure, or availability.

# ANTIMETABOLITES 

'Native' Methotrexate (MTX) sensitivity in man appears to be related to predictable from rate of transmembrane transport into the target cell, ${ }^{44}$ and the requirement of the cell for endogenous conversion of deoxyuridylate to thymidylate, for DNA synthesis. ${ }^{45}$ This is true for animal tumors and for human leukemias. ${ }^{46}$ In human solid tumors, where studies of in vitro uptake are done only with difficulty, it is not clear whether the much lower rate of MTX sensitivity is due to lack of adequate membrane transport, or different pathways for obtaining DNA thymidine. There is a natural lack of enthusiasm for detailed studies of innate resistance when a drug is quite ineffective; however, it would be worthwhile to administer tagged MTX to a number of patients with resistant (e.g. kidney adenoca) and sensitive (e.g. choriocarcinoma) tumors prior to biopsy, for the possibility of differential retention.

Acquired resistance to MTX by animal tumors is commonly accompanied by disappearance of specific-access mechanisms, as well as by large increases in the target enzyme, dihydrofolate reductase. ${ }^{47}$ The former, but not the latter, appears in man, hence one can select those MTX-treated patients who retain some aspect of drug sensitivity by examining the in vitro uptake of labelled MTX by isolated leukemic cells.

The elegant work of Brockman demonstrated that one could predictwhich rodent leukemias were responsive to 6-mercaptopurine (6MP) by their content of the phosphoribosyltransferase which converted 6MP to 6MPRP. ${ }^{48}$ When Davidson and Winter attempted to predict human leukemia 6-MP sensitivity by assaying for this enzyme in cell-free extracts, the correlation was not impressive. ${ }^{49}$ However, when we examined the capacity of intact leukemia cells to phosphorylate the drug in vitro, the correlation with subsequent responsiveness was excellent. ${ }^{50}$ The correlation also held for late resistance appearing after prolonged exposure to the drug of initially sensitive cells. Recently Sartorelli's group has suggested that assay for a phospatase capable of clearing 6MPRP may help predict drug resistance. ${ }^{51}$ The reasons for the extraordinary resistance of most human solid tumors to 6-MP have never been examined systematically, and this should be done. Recently, 6 -thoguanine ( 6 TG ) has been found to be more effective than 6-MP against acute myelogenous leukemia. ${ }^{52}$ We found that 6TG is phosphorylated extensively by leukemia cells later shown to be sensitive to the drug, and that the same in vitro cell suspensions phosphorylate 6TG much more extensively than they do 6MP.

Fluorouracil ( Fu ), as all antimetabolite bases and nucleosides, needs to be converted to the nucleotide in order to inhibit its target enzyme, thymidylate synthetase. The explanation for Fu's lack of effect in human leukemia seems to be the relative absence of both a phosphoribosyltransferase and a phosphorylase, so that neither FuMP nor FuR is formed. ${ }^{53}$ In mouse solid tumors, on the other hand, the variable amounts of pyrimidine phosphoribosyltransferase (PPRT), predict quite well for response to $\mathrm{Fu} .{ }^{54}$ Preliminary data in human solid tumors also suggest that this enzyme is predictive for initial sensitivity. In mouse leukemias, drug resistance is often accompanied by an increase in thymidine kinase (TK), suggesting that such resistant cells are using preformed thymidine and thus decreasing their dependence upon the Fu sensitive enzyme, thymidylate synthetase (TS). ${ }^{55}$ Hence, it can be seen that prediction of Fu responsiveness, for example in colon and breast cancers, might need simultaneous assay for TS, TK, and PPRT. It is of interest to note that the resistance of human leukemias to Fu could have been predicted by examination of a dozen or so patients' cells in vitro. However, hundreds of patients were treated empirically with this drug before it was realized that human leukemia differed so markedly from mouse leukemia. Simple in vitro tests should prevent such an occurrence in future.

Cytosine Arabinoside has revolutionized the treatment of acute myelogenous leukemia. Prediction of sensitivity can be done almost uniformly in vitro on the basis of the leukemic cells' capacity to phosphorylate the drug using deoxycytidine kinase. ${ }^{56,57}$ Different tissues deaminate cytarabine to the inactive product uracil arabinoside. However, deaminase content oftarget cells does not appear to be involved in drug effectiveness in man ${ }^{58}$ or rodents. ${ }^{14}$ We have seen one patient in whom drug resistance developed while his cells' capacity to phosphorylate cytarabine in vitro remained intact. He demonstrated when resistant, however, a markedly shortened plasma cytarabine half-life, possibly due to hepatic deamination which prevented adequate nucleoside from reaching the target cells. For this reason, a positive prediction of response to cytarabine requires both in vitro phosphorylation and a long drug half-life.

# OTHER DRUGS 

Several anti-tumor antibiotics interclate with DNA and appear to 'bind' primarily when the cells are actively dividing; hence 'innate' sensitivity to actinomycin, daunomycin, adriamycin, and the terephthalanalides all require actual administration of tracer doses to the intact tumor-bearing host. ${ }^{59}$ There appears to be little cellular metabolism of actinomycin D; however, daunorubicin appears to be metabolized to an active derivative, and the presence of the enzyme can be detected in vitro and used as a predictive test for response. ${ }^{60}$ Acquired resistance to such bulky molecules involves decrease in the hydrolytic and increase in the synthetic activities of cell wall glycoproteins, building up a 'thick' cell wall through which the drugs no longer pass. ${ }^{61}$ For other drugs, of unknown mode of action, prediction of long-range effect can usually be inferred from the study of short-term effects on DNA synthesis following administration of a pulse-dose of stable drug at the usual clinic dose size. ${ }^{62}$ However, this requires repeated sampling of tumor, a relatively easy task in the leukemias, but difficult indeed for many solid tumors. Asparaginase is an enzyme which strips asparagine residues from plasma membrane glycoproteins and depletes the plasma of asparagine so that synthesis of the asparagine-rich plasma membrane of lymphoid tissues is interfered with and the cells lyse. ${ }^{63}$ The best predicting tests for asparagine are the in vitro study of the composition and synthetic rates of target cell wall glycoproteins. A suggested predictive role for asparagine synthetase levels in the target cells has not been proven by experience. The vinca alkaloids are excluded from transport by the same cell walls as exclude actinomycin D. Since they react with cytoplasmic microtubules, it would seem reasonable to examine tumors by electron micrograph for the presence of such microtubules as a possible predictive test for vinca sensitivity.

## PREDICTION SYSTEMS APPLIED TO SPECIFIC TUMORS

In acute leukemia, the systems outlined above have bèen of great value. Using a combination of drug uptake and phosphorylation effects on DNAsynthesis over 24-48 hours one can predict with considerable certainty both responders and non-responders to a variety of single and combination drug regimens. Such in vitro data also permit the selection of two-drug regimens which induce remissions and cause low toxicity. Since drug resistance is a constant feature of some cells, these tests do not increase the numbers of patients capable of responding to the currently available drugs. However, by identifying resistant patients promptly, it becomes possible to move promptly and confidently to new and hopeful agents, and by eliminating unnecessary drugs, host toxicity is diminished.

In breast cancer, it remains to be learned whether observed differences in content of steroid-binding proteins in tumor masses represent varying ligand levels in each and all of the cells of the mass, or different frequency distributions of cells, some of which have much ligand and others which have none. If the latter were true, such cells, while resistant to steroids at all drug levels, might be independently sensitive to cytotoxic agents such as Fu or to adriamycin. The most rational predictive tests for the combination therapy of breast cancer would include measurements of 8 -S steroid binding proteins in cytoplasm, 5-S ligand in nucleus, of adriamycin reductase for Fu phosphorylation, and of 'salvage,' or preformed, thymidine kinase. Many of these same assays could be of help in predicting the responses of prostate cancer; however, assays of androgen reductase should then be added.

CONCLUSIONS
There are sufficient data on the nature of determinants of activity of specific drugs and the general distribution of these factors among tumor tissues to permit the design of in vitro clinical predictive tests for the effectiveness of drugs and combinations in a wide variety of human cancers. The benefits of such assays would be: (a) to increase the effective application of existing drugs alone or in combination in the treatment of specific patients; (b) to decrease host toxicity by eliminating drugs without anti-tumor activity from specific regimens; (c) to increase the speed and confidence with which one tries new drugs in patients who would be resistant to existing drugs; (d) to increase the use and effectiveness of drug combinations by excluding the ineffective members; (e) to speed the preliminary testing of new drugs in man.

# REFERENCES 

[^0]
[^0]:    1 Krant, M.J. et al. Comparative trial of chemotherapy and radiology in non-resectable cancer of the lung, Am. J. Med. 35: 363-373, 1963
    2 Spratt, J.S. and Donegan, W.L. In Cancer of the Breast, p. 203. Philadelphia, Pa.: W. B. Saunders Co., 19673 Ansfield, F.J. Chemotherapy of Disseminated Solid Tumors, p. 10. Springfield, Ill.: C.C. Thomas, 1966

4 Morton, D.L. and Eilber, F.R. Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms, Nat. Cancer Inst. Monogr., 34: 103-108, 1971
5 Sokal, T.E. and Aungst, C.W. Cellular immune responses and prognosis in malignant lymphomas, Nat. Cancer Inst. Monogr., 34: 109-112, 1971
6 Hall, T.C. et al. Pattern of drug effects on nucleic acid synthesis in human leukemia. pp. 478-482. In Erythrocytes, Thrombocytes, Leukocytes (Gerlach, K., Moser, E., Deutsch, W., Wilmanns, W., eds.), pp. 478-482. Stuttgart: G. Thieme, 1973
7 Brockman, R.W. Mechanisms of resistance to anticancer agents, Advances in Cancer Research, 7: 129-234, 1963
8 Kondo, T., Inamura, T., and Ichibashi, H. In vitro test for sensitivity of tumor to carcinostatic agents. Gann., 57: 113-121, 1966
9 Knock, F.C. Sensitivity tests for cancer chemotherapy, Arch Surg., 91: 376-385, 1965
10 Eagle, H. and Foley, G.E. The cytotoxic activation of carcinolytic agents in tissue culture. Am. J. Med., 21: 639-649, 1956
11 Dao, T.L. and Libby, P.R. Conjugation of steroid hormones by breast cancer tissue and selection of patients for adrenalectomy. Surgery, 66: 162-166, 1969
12 Bulbrook, R.D. Relation between endogenous steroids and etiology and clinical course of breast cancer. In Breast Cancer: Early and Late, pp. 51-58. Chicago: Year Book Med. Pub., 1970
13 Redetzki, H.M., Redetzki, T.E., and Elias, A.C. Resistance of the rabbit to methotrexate: Isolation of a drug metabolite with decreased cytotoxicity. Biochem. Pharm., 15: 425, 1966
14 Camiener, G.W. and Smith, C.C. Studies of the enzymatic deamination of cytosine Arabinoside I: Enzyme distribution and species specificity. Biochem. Pharm., 14: 1405-1416, 1965
15 Folsch, E. and Bertino, J.R. Inactivation by mouse serum of a tightly bound inhibitor of dihydrofolate reductase. Pharm., 6: 95, 1970
16 Benjamin, R.S., Riggs, C.E., and Bachur, N.R. The pharmacokinetics and metabolism of adriamycin in man. Clin. Pharmacol. Ther., 14: 592-600, 1973
17 Hall, T.C. Limited role of cell kinetics in prediction of response to cancer therapy. Nat. Cancer Inst. Monogr., 34: 19-24, 1971
18 Hall, T.C. Medical progress: Chemotherapy of cancer, New Engl. J. Med., 266: 129-134, 178-185, 238-245, 289-296, 1962
19 Cline, M.J. and Rosenbaum, E. Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. Cancer Research, 28: 2516-2521, 1968
20 Wheeler, G.P. Studies related to mechanisms of resistance to biological alkylating agents. Cancer Research, 23: 1334-1349, 1963
21 Goldenberg, G.J. and Land, H.B. Evidence for carrier mediated transport of cyclophosphamide in L5178Y lymphoblasts. Proc. Am. Assoc. Cancer Research, 14: 50, 1973
22 Kessel, D., Myers, M., and Wodinsky, I. Accumulation of two alkylating agents, nitrogen mustard and busulfan, by murine leukemia cells. Biochem. Pharm., 18: 1229-1234, 1969
23 Roberts, D. and Hall, T.C. Enzyme activities and deoxynucleoside utilization of leukemic leukocytes in relation to drug therapy and resistance. Cancer Research, 29: 166-173, 196924 Jensen, E.V., De Sombre, E.R. et al. Estrogen-receptor interactions in target tissues. Arch. Anat. Micro. Exp., Suppl., 56: 547-569, 1967
25 Samuels, H. H. and Tomkins, G.M. Relation of steroid structure to enzyme induction in hepatoma tissue culture cells. J. Mol. Biol., 52: 57-74, 1970
26 O'Malley, B.W., Sherman, M.R., and Taft, D.O. Isclation of receptors for progesterone in the cytoplasm and nucleus of the chick oviduct. Proc. Nat. Acad. Sci., 67: 501-508, 1970
27 McGuire, W.L. and Julian, J.A. Comparison of macromolecular binding of estradiol in hormone dependent and hormone independent rat mammary carcinoma. Cancer Research, 31: 1440, 1971
28 Jensen, E.V. et al. Estrogen receptors and breast cancer response to Adrenalectomy, Nat. Cancer Inst. Monogr., 34: 55-70, 1971
29 Braunsberg, H. et al. Prognostic significance of estrogen uptake by human breast cancer tissue. Lancet, 1: 163-165, 1973
30 James, F., James, V.H.T., Carter, A.E., and Irvine, W.T. A comparison of in vivo and in vitro uptake of estradiol by human breast tumors, and the relationship to steroid excretion. Cancer Research, 31: 1268, 1971
31 Shyamala, G. Estrogen receptors in mouse mammary tumors: Absence of the transfer of bound estradiol from the cytoplasm to the nucleus. Biochem. Biophys. Res. Comm., 46: 1623-1630, 1972
32 Wittliff, J.L. et al. Specific estradiol binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. Cancer Research, 32: 1983-1992, 1972
33 Korenman, S.G. and Dukes, B.A. Specific estrogen binding by the cytoplasm of human breast carcinoma, J. Clin. Endocrinol. and Metabolism, 30: 639, 1970
34 Feherty, P. et al. Oestradiol receptors in carcinoma and benign disease of the breast: An in vitro assay. Brit. J. Cancer, 25: 697-710, 1971
35 Johansson, E. et al. The binding of estradiol-17B to human breast cancers and other tissues in vitro. Cancer Research, 30: 692-698, 1970
36 Hahnell, R. et al. Estrogen receptors in human breast cancer. Steroids, 18: $681-708,1971$
37 Maass, H. et al. Estrogen receptors in human breast cancer tissues. Am. J. Obstet. Gynecol., 113: 377-382, 1972
38 Leung, B.S. et al. Predictability of response of endocrine ablation in adrenal breast carcinoma, a correlation to estrogen receptor and steroid sulfurylation. Arch. Surg., 106: 515-519, 1973
39 Lemon, H.M. et al. Competition between steroids for hormonal receptor. Nat. Cancer Inst. Monogr., 34: 77-83, 1971
40 Dao, T.L. and Libby, P.R. Conjugation of steroid hormones by breast cancer tissue and selection of patients for adrenalectomy, Surgery, 66: 162-166, 1969
41 Wilson, J.D. and Gloyna, R.E. The intranuclear metabolism of testosterone in the accessory organs of reproduction. Rec. Prog. Horm. Res., 36: 309-336, 1970
42 Baxter, J.D. et al. Glucocorticoid receptors in lymphomas cells in culture: Relationship to glucocorticoid killing activity. Science, 171: 189-191, 1971
43 Kirkpatrick, A.F., Milholland, R.J., and Rosen, F. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma $P$ 1798. Nature, New Biol., 232: 216, 1971
44 Kessel, D. et al. Uptake as a determinant of methotrexate response in mouse leukemias. Science, 150: 752-754, 1965
45 Wolberg, W. Biochemical approaches to prediction of response in solid tumors, Nat. Cancer Inst. Monogr., 34: 189-203, 197146 Kessel, D., Hall, T.C., and Roberts, D. Modes of uptake of methotrexate by normal and leukemic human leukocytes in vitro and their relation to drug response. Cancer Research, 28: 564-570, 1968
47 Fischer, G.A. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Bioch. Pharm., 7: 75, 1961
48 Brockman, R.W., Sparks, M.C., and Simpson, M.S. A comparison of the metabolism of purines and purine analogs by susceptible and drug-resistant bacterial and neoplastic cells. Biochim. Biophys. Acta, 26: 671, 1957
49 Davidson, J.D. and Winter, T.S. Purine nucleotide pyrophyosphorylases in 6-mercapto purine sensitive and resistant human leukemias. Cancer Research, 24: 261,1964
50 Kessel, D. and Hall, T.C. Retention of 6-mercapto purine derivatives by intact cells as an index of drug response in human and murine leukemias. Cancer Research, 29: $2116-2119,1969$
51 Woipert, K.C. et al. Mechanism of resistance of neoplastic cells to 6 -thio purines: Role of phosphohydrolases. Cancer Research, 31: 1620-1626, 1971
52 Gee, T.S., Yu, K.P., and Glarkson, B.D. Treatment of adult acute leukemia with arabinosyl cytosine and thioguanine. Cancer, 23: 1019-1032, 1969
53 Hall, T.C. Biochemical factors predicting response to chemotherapeutic agents. In Cancer Chemotherapy II, pp. 93-101 (Brodsky, I. and Kahn, S.P., eds.). New York: Grune \& Stratton, 1972
54 Reyes, P. and Hall, T.C. Synthesis of 5 -fluorouridine-5'-phosphate by a pyrimidine phosphoribosyl transferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5 -fluoracil promoted increase in survival of tumorbearing mice. Bioch. Pharm., 18: 2587-2590, 1969
55 Kessel, D., Reyes, P., and Hall, T.C. Thymidine kinase as a determinant of 5 -fluoro 2'-deoxyuridine in transplantable murine leukemias. J. Mol. Pharm., 6: 251-254, 1970
56 Kessel, D., Hall, T.C., and Wodinsky, I. Transport and phosphorylation as factors in the anti-tumor action of cytosine arabinoside. Science, 156: 1240-1241, 1967
57 Kessel, D., Hall, T.C., and Rosenthal, D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic blood cells in vitro. Cancer Research, 29: 459-464, 1969
58 Hall, T.C. and Levine, R. Deamination of cytosine arabinoside by normal and malignant tissues. Proc. Am. Assoc. Cancer Research, 8: 24, 1967
59 Kessel, D. and Bosmann, H.B. On the characteristics of actinomycin and resistance in L5178y cells. Cancer Research, 30: 2695-2701, 1970
60 Greene, W. et al. High dose daunorubicin toxicity for acute non-lymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity. Cancer, 30: 1419-1427, 1972
61 Bosmann, H.B. and Kessel, D. Altered glycosidase levels in drug-resistant mouse leukemias, Mol. Pharm., 6: 345-349, 1970
62 Roberts, D., Hall, T.C., and Rosenthal, D. Coordinated changes in thymidine-5'monophosphate metabolism of leukocytes following vincristine administration to patients with acute granulocytic leukemia. Cancer Research, 29: 789-794, 1969
63 Kessel, D. and Bosmann, H.D. Effects of 1-asparaginase on protein and glycoprotein synthesis. FEBS Letters, 10: 85-88, 1970# The measurement of the effects of anti-cancer agents 

W. R. BRUCE<br>Ontario Cancer Institute, Toronto, Canada

We are guided in our search for more effective treatments for cancer by careful measurements of the effects of well-defined treatments on a number of well-described tumors. Of critical importance in this process is the method of measurement, for it determines the efficiency with which new treatments can be evaluated, and thus it determines the rate at which progress can be made. What is the most effective way to measure the response of a tumor to treatment?

Many different measures of the effectiveness of anti-cancer agents are possible with experimental animal tumors. In this paper we shall consider four such tumors. Two are transplanted and two are 'spontaneous.' Two are leukemias and two are solid tumors. With each we have used two or more measurement assays. We have measured both the effect of treatment on the growth of the tumors in situ and the effects of treatment on the capacity of tumor cells to proliferate as malignant cells on transplantation. We shall outline the results we have obtained with each of these model tumors in turn and then return to the more general question.

## EXPERIMENTAL TUMORS IN MICE

## Transplanted AKR leukemia

The first tumor we examined was a leukemia transplanted in AKR mice. This tumor arose from the thymus of an AKR mouse with spontaneous leukemia and was transplanted at approximately weekly intervals by intravenous injection of $10^{6}$ cells from the spleens of donor animals. ${ }^{1}$ The transplanted cells grow with a doubling time of about 12 hours and proliferate in all major organs throughout the animal until, after a period of 6-7 days, the recipients die with greatly enlarged spleens, livers, and evidence of tumor throughout their kidneys, lymph nodes, skin, and brain.

The number of leukemic tumor cells with a capacity for proliferation can be measured by transplantation, using either a colony or a dilution assay. The colony assay rests on the observation that transplanted tumor cells giverise to discrete colonies in the spleens of recipients and that the number of these colonies depends directly on the number of cells transplanted. ${ }^{2}$ This assay thus permits us to measure the effects of a treatment on groups of mice with leukemia. Results obtained with the assay showed that many chemotherapeutic agents were highly selective in their effects on leukemic cells. ${ }^{3,4}$ Many of these agents reduced the number of leukemic colonyforming cells by a factor of $10^{4}$ at dosages far below the toxic levels for the mouse.

Difficulties arose, however, when the survival of mice, following administration of the supposedly effective drugs, was compared with the predictions based on the colony assay. ${ }^{5}$ There was good agreement for drug dosages corresponding to cell survivals down to one in $10^{4}$. but there was no explanation for the failure of treatments when the number of tumor cells exceeded $10^{5}$ to $10^{6}$ viable cells. This discrepancy prompted us to extend our survivalcurve measurements to much lower values by means of a dilution assay.

The dilution assay is based on the assumption that the death of a mouse inoculated with a dilution of tumor cells can result from the transplantation of one viable malignant cell. ${ }^{6}$ This assumption applies for the transplanted AKR leukemia. ${ }^{7}$ Serial dilutions of a tumor-cell suspension could thus be used to measure the number of tumor cells through a range of 7 orders of magnitude. The results obtained with this assay demonstrated the reason for our therapeutic failures. The survival of malignant cells, when plotted as a function of dose, extended linearly down through 4-5 decades for many agents. However, at higher doses the slope was markedly less steep. Thus, persistent, protected, or resistant cells provided the reason that most of the drugs were effective in dealing with animals with advanced disease. Detailed examination of the survival curves obtained did, however, suggest combinations of drugs which were effective together. One combination, cyclophosphamide and BCNU, proved to be the most effective in the treatment of the advanced leukemia. ${ }^{8}$

The studies with the transplanted AKR leukemia thus demonstrated the importance of using more than one measure of the effects of anti-cancer agents. The apparent discrepancy between two assays led to a chemotherapy strategy which effectively dealt with this tumor.

# Spontaneous AKR leukemia 

A large fraction of adult AKR mice develop 'spontaneous' leukemia, presumably because of their abnormal endocrine status and their transmission of the Gross virus. We obtained a supply of animals with spontaneous disease from a colony of about 1000 retired breeder female mice aged 6-11 months. ${ }^{9}$ These animals were examined weekly for the presence of enlarged inguinal nodes and splenomegaly. Animals with these physical findingsinvariably had disseminated acute lymphatic leukemia and, if untreated, died in 1 to 40 days. Their median survival time was 18 days.

An assay for malignant cells in these animals poses a problem. The endpoint dilution assay can be used, but the time required for the assessment, if death of the recipient is to be used as the end-point, is over 4 months. At that time some of the animals may come down with the spontaneous disease. We found that a more rapid assay was possible by assessing the number of recipients with enlarged spleens. This assay yielded results identical with the results based on death of the recipient animal. Since it required much less time, we used it in our investigation of the effects of many different chemotherapeutic agents. ${ }^{9}$ A striking feature of the results obtained was the marked differences in the number of malignant cells obtainable from different animals with leukemia. The range from animal to animal often extended over 2 orders of magnitude, and thus demonstrated a marked heterogeneity in the spontaneous disease. Despite this variability, dose-effect curves could be constructed effectively by taking median values obtained for 5-10 leukemia animals. These curves were found to agree, in general, with those obtained with the transplanted leukemia. There were two interesting exceptions - the corticosteroids and asparaginase. Both of these agents had no demonstrable effect on the transplanted tumor but affected a relatively large fraction of animals with spontaneous leukemia.

Results of studies with combinations of chemotherapeutic agents on the spontaneous leukemia were also interesting. They demonstrated that the cells from the spontaneous leukemia had a markedly increased sensitivity to vincristine and cyclophosphamide when the drugs were given together with the corticosteroids. A lesser degree of synergism was observed with cyclophosphamide and arabinosyl cytosine.

We attempted to cure animals of spontaneous leukemia by utilizing a schedule of vincristine and corticosteroid, followed by repeated schedules of cyclophosphamide and arabinosyl cytosine. This treatment schedu'e led to a decreasing population of tumor cells throughout the animal as assayed by the splenomegaly assay. In fact, following four courses of treatment with these drugs, no tumor cells could be detected in the animals by transplantation. However, even under these circumstances, the AKR mice were not cured of their disease. Tumor cells reappeared first in the thymuses, and then throughout the bodies of the treated mice. We then attempted thymectomy, though we found the operative risk high in animals that had received the chemotherapy. Only a small number of mice which were treated with the chemotherapy schedule and then subjected to thymectomy survived, but they were without leukemia for more than one year. ${ }^{9}$ This treatment schedule cannot be considered effective and our understanding of this model tumor remains incomplete.# Transplanted KHT fibrosarcoma 

The KHT is a solid tumor which arose spontaneously in a C3H mouse. ${ }^{10}$ The tumor has been extensively studied in radiobiological investigations. ${ }^{10,11}$ Cells of the tumor have a doubling time of approximately 24 hours and most, if not all, tumor cells are capable of proliferation. In our experiments, the tumor was transplanted by subcutaneous injection of $10^{5}$ cells in the flank. Ten days later these cells grew to a solid, though hemorrhagic, tumor of about $400-\mathrm{mg}$ size. These tumors formed the basis of our therapeutic studies.

A measure of the proliferative capacity of cells in the tumor was obtained using the lung colony assay developed by Hill \& Bush. ${ }^{11}$ This assay rests on the observations that cell suspensions transplanted from the tumor into normal recipients give rise to metastatic lung colonies and that the number of these colonies depends directly on the number of cells injected. Results obtained with this colony assay were similar to those obtained for the transplanted leukemia, though the tumor cells from the solid tumor were slightly less sensitive to most of the drugs than were the leukemias. ${ }^{12}$ Even the most effective drugs reduced the number of viable tumor cells only 3-4 decades before insensitive populations appeared.

The results obtained with the colony assay compared closely with the results of measurements on the growth of tumor cells in situ. The method which we developed for the in situ studies is particularly effective and easy to use. In brief, groups of mice were inoculated subcutaneously with tumor cells and then, 4-5 days later, were given the drugs to be tested. Each tumor was then examined daily and the time interval, until it reached a specific diameter (usually 8 mm ), was determined. All of the drugs studied were found to introduce highly reproducible delays in this time. Furthermore, the delay measured by this simple procedure agreed closely with the predictions based on the lung colony assay and the known doubling time of the tumor. While the colony assay is carried out with relative ease, it is cumbersome when compared with growth delay assay. We therefore used this assay extensively and in time found several agents that were effective in combination. The effectiveness of one such combination, cyclophosphamide and BCNU, was demonstrated by subsequent studies. A majority of mice with advanced transplanted KHT tumors can be cured of their tumor by appropriate treatments with these two agents.

## First-generation transplant C3H mammary tumor

Mammary tumors develop in a large fraction of female C3H mice carrying the Bittner virus factor. Mice with such tumors are selected weekly from a colony of about 1000, 6-12-month animals. ${ }^{13}$ When these tumors reach$10-12 \mathrm{~mm}$ in diameter, they are removed and passaged in syngeneic recipients. The growth of these primary transplants is usually remarkably similar within one group of animals that have received cells from one primary tumor, but it may vary markedly between groups from one primary tumor to another. In most cases the doubling time of the tumor is $3-5$ days, and the tumor reaches a $6-\mathrm{mm}$ size in approximately 20 days, and a $12-\mathrm{mm}$ size $10-16$ days later.

A transplantation assays for malignant cells in these tumors is possible using a dilution technique. The end-point used to define a malignant cell is the appearance of a nodule at the site of injection. ${ }^{13}$ A growth delay assay for tumor cells growing in situ has also been developed. ${ }^{14}$ In the latter assay mice bearing tumors 6 mm in diameter are randomized, assigned to groups, and then treated with appropriate agents. The time required for the tumor to reach 12 mm is determined and plotted as a function of the drug dose used. The results obtained with this simple method are reproducible and consistent with the results obtained by the dilution assay. The two assays, therefore, permit detailed studies of the action of chemotherapeutic agents on this tumor.

Only a few of the chemotherapeutic agents significantly affect the growth of the mammary tumor cells. No chemotherapeutic agent we have studied has an effect as great as the effect of local irradiation. None selectively kills the tumor cells more effectively than normal marrow stem cells. We have, however, noted a significant measure of synergism between cyclophosphamide and adriamycin. ${ }^{14}$ This combination, together with combinations of methotrexate and 5 -fluorouracil, may prove to be effective in dealing with this tumor.

# CONCLUSIONS 

We have outlined the results of our studies with four experimental tumors. From these results we may draw several conclusions about the measurement of the response of experimental tumors to chemotherapy.

First it is clear that the use of two independent measurements leads to a much firmer understanding of the tumor response than one. In all four tumors we have studied the effects of chemotherapy by both measurements of the growth of the tumor in situ and measurements of malignant cells in the tumor by transplantation. The convergence of results obtained by these two different approaches precludes serious. artefacts which might make interpretation of one approach hazardous. For instance, assays for the viability of tumor cells by transplantation are potentially biased by the transplantation procedure. The demonstration that the results obtained bythis assay are consistent with the results obtained when the tumor is left in situ adds credibility to both assays. The four tumor models and the assays described are likely therefore to be effective vehicles for the further investigation of anti-cancer agents.

Next we have demonstrated that, despite the fact that many chemotherapeutic agents are very effective in checking the growth of tumor cells, no single agent by itself is effective in treating any of the four experimental tumors. Drug toxicity is always a problem before the growth of tumors of a large size can be controlled. Effective treatment is only possible when agents are used in combination and a degree of synergism is present. Several combinations of agents showed synergism - prednisone and vincristine with the spontaneous leukemias, cyclophosphamide and BCNU with the fibrosarcoma, and transplanted leukemias, cyclophosphamide and adriamycin with the mammary tumor. The mechanisms for these synergistic effects are not known but are obviously of great importance.

We have also shown that there is a striking difference in the response of the four tumors to chemotherapeutic agents. This is illustrated in Figure 1
![img-29.jpeg](img-29.jpeg)

Figure 1 Survival of four tumor cells and normal hematopoietic colony-forming cells after exposure to, (a) radiation and, (b) cyclophosphamide in vivo. Data are redrawn from references $2,3,9,12,14 \& 17$.which shows dose-survival curves based on the transplantation assays. Curves are shown for each of the four experimental tumors described and, in addition, for the normal hematopoietic colony-forming stem cell. ${ }^{15}$ Figure 1 (a) is for $\gamma$-radiation. As has been noted frequently in earlier studies, all the survival curves have approximately the same slope (see for instance Ref. 16). The least sensitive tumors, the KHT and the mammary tumor, have a final slope about one-third that of the others. This is presumably a consequence of the high percentage of anoxic cells within their tumor mass, as has been demonstrated previously. ${ }^{17,18}$ Figure 1 (b) is for cyclophosphamide, one of the most effective drugs for all tumors. There is a marked selectivity for the leukemias and the rapidly proliferating KHT cells compared with the normal bone marrow cells. The difference in slope is tenfold. But the effect of cyclophosphamide on the mammary tumor is substantially less than that on normal marrow stem cells. The absence of any significant selectivity for the mammary tumor cells among any of the present chemotherapeutic agents is puzzling. Is it a consequence of poor blood supply to the cells of these tumors; to a low fraction of cells in cell cycle; or is it perhaps a consequence of the very methodology used in looking for potential anti-cancer agents? We have searched for new drugs, guided by measurements of the response of rapidly growing animal tumors, and we have found agents that deal effectively with rapidly growing animal tumors, but not necessarily with other types of tumors.

Finally, let us consider the measurement procedure as it applies to the improvement of clinical treatment strategy. We need measurements which permit the easy comparison of the response of human tumors to different agents and combinations of agents. The measures should be simple and easy to use but, more important, they should be efficient and rapid. I do not think that the measures we now use to describe clinical responses meet these criteria. An assay which is based on the survival of the patient is often too erratic and depends too heavily on factors not relating to the effect of treatment on the tumor. It is useful when the tumor is a rapidly growing one such as the experimental leukemias, but it is not so useful with the more slowly growing solid tumors. An assay based on the fraction of tumors which shrink following treatment suffers a similar difficulty. It excludes from consideration any potentially effective agent which simply checks the growth of the tumor. What other possibilities are there? Colony assays in vitro, assays of tumor products, but perhaps most practical would be the application of the growth delay assay adapted to a clinical setting. In any case, the improvement of our ability to measure is very important, for the measurement not only provides a bridge from the experimental studies to the clinical, it also determines in large measure the rapidity with which we can develop optimum treatments for our patients.# ACKNOWLEDGMENTS 

This is a summary of work done in collaboration with H. Vandergaag, B.E. Meeker, R. Furrer, Dr R.S. Bush, Dr F.A. Valeriote, Dr H Lin, and Dr A.C. Eaves. It has been financed by the National Cancer Institute of Canada.

## REFERENCES

1 Bruce, W.R. and Meeker, B.E. Dissemination and growth of transplanted isologous murine lymphoma cells. J. Natl. Cancer Inst., 32: 1145-1159, 1964
2 Bush, R.S. and Bruce, W.R. The radiation sensitivity of transplanted lymphoma cells as determined by the spleen colony method. Radiation Research, 21: 612-621, 1964
3 Bruce, W.R., Meeker, B.E., and Valeriote, F.A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J. Natl. Cancer Inst., 37: 233-245, 1966
4 Bruce, W.R., Meeker, B.E., Powers, W.E., and Valeriote, F.A. Comparison of the dose- and time-survival curves for normal hematopoietic and lymphoma colonyforming cells exposed to vinblastine, vincristine, arabinosyl cytosine and amethopterin. J. Natl. Cancer Inst., 42: 1015-1023, 1969
5 Bruce, W.R., Valeriote, F.A., and Meeker, B.E. Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5 -fluorouracil or 1,3-bis(2-chloroethyl)-1-nitrosourea. J. Natl. Cancer Inst., 39: 257-266, 1967
6 Hewitt, H.B. and Wilson, A. A survival curve for mammalian leukemia cells irradiated in vivo. (Implications for the treatment of mouse leukemia by whole body irradiation.) Brit. J. Cancer, 13: 115-125, 1959
7 Bush, R.S. and Bruce, W.R. The radiation sensitivity of a transplanted murine lymphoma as determined by two different assay methods. Radiation Research, 25: 503-513, 1965
8 Valeriote, F.A., Bruce, W.R., and Meeker, B.E. Synergistic action of cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on a transplanted murine lymphoma. J. Natl. Cancer Inst., 40: 935-944, 1968
9 Lin, H. and Bruce, W.R. A cellular approach to the chemotherapy of spontaneous leukemia of AKR mice. Ser. Haemat., 5: 73-88, 1972
10 Kallman, R.F., Silini, G., and Van Putten, L.M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J. Natl. Cancer Inst., 39: 539-549, 1967
11 Hill, R.P. and Bush, R.S. A lung-colony assay to determine the radiosensitivity of cells of a solid tumor. Intern. J. Radiat. Biol., 15: 435-444, 1969
12 Lin, H. and Bruce, W.R. Chemotherapy of the transplanted KHT fibrosarcoma in mice. Ser. Haemat., 5: 89-104, 1972
13 Lin, H. and Bruce, W.R. Effect of amethopterin on cells of experimental tumors. Ann. N.Y. Acad. Sci., 186: 325-329, 1971
14 Bruce, W.R. Work in preparation
15 Becker, A.J., McCulloch, E.A., and Till, J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature, 197: 452-454, 196316 Berry, Roger J. Radiotherapy plus chemotherapy - Have we gained anything by combining them in the treatment of human cancer? Front. Radiation Ther. Onc., 4: $1-16,1969$
17 Hill, R.P., Bush, R.S., and Yeung, P. The effect of anaemia on the fraction of hypoxic cells in an experimental tumor. Brit. J. Radiol., 44: 299-304, 1971
18 Hewitt, H.B., Chan, D.P-S., and Blake, E.R. Survival curves for clonogenic cells of a murine keratinizing squamous carcinoma irradiated in vivo or under hypoxic conditions. Intern. J. Radiat. Biol., 12: 535-549, 1967# Some model systems in cancer chemotherapy 

G.A. LePAGE<br>McEachern Laboratory, University of Alberta, Edmonton, Canada T6G 2E1

A relatively short time ago Bruce, ${ }^{2}$ in a discussion of the task faced in arriving at successful chemotherapy for cancer, indicated that we must reduce the hematopoietic stem cell population 2 logs or less while destroying all of the cancer cells. The latter would presumably involve a 9 log or more destruction. This was supported by data on the L1210 leukemia system in mice. It now appears that the situation may be more favourable, since we may be able to enlist the help of the immunological system in the killing of the final few logs of tumor cells. This would require that we design our therapy to preserve an appreciable fraction of the immune response.

Most, if not all, of the metabolic parameters we have to work with in discriminating between normal and neoplastic tissues (rates of drug concentration, activation, degradation) with chemotherapy are only quantitatively different. Certainly growth fraction alone is not a favourable factor, since essential normal tissues of the hematopoietic system and gastrointestinal epithelium have higher growth fractions than do most neoplastic tissues. Nonetheless, the success of chemotherapy to date has been in cancers with high growth fractions (e.g., acute leukemia, Wilm's tumor, Burkitt's lymphoma, choriocarcinoma). Our experimental systems in animals, usually transplanted tumors, for selecting chemotherapeutic agents are likely to select agents effective against growing cells. While bearing this in mind, it is difficult to avoid the attractions of the synthesis of DNA, RNA, and protein required in the replication of cells as the selected target area for seeking carcinostatic agents.

We have some drugs that are relatively successful in limited areas of cancer chemotherapy. It would be useful to consider the basis of their success and how to use them optimally.

If we are to assume that study will be directed to agents that interfere with DNA or RNA or protein synthesis or damage these components in a lethal way, what characteristics would be useful? One would be that the agent not interfere with the cycling of growing cells, so that successive popu-lations would advance through the cycle to the phase where they are most sensitive. Relatively short half-life of a drug in tissues would perhaps be desirable, since discrimination between normal and neoplastic cells would be more difficult if the drug is present for prolonged periods. This also makes rate of degradation a possibility in discriminating between normal and neoplastic cells. Where toxicity to normal cells must be accepted, we would also like to have simplicity in the toxic effects. For example, an effect upon only one normal tissue would be preferable to generalized tissue toxicity.

A suggestion that DNA synthesis in target normal tissues be differentially inhibited by steroid hormone control ${ }^{9}$ during chemotherapy has not been exploited. However, some results have been generated with an antimetabolite to which DNA synthesis in normal tissues is quite sensitive, $9-\beta$-D-arabinofuranosylcytosine (Ara-C). ${ }^{10}$ Ara-C has been shown to inhibit DNA synthesis in mammalian tissues, probably by inhibiting DNA polymerase, ${ }^{3}$ though this may not be how Ara-C produces lethal effects on cells.

The effect of a limited exposure of mouse bone marrow to Ara-C in vivo appears to be a relatively brief and reversible inhibition of DNA synthesis. As will be mentioned later, the mouse is a somewhat artificial model in that the degradation of Ara-C (deamination) in mouse tissues is negligible except in the liver and kidney. Mouse tumors possessing appreciable degradative capacity for Ara-C have apparently not been reported. The situation in humans appears different.

A second antimetabolite, 6-thioguanine (6-TG), has received detailed study in my laboratories. ${ }^{5,6,7}$ This agent has a number of metabolic effects and it is incorporated into both RNA and DNA. The incorporation into RNA and other effects (e.g. feedback inhibition of purine nucleotide synthesis and inhibition of purine interchanges) occur in cell lines that are not inhibited by 6-TG. The only effect observed to correlate with cell toxicity was the incorporation into DNA at relatively high levels. Toxicity to the mice was limited to bone marrow. This was substantiated by the rescue of inbred mice from lethal doses of 6-TG with infusions of marrow suspension from donors of the same strain. ${ }^{15}$

Experiments in a variety of mouse tumor lines led to the finding of four different mechanisms by which cells became resistant to 6-TG. These included: (a) deletion of the HGPRT enzyme needed to convert 6-TG to ribonucleotide; (b) possession of a guanase activity that protected the cells by deaminating 6-TG to 6-TX; (c) inability to convert 6-TG ribonucleotide to deoxyribonucleotide so that incorporation occurred in RNA but not in DNA; (d) lowered accumulation of TG-ribonucleotide under conditions where HGPRT enzyme was adequate; this latter form now appears to have been defined ${ }^{17}$ as increased rate of breakdown of TG ribonucleotide by phosphohydrolases. The logical solution to these resistance mechanismsappeared to be the use of $\beta$-2'-deoxythioguanosine ( $\beta$-TGdR), if this were converted to nucleotide in cells. ${ }^{8}$ From the results of surveys on experimental tumors and clinical cancer biopsies, this 'kinase' activity is widely distributed, ${ }^{13,14}$ and $\beta$-TGdR was found to be effective on $6-\mathrm{TG}$ resistant tumor lines. ${ }^{8}$ We have, therefore, continued our studies with $\beta$-TGdR rather than with 6-TG. They appear to be equivalent on a molar basis and the $\beta$-TGdR is assumed to represent a potential for superiority on 6-TG resistant components of a cell population.

Since the lethal effect is related to incorporation of 6-TG or $\beta$-TGdR into DNA, the toxicity to cells should depend upon the timing of dosages. Bone marrow in the mouse has a relatively short cell cycle of 18-24 hours, about 6 hours of this involving DNA synthesis. Thus a relatively closely spaced dosage regimen should trap most cells into the 'lethal synthesis' of 6-TG into DNA. A more spread-out sequence would spare some cells. Table I illustrates this. An interval of only 12 hours does not spare enough marrow. An interval of 24 hours is much less toxic. It is necessary to increase the dose several fold to achieve the same toxicity with a 24 -hour interval that is observed with a 12 -hour schedule.

TABLE I
Toxicity tests with 6-thioguanine in C3H mice*

| No. mice | Dose $(\mathrm{mg} / \mathrm{kg})$ | Interval (hr.) | No. doses | Total dosage ( $\mathrm{mg} / \mathrm{kg}$ ) | No. deaths | Max. wt. loss in survivors (\%) | Time for regain of body wt. (days) |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| 10 | 110 |  | 1 | 110 | 9 |  |  |
| 10 | 90 |  | 1 | 90 | 1 | 30 | 8 |
| 15 | 10 | 12 | 5 | 50 | 8 | 22 | 9 |
| 10 | 14 | 24 | 5 | 70 | 0 | 20 | 7 |
| 10 | 16 | 24 | 5 | 80 | 2 | 26 | 8 |
| 15 | 4 | 12 | 10 | 40 | 15 |  |  |
| 15 | 8 | 24 | 5 | 40 | 0 | 8 | 6 |
| 15 | 20 | 12 | 3 | 60 | 0 | 30 | 9 |
| 15 | 24 | 12 | 3 | 72 | 5 | 32 | 10 |
| 15 | 20 | 24 | 3 | 60 | 0 | 22 | 6 |
| 15 | 24 | 24 | 3 | 72 | 0 | 27 | 8 |
| 20 | 3 | 12 | 12 | 36 | 12 | 25 | 9 |

[^0]On the same basis, spontaneous mammary tumors in C 3 H mice would have a longer and more variable cell cycle; it involved an average cell cycle of 120 hours with only 10 hours of DNA synthesis. ${ }^{12}$ A more spread-out dosage sequence should be most effective on such a tumor cell population. Table II illustrates that a 24 -hour interval between treatments with 6-TG


[^0]:    * Tests were conducted with C3H females 3-6 months of age. Thioguanine was given intraperitoneally in isotonic saline at pH 8 in $0.25-0.75 \mathrm{ml}$. Mice were weighed daily and supplied with an adequate cubed diet ad libitum.TABLE II
Incorporation of thioguanine-8- $\mathrm{C}^{14}$ into nucleic acids and inhibition of growth in spontaneous mammary tumors of C3H mice*

| Group | Tumor weights <br> $(\mathrm{mg})$ | Thioguanine-C ${ }^{14}$ in nucleic <br> acids ( $\mu \mathrm{g} / \mathrm{gm}$ cells) |
| :-- | :--: | :--: |
| Controls, sacrificed initially | $860(630-970)$ |  |
| Controls, sacrificed after 7 days | $1640(1090-1820)$ |  |
| Treated 5 X at 12-hr. intervals | $1132(940-1370)$ | $1.52(0.83-1.92)$ |
| Treated 5 X at 24-hr. intervals | $870(642-995)$ | $2.24(1.63-2.92)$ |

* Groups were matched initially on the basis of tumor size, as measured in two dimensions with calipers. Thioguanine treatments were at $8.0 \mathrm{mg} / \mathrm{kg}$. Those receiving thioguanine-8- $\mathrm{C}^{14}$ were sacrificed two hours after the final dose. There were eight mice per group. The average tumor weight (or thioguanine content) is given, with the range in parentheses.
was more effective than a 12 -hour interval. With an extended therapy, some 11 per cent of such spontaneous mammary tumors were apparently cured. ${ }^{6}$

A series of studies with synchronized Chinese Hamster Ovary (CHO) cells in culture was carried out by Barranco and Humphrey ${ }^{1}$ on $\beta$-TGdR. Data from this study are illustrated in Figures 1-5, with the permission of the authors. Two important properties of this drug are illustrated in these figures: (a) $\beta$-TGdR produced lethal effects only during the period when DNA synthesis would be taking place, i.e., in S-phase, and most pronouncedly when added to the culture medium in early S-phase; (b) the progression of cells through the cell cycle was unimpaired by $\beta$-TGdR. As mentioned earlier this is a most desirable property.

It was reported that treatment of mice with Ara-C allowed the use of otherwise lethal doses of $6-\mathrm{TG} .{ }^{16}$ Some data illustrating this are given in Table III for Ara-C and $\beta$-TGdR. Ara-C spared mice from a lethal sequence of treatments with $\beta$-TGdR, provided the two drugs were given almost simultaneously, but not if they were given at an interval of 16 hours. This becomes logical when we observe, as illustrated in Figure 6, that such a dose of Ara-C immediately reduces DNA synthesis in mouse bone marrow to a relatively low level. Recovery of DNA synthesis occurred in 6-8 hours and an 'overshoot' occurred between 8 and 18 hours. Figure 6 also shows that the treatment of mice with Ara-C daily for at least five days produced a reversible effect, since the recovery curve for DNA synthesis was the same after one treatment or five daily treatments. That this would apply also to $6-\mathrm{TG}$ or to $\beta-\mathrm{TGdR}$ and was not limited to the thymidine precursor is illustrated in Figure7, which compares the three precursors and shows that the results are essentially the same with $\mathrm{TdR}-{ }^{3} \mathrm{H}$ or $\beta-\mathrm{TGdR}-{ }^{35} \mathrm{~S}$ as monitor of DNA synthesis after inhibition with Ara-C.

Figure 8 shows the rates of recovery of DNA s'thesis in two experimental tumors of mice after treatment with Ara-C, monitored with $\mathrm{TdR}^{3} \mathrm{H}$.![img-30.jpeg](img-30.jpeg)

Figure 1 The effect of $\beta$-TGdR on survival of synchronized CHO cells treated in $\mathrm{G}_{1}$ and early $S$ phase of the cell cycle.

# TABLE III 

Toxicity of $\beta$-2'-deoxythioguanosine ( $\beta$-TGdR) and its modification by arabinosylcytosine (Ara-C)*

| Treatment | No. deaths | Max. wt. loss (\%) |
| :-- | :--: | :--: |
| $\beta-\mathrm{TGdR}, 13.6 \mathrm{mg} / \mathrm{kg}$, daily, X9 | 10 | 28 |
| Ara-C, $10 \mathrm{mg} / \mathrm{kg}$ followed in 10 min by $\beta-\mathrm{TGdR}$, | 0 | 11 |
| $13.6 \mathrm{mg} / \mathrm{kg}$, daily, X9 | 10 | 32 |
| Ara-C, $10 \mathrm{mg} / \mathrm{kg}$ followed in 16 hr by $\beta-\mathrm{TGdR}$, |  |  |
| $13.6 \mathrm{mg} / \mathrm{kg}$, daily, X9 |  |  |

[^0]
[^0]:    - Groups of 10 C 3 H female mice $12-14$ weeks old, initially weighing 20 gm each, were used. Surviving mice had regained initial weight by day 20 . Those dying did so in the period $14-16$ days from the start of the treatment.![img-31.jpeg](img-31.jpeg)

Figure 2 The effect of $\beta$-TGdR on survival of synchronized CHO cells treated in $\mathrm{S}, \mathrm{G}_{2}$, and $M$ phases of the cell cycle.

Mecca lymphosarcoma recovers rapidly and greatly exceeds control values during the period $8-24$ hours. It should be vulnerable to $\beta$-TGdR during this overshoot period. The L1210 is very sensitive to Ara-C and does not recover appreciably before 16 hours. However, when redosed at 24 hours, a second recovery was much more rapid. Such redosed L1210 cell populations do not take up and phosphorylate any less Ara-C. Their behaviour is not as yet explained.

The data of Figures 6 and 8 show that there are great variations between bone marrow and tumors in rates of recovery of DNA synthesis from Ara-C. These differences could probably be exploited for therapeutic pur-![img-32.jpeg](img-32.jpeg)

Figure 3 The effects of increasing doses of $\beta$-TGdR on survival of synchronized CHO cells treated in mitosis, $G_{1}$ phase, early $S$ phase, or late $S$ phase.
poses. It is also necessary to know how long $\beta$-TGdR and the resulting nucleotides would be present in the target cells in appreciable amounts in order to design therapy schedules. Figure 9 presents data on the amounts of mononucleotide in mouse bone marrow at intervals after a dose of $\beta$-TGdR at $8.5 \mathrm{mg} / \mathrm{kg}$. The content in DNA is also given, though this is less significant since it is a composite of continued incorporation and cell death. The mononucleotide had a half-life of approximately 3 hours and had declined to a relatively low level by 6 hours. Figure 10 gives the data for a similar experiment on L1210 cells, again indicating a half-life of 3 hours.

Thus a model system has emerged from these studies where we have a $\operatorname{drug}(\beta-\mathrm{TGdR})$ that is toxic only to the bone marrow of the host, is toxic![img-33.jpeg](img-33.jpeg)

Figure 4 Effect on cell progression after $\beta$-TGdR treatment of synchronized cells in mitosis.
![img-34.jpeg](img-34.jpeg)

Figure 5 Effect on cell progression after $\beta$-TGdR treatment of synchronized cells in $\mathrm{G}_{1}$ phase.
only during S-phase, has a relatively short residence time in cells, and does not interfere with the cycling of cells. We appear to have a second agent (Ara-C) that permits us to protect the bone marrow from toxicity by reversibly inhibiting DNA synthesis. The DNA synthesis of experimental tumors can be manipulated with Ara-C in a manner such as to discriminate between bone marrow and tumor. Further studies of the model system with![img-35.jpeg](img-35.jpeg)

Figure 6 Recovery of DNA synthesis after treatment with Ara-C. Mice were treated i.p. with Ara-C and then given $20 \mu \mathrm{Ci}$ TdR-3H. After 30 minutes each mouse was sacrificed and bone marrow obtained from the long bones of the legs. Points represent averages of analyses on three mice and are plotted for the time TdR-3H was given.
![img-36.jpeg](img-36.jpeg)

Figure 7 Recovery of DNA synthesis after treatment with Ara-C $(15 \mathrm{mg} / \mathrm{kg})$ in mouse bone marrow. Conditions were as described in Figure 6.![img-37.jpeg](img-37.jpeg)

Figure 8 DNA synthesis in L1210 cells in vivo after i.p. injection of Ara-C at $15 \mathrm{mg} / \mathrm{kg}$. Each point represents analyses of cells from three mice. Each mouse was injected i.p. with $1 \times 10^{5} \mathrm{~L} 1210$ cells. On day 5 each mouse received Ara-C and was injected i.p. with $20 \mu \mathrm{Ci}$ TdR-3H 30 minutes before sacrifice. L1210 cells were grown in CDF1 female mice. Mecca lymphosarcoma cells were grown in AKD2F1 female mice. Times plotted are for intervals after Ara-C injection. The experiment is exemplary of several experiments giving essentially the same result.
various tumors, including therapy tests is obviously required. We are already able to obtain about 30 per cent of tumor-free survivors in mice bearing L1210 implants, with a limited number of treatments and little host toxicity.

In turning to the human host, we find that there are certain critical differences from the model system in the mouse. When Ara-C and $\beta$-TGdR were given to patients simultaneously, very high incorporation of $\beta$-TGdR into bone marrow DNA was observed.* Only some hours later does Ara-C produce inhibition of DNA synthesis. The good results of Gee et al. ${ }^{4}$ in the treatment of adult acute leukemia are compatible with these experimental

[^0]
[^0]:    * Unpublished observations, G.A. LePage and J.A. Gottlieb![img-38.jpeg](img-38.jpeg)

Figure 9 Persistence of 6-TG nucleotides in mouse bone marrows after treatment with $\beta$-TGdR-30S. Each point represents analyses of bone marrows from 3 CDF1 female mice after single i.p. doses with $\beta$-TGdR-30S at $8.5 \mathrm{mg} / \mathrm{kg}$, expressed as $\mu \mathrm{g}$ 6-TG present per mg DNA. Replicate analyses agreed within 5 per cent.
![img-39.jpeg](img-39.jpeg)

Figure 10 Persistence of 6-TG nucleotides in L1210 cells in vivo after single i.p. dosage with $\beta$-TGdR-30S at $8.5 \mathrm{mg} / \mathrm{kg}$. Each point represents analyses of cells from 5 day growths in 3 CDF1 female mice. Results are expressed as $\mu \mathrm{g} 6-\mathrm{TG}$ present per mg DNA. Replicate analyses agreed within 5 per cent.results, since they administered Ara-C i.v. and 6-TG orally. The latter would peak in the blood several hours later ${ }^{11}$ when Ara-C had produced inhibition of DNA synthesis in bone marrow.

An additional factor that might be involved in humans, not applicable in the mouse model, would be the variation in susceptibility to Ara-C. While mouse bone marrow has a negligible level of deaminase (deoxycytidine deaminase) for inactivating Ara-C and adequate levels of kinase(s) for its activation to nucleotide, human marrows apparently vary considerably in this regard. Some data to illustrate this are shown in Table IV. The relationship between rates of activation and degradation should logically influence

TABLE IV
Assays for deamination and phosphorylation of Ara-C in human bone marrows obtained at surgery (rib marrows)

| Patient | Deamination <br> ( $\mu$ mole/hr/mg DNA) | Phosphorylation | Ratio |
| :-- | :--: | :--: | :--: |
| O.L. | 1.00 | 0.030 | 33 |
| M.W. | 2.96 | 0.10 | 29.6 |
| B.M. | 18.0 | 0.035 | 514 |
| R.H. | 43.0 | 0.45 | 95 |
| U.N. | 1.51 | 0.034 | 44 |
| M.C. | 4.30 | 0.029 | 148 |
| G.O. | 2.40 | 0.17 | 14 |
| J.C. | 2.40 | 0.057 | 42 |

the susceptibility to Ara-C and the ratios between these activities varied from 14 to 514 . A large part of the variation was in the level of deaminase, which is essentially absent in the mouse bone marrow. Similar wide variations in deaminase-kinase activities have been observed in human leukemic cell populations. The further development and utilization of this model for a clinical therapy will have to take account of these differences in the human cells from the mouse models. As mentioned, no mouse tumor has been found that possesses the capacity for Ara-C deamination that is observed in human cell lines. The possession by human neoplastic cells of such deaminase capacity would presumably be exploitable in some cases in protecting bone marrow from $\beta$-TGdR with Ara-C where the neoplasm was not thus protected because of its unresponsiveness to Ara-C. Solid tumors in humans have, in many instances, relatively low growth fractions. It would become even more necessary to be able to protect growing normal tissues from toxicity in treating such solid tumors with agents like $\beta$-TGdR that affect cells in cycle, because a prolonged 'chronic' treatment would seem to be indicated.# REFERENCES 

1 Barranco, S.C. and Humphrey, R.M. The effects of $\beta$-2'-deoxythioguanosine on survival and progression in mammalian cells. Cancer Research, 31: 583-586, 1971
2 Bruce, W.R. The action of chemotherapeutic agents at the cellular level and the effects of those agents on hematopoietic and lymphomatous tissue. Can. Cancer Conf., 7: $83-64,1967$
3 Furth, J.J. and Cohen, S.S. Inhibition of mammalian DNA polymerase by the $5^{\prime}$-triphosphate of $9-\beta$-D-arabinofuranosylcytosine and the $5^{\prime}$-triphosphate of 9 - $\beta$-D-arabinofuranosyladenine. Cancer Research, 28: 2061-2067, 1968
4 Gee, T.S., Yu, K.P., and Clarkson, B.D. Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer, 23: 1019-1032, 1969
5 LePage, G.A. Incorporation of 6-thioguanine into nucleic acids. Cancer Research, 20: 403-408, 1960
6 LePage, G.A. Basic biochemical effects and mechanism of action of 6-thioguanine. Cancer Research, 23: 1202-1206, 1963
7 LePage, G.A. and Jones, M. Further studies on the mechanism of action of 6-thioguanine. Cancer Research, 21: 1590-1594, 1961
8 LePage, G.A., Junga, J.G., and Bowman, B. Biochemical and carcinostatic effects of 2'-deoxythioguanosine. Cancer Research, 24: 835-840, 1964
9 LePage, G.A. and Kaneko, T. Effective means of reducing toxicity without concomitant sacrifice of efficacy of carcinostatic therapy. Cancer Research, 29: 2314-2318, 1969
10 LePage, G.A. and White, S.C. Scheduling of arabinosylcytosine and 6-thioguanine therapy. Cancer Research, 33: 946-949, 1973
11 LePage, G.A. and Whitecar, J.P., Jr. Pharmacology of 6-thioguanine in man. Cancer Research, 31: 1627-1631, 1971
12 Mendelsohn, M.L., Dohan, F.C., Jr., and Moore, H.A., Jr. Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. I. Typical cell cycle and timing of DNA synthesis. J. Natl. Cancer Inst., 25: 477-484, 1960
13 Nakai, Y. and LePage, G.A. Characterization of the kinase(s) involved in the phosphorylation of $\alpha$ - and $\beta$-2'-deoxythioguanosine. Cancer Research, 32: 2445-2451, 1972
14 Peery, A. and LePage, G.A. Nucleotide formation from $\alpha$ - and $\beta$-2'-deoxythioguanosine in extracts of murine and human tissues. Cancer Research, 29: 617-623, 1969
15 Sartorelli, A.C. and LePage, G.A. Modification of thioguanine toxicity in tumorbearing mice with bone marrow transplants. Proc. Am. Assoc. Cancer Res., 2: 246,1957
16 Schmidt, L.H., Montgomery, J.A., Laster, W.R., and Schabel, F.M., Jr. Combination therapy with arabinosyl cytosine and thioguanine. Proc. Am. Assoc. Cancer Res., 11: 70,1970
17 Wolpert, M.K., Damle, S.P., Brown, J.E., Sznycer, E., Agarwal, K.C., and Sartorelli, A.C. The role of phosphohydrolases in the mechanism of resistance of neoplastic cells to 6 -thiopurines. Cancer Research, 31: 1620-1626, 1971Document generated by Anna's Archive around 2023-2024 as part of the DuXiu collection (https://annas-blog.org/duxiu-exclusive.html).

Images have been losslessly embedded. Information about the original file can be found in PDF attachments. Some stats (more in the PDF attachments):
\{
"filename": "NDAxMTExMTZfUFJPQ0VFREIOR1MgT0YgVEhFIFRFTIRIIENBTkFESUFOIENBTkNFUiBSRVNFQVJDSCBDT05GRV JFTkNFX3AxODMuemIw",
"filename_decoded": "40111116_PROCEEDINGS OF THE TENTH CANADIAN CANCER RESEARCH CONFERENCE_p183.zip", "filesize": 17115692,
"md5": "5041ed93c91432e8920ba6f17fbefa9b",
"header_md5": "b8493a7c7a2d92beff6e0b9b939f8b05",
"sha1": "765da0bc641689089cb8a5d36a44b33bc0125fae",
"sha256": "9523cd87dbc85dba978c2ae98f94aaf1f7583204b4a74a503853f3605251bcca",
"crc32": 4051175655,
"zip_password": "6622Ee",
"uncompressed_size": 17056818,
"pdg_dir_name": "40111116_PROCEEDINGS OF THE TENTH CANADIAN CANCER RESEARCH CONFERENCE_p183",
"pdg_main_pages_found": 183,
"pdg_main_pages_max": 183,
"total_pages": 189,
"total_pixels": 858250369,
"pdf_generation_missing_pages": false
\}